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Abstract 
Using label-free proteomics to elucidate factors involved in the human 
response to orthohantavirus infection 
Sarah Brun Bar-Yaacov 
Orthohantaviruses are a genus of Bunyaviruses carried by a range of rodent hosts. They 
are found in endemic foci across the globe and are associated with the zoonotic diseases 
haemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. 
Orthohantaviruses are enzootic to south-eastern, central and northern parts of continental 
Europe. The virus has historically been considered absent from the British Isles, but the 
endemic presence of Seoul orthohantavirus (SEOV) was demonstrated in wild and pet rats 
in the UK in 2012. For the last six years several human cases of orthohantavirus-infections 
have been diagnosed in the UK with associated acute renal failure. Currently, treatment for 
haemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome is 
purely symptomatic. The mechanisms underlying the pathogenesis of orthohantavirus 
infections are not fully understood though several lines of enquiry have demonstrated the 
multifaceted nature of the disease, with direct virally mediated mechanisms, indirect 
immune mediate mechanism and genetic host factors all likely contributors to the clinical 
picture.   
Clinical proteomics is a field of study in which high-throughput analytical approaches 
are used to investigate proteins in clinical samples. A major advantage of the proteomic 
approach is that no a priori knowledge is required for proteome analysis, making it an 
excellent hypothesis generating experimental method. The high-throughput facets of 
proteomic methods also make the approach very useful for infections such as 
orthohantavirus, for which aspects of its pathology remains unclear, and the relative rarity 
of the associated diseases result in limited access to biological samples.    
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The aims of this study were to use label-free proteomics to discover biomarkers of 
orthohantavirus infection in clinical human sera and to study the cellular interactome of 
recombinant SEOV Cherwell glycoproteins in a human kidney cell line, with the objective of 
gaining further insights into mechanism involved in the processing of viral proteins through 
host cells. 
A pipeline for investigating the human serum proteome during diseased and healthy 
conditions was established. Using label-free proteomics in association with immunological 
methods, afamin and galectin 3-binding protein were identified and evaluated as putative 
biomarkers of orthohantavirus infection. Both proteins showed promise as factors involved 
in the response to acute Seoul orthohantavirus infection. Their relevance as markers of 
disease were supported by their functional annotation, with afamin playing a possible role 
in the cellular response to oxidative stress, and galectin 3-binding protein being associated 
with pro-inflammatory and pro-coagulant activity. Further validation studies with larger 
sample cohorts are warranted. Initial investigations into the in vitro interactome of 
recombinant SEOV Cherwell glycoproteins identified 12 potential associations between 
host and viral proteins. While functional analysis of selected proteins revealed a potential 
for relevance in the viral life cycle, further follow-up of these findings will be required to 
establish whether the identified associations are firstly, true associations, and secondly, 
biologically relevant interactions.      
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Chapter 1: Literature review 
1.1 Epidemiology of the Hantaviridae 
Orthohantaviruses are enzootic viruses maintained as apparently asymptomatic 
infections in rodent-, insectivore- and bat populations (Vaheri, Strandin, et al., 2013). They 
belong to the Hantaviridae family of the order Bunyaviridae, and to date 41 
orthohantavirus species have been officially recognized by the International Committee on 
Taxonomy of Viruses (ICTV, 2014).The phylogenetic division of orthohantaviruses coincide 
with the phylogenetic division of their carrier hosts; Murinae-borne, Arvicolinea-borne, 
Sigmodontinae/Neotominae-borne, and lastly Chiroptera- and Soricidae-borne (figure 1.1). 
The rodent-borne orthohantaviruses are the only ones currently known to cause human 
disease and will be the orthohantaviruses referred to in this thesis. Orthohantaviruses are 
found in endemic foci across the globe, though due to the close association of each viral 
species with a specific mammalian host, the presence of a specific orthohantavirus in a 
geographic location is dependent on the presence of its carrier. Seoul orthohantavirus 
(SEOV) is the only orthohantavirus with global distribution, a consequence of the 
ubiquitous dispersal of its host the brown rat (Rattus norvegicus) (Jonsson et al., 2010; 
Vaheri, Henttonen, et al., 2013).  
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Figure 1.1. Orthohantavirus phylogeny reprinted by permission from Springer Nature: 
[Nature][Nature Reviews Microbiology](Vaheri, Strandin, et al., 2013) [Copyright 2013] 
(license number: 4461321436935). Species in red are associated with hemorrhagic fever 
with renal syndrome, species in blue are associated with hantavirus cardiopulmonary 
syndrome, and species in green are not associated with human disease. *In a 2016 update 
on the Bunyavirales order, the ICTV removed Saarema virus and Rio Mamore virus as 
separate viral species of the Hantaviridae family. The ICTV have advised they should be 
considered strains of Dobrava-Belgrade virus and Laguna Negra virus respectively (Briese et 
al., 2016).  
Unlike other members of the Bunyavirdae family, no arthropod vector is involved in the 
viral transmission cycle of orthohantaviruses. In the rodent host viral replication is 
persistent. Virus is shed in saliva, urine and feces, and transmission occurs horizontally 
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within the population. Transmission to humans is mainly the result of inhalation of 
aerosolized rodent excreta in circumstances where humans come into direct contact with 
the animals or their dwellings (Vaheri, Strandin, et al., 2013). 
 
1.1.1 The Americas  
Several species of orthohantavirus, carried by a range of rodent hosts throughout the 
Americas, have been described in the literature (Jonsson et al., 2010). So far 13 of these 
have been reported as causative agents of human disease (table 1). All pathogenic 
sigmodontinae-borne viruses are associated with the development of hantavirus 
cardiopulmonary syndrome (HPS). The first identification of a pathogenic orthohantavirus 
in the Americas occurred in 1993, during an outbreak of an unknown acute respiratory 
illness in the Four Corners Region of southwestern USA. The outbreak affected 48 people, 
and resulted in 27 fatalities (Prevention, 2017). The etiological agent was isolated from deer 
mice (Peromyscus maniculatus) in the area, and within a few weeks identified as a novel 
orthohantavirus species, given the name Sin Nombre virus (SNV). The respiratory disease 
has since become known as HPS. Compared to cases of haemorrhagic fever with renal 
syndrome (HFRS) in Europe and Asia, the prognosis of an infection with HPS-causing viruses 
seems to have a generally less favorable clinical course, with some outbreaks having 
reached mortality rates of approximately 60 %. Although the isolation of SNV was the first 
official recognition of the presence of a pathogenic orthohantavirus in the USA, sporadic 
cases displaying similar symptoms were anecdotally reported to have occurred by 
traditional healers living in the area (Jonsson et al., 2010). Incidence of HPS in North 
America is low, and since the initial outbreak of 1993 through to December 2013, 637 were 
reported in the USA, with an overall case fatality rate of 36 % (Prevention, 2017) 
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Table 1 Pathogenic orthohantaviruses 
Distribution Virus Host Host phylogeny Disease 
Global  
Seoul  Rattus spp. Muridae HFRS 
Asia     
Haantan  Apodemus agrarius Muridae HFRS 
Amur Apodemus peninsulae Muridae HFRS 
Thailand virus Bandicota indica Muridae HFRS 
Europe     
Puumala  Myodes glareoles Cricetidae, 
arvicolinae 
NE 
Dobrava –
Belgrade  
Apodemius flavicollis 
Apodemus ponticus 
Apodemus agrarius 
Muridae HFRS 
Tula* Microtus arvalis Cricetidae, 
arvicolinae 
HFRS 
America     
Sin nombre  Peromyscus 
maniculatus 
Cricetidae, 
sigmodontinae 
HPS 
Andes  Oligoryzomys 
longicaudatus 
Cricetidae, 
sigmodontinae 
HPS 
Choclo Oligoryzomys 
fulvescens 
Cricetidae, 
sigmodontinae 
HPS 
Laguna Negra Calomys callidus 
Calomys laucha 
Cricetidae, 
sigmodontinae 
HPS 
Araraquara Necromys lasiurus Cricetidae, 
sigmodontinae 
HPS 
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Bayou Oryzomys palustris Cricetidae, 
sigmodontinae 
HPS 
Black Creek 
Canal 
Sigmodon hispidus Cricetidae, 
sigmodontinae 
HPS 
Juquitiba Oligoryzomys nigripes 
 
Cricetidae, 
sigmodontinae 
HPS 
Monongahela Permomyscus leucopus 
Peromyscus 
maniculatus 
Cricetidae, 
sigmodontinae 
HPS 
Bermejo Oligoryzomys 
chocoensis 
Cricetidae, 
sigmodontinae 
HPS 
Maciel Bolomys obscurus Cricetidae, 
sigmodontinae 
HPS 
Castelo dos 
Sohonos 
Oligoryzomys moojeni Cricetidae, 
sigmodontinae 
HPS 
Anajatuba Oligoryzomys fornesi 
 
Cricetidae, 
sigmodontinae 
HPS 
*possible Tula-associated HFRS case from Switzerland diagnosed by serology, and 
molecular documented case in an immunocompromised patient from the Czech Republic 
(Schultze et al., 2002; Zelena et al., 2013)  
1993 also saw the first reported cases of HPS from South America, with an outbreak in 
the Sao Paulo metropolitan area of Brazil. This outbreak was caused by Juquitiba virus, and 
is one of the most deadly outbreaks of a Hantaviridae species recorded, with a case fatality 
rate reaching 66 % (Jonsson et al., 2010). Between 1993 and 2009 approximately 1000 HPS 
cases have been reported from Brazil. Viruses of five different lineages seem to be 
responsible for most of these: Juquitiba virus, Castelo dos Sonhos virus, Araraquara virus, 
Laguna Negra virus and Anajatuba virus. By 2013 more than 4000 cases of HPS caused by 
various hantaviral strains have been reported throughout South America (Kruger et al., 
2015). Andes virus (ANDV) is one of the most prominent disease-causing strains in South 
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America, especially important as a public health concern in Argentina and Chile. In 
Argentina three lineages of ANDV have been found to circulate in separate regions of 
endemnicity, whereas in neighboring Chile, a single ANDV strain has been described 
(Jonsson et al., 2010).  A unique feature of ANDV is the evidence of human-to-human 
transmission (Wells et al., 1997; Padula et al., 1998; Martinez-Valdebenito et al., 2014). No 
cases of HPS have been reported from Mexico, despite cases occurring both north and 
south of its borders. There is, however, evidence that the area is endemic, as rodents have 
been found to harbor both hantavirus- specific antibodies and viral RNA, and seropositivity 
for Hantavirus infection has been detected in the general population of the Yucutan area 
(Jonsson et al., 2010). 
In July 2014, during an outbreak of an orthohantavirus in Panama, a case of HPS was 
diagnosed in a British woman returning to Britain after a residential stay in the area. Viral 
RNA was isolated from a serum sample from the woman, and sequence analysis by RT-PCR 
confirmed the causative virus to be Choclo virus, the only known orthohantavirus known to 
circulate in the region (Atkinson et al., 2015). 
Though orthohantavirus infection in the Americas is almost exclusively associated with 
HPS, there does exist reports of HFRS on this continent (Glass et al., 1993). In 2008 a case of 
HFRS was reported from Maryland, Baltimore. The patient did not report to have travelled 
outside his residential area, leading to the conclusion of a domestically acquired infection. 
The etiological agent was identified as SEOV by serological and molecular methods (Woods 
et al., 2009).  In January 2017 a multi-state outbreak of SEOV linked to several rat-breeder 
sites in the USA was reported by the Center for Disease Control and Prevention. During the 
course of the outbreak 17 cases of human SEOV infection were laboratory confirmed across 
11 states (Updates, no date). 
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1.1.2 Asia 
Hantaan virus (HNTV) was first isolated from the lung tissue of a striped field mouse 
(Apodemus agrarius) in 1978 by Lee et al, and identified as the etiological agent of a disease 
known at the time as Korean hemorrhagic fever, outbreaks of which heavily affected UN 
troops during the Korean War in the 1950s (Lee et al., 1978). Korean hemorrhagic fever is 
now known as a severe manifestation of HFRS, and HTNV is the major causative agent of 
the disease in Asia (Zhang et al., 2010). HFRS has been reported in China since 1931, and 
there are descriptions of HFRS-like disease dating back approximately 1000 years, 
suggesting that the disease has long been considered a major public health problem. 
Annually more than 11 000 cases of HFRS are reported in China, caused by HTNV and SEOV. 
Cases have been reported nationwide, though the vast majority occurs in specific 
geographic regions. As human populations have become increasingly urban, a link has been 
made with the observed relative increase in the proportion of milder SEOV- caused HFRS 
cases compared to severe HTNV- associated cases and the accompanying migration of rats 
with human activity to urban centers (Zhang et al., 2010). However, definitive data on the 
causative agent of HFRS in China is limited, as diagnosis relies on immunological testing 
where cross-reactions between the two strains are common (Zhang et al., 2011). Korea is 
the second major endemic region for HFRS in Asia, and in South-Korea 300-400 HRFS cases 
were reported annually in the time period 2001 - 2008 (Kruger et al., 2015). Since the early 
1990’s both China and Korea have made use of inactivated orthohantavirus vaccines as 
preventive control measures. In Korea Hantavax, a formalin inactivated HTNV vaccine 
derived from mouse brain tissue, has been used, while in China four inactivated vaccines 
targeting HNTV or HTNV and SEOV have been introduced (Sohn et al., 2001; Zhang et al., 
2010). There seems to have been a trend towards a decrease in cases following the 
implementation of vaccination programs but public health education, rodent control and 
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improved living conditions are all measures that have certainly also contributed 
substantially to lowering the incidence of HFRS (Zhang et al., 2010).  
In the Asian parts of Russia, HRFS is caused by the same species of orthohantavirus as 
those found in China and Korea. The incidence of HFRS is higher in the European regions of 
the county, but the associated mortality rates are highest in the Far East (Lokugamage et 
al., 2002; Garanina et al., 2009). Thailand virus is a genetically unique rat-borne 
orthohantavirus carried by the bandicoot rat (Bandicota indica). Presence of Thailand virus- 
specific antibodies have been confirmed in rodents and patients presenting with unknown 
febrile illnesses in Sri Lanka, Thailand and India (Pattamadilok et al., 2006; Nakamura et al., 
2008; Chandy et al., 2009; Gamage et al., 2011).  
1.1.3 Africa 
2006 marked the first discovery of an orthohantavirus species on the African continent. 
Sangassou virus was isolated and cultured from an African wood mouse (Hylomyscus simus) 
in Guinea (Klempa et al., 2006, 2012). The detection of a novel hanta-RNA genome was 
made possible by using a nested PCR-assay (figure 1.6) with highly degenerated primers 
designed from an alignment of all know nucleotide sequences of the conserved L segment 
of orthohantavirus genomes. Seroepidemiological investigations were conducted in the 
area to follow up on the discovery of this novel viral species and provided evidence of 
human infection by the detection of Sangassou virus-specific antibodies. A seroprevalance 
of 1.2 % was detected in a population-based survey conducted in Forest Guinea, while a 
seroprevalence of 4.4 % was detected in a cohort of patients with fever of unknown origin 
in Sangassou village (Klempa et al., 2010). 
1.1.4 Europe 
Orthohantaviruses have been found in both rodents and insectivores in Europe, and 
different species and strains co-circulate in the rodent populations in certain parts of the 
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continent (Vaheri, Henttonen, et al., 2013). Rodent-borne viruses endemic to Europe are 
Puumala (PUUV), Dobrava-Belgrade (DOBV), SEOV and Tula (TULV). PUUV and TULV are 
carried by the bank vole (Myodes glareolus) and common vole (Microtus spp.) respectively, 
while DOBV is carried by Apodemus spp.  
Cases of HFRS have been widely reported across continental Europe, though there are 
major regional differences in case numbers and the extent of human exposure. Most cases 
originate from specific endemic areas. In the period 2010 - 2014 the annual number of 
reported HFRS cases in the EU/EEA ranged between 2000 – 4000 (European Centre for 
Disease Control and Prevention, 2016). By including cases reported from Russia the annual 
incidence increases to more than 10 000 (Heyman et al., 2011). The Nordic countries can be 
considered to be endemic hotspots, with Finland reporting as much as 70 % of all European 
HFRS cases, excluding Russia (Vaheri, Henttonen, et al., 2013). In many regions of Europe, 
though few cases of HFRS are reported, serosurveillance has demonstrated a relatively high 
level of exposure to orthohantaviruses in the population.  
The two viral species responsible for the vast majority of European HFRS cases are 
PUUV and DOBV. PUUV is the causative agent of a mild form of HFRS known as 
nephropathia epidemica (NE), a disease known to have occurred in Sweden since the 1930s 
(Lundkvist and Niklasson, 1992). This is the most common manifestation of orthohantaviral 
disease in Europe, and the clinical prognosis is generally good. DOBV infections, though less 
common, generally result in an infection with a far more severe clinical picture, with 
reported mortality rates as high as 12 % (Vaheri, Henttonen, et al., 2013). DOBV is carried 
by three different Apodemus species; yellow-necked field mouse (Apodemius flavicollis), 
black sea field mouse (Apodemus ponticus) and the striped field mouse (Apodemus 
agrarius). Intriguingly different degrees of virulence are associated with DOBV infections 
originating from the different carriers.  Generally, DOBV-af is associated with severe 
  25 
disease, DOBV-ap with moderate-severe disease and DOBV-aa1 with a mild clinical course 
(Klempa et al., 2013).   Though there is overlap between the geographic distributions of 
DOBV strains, DOBV-af infection is most prevalent in the Balkan states and southeastern 
parts of Europe, DOBV-aa occurs most frequently in central Europe and DOBV-ap is 
predominantly present in the European and Russian areas surrounding the Black Sea.  
1.1.5 British Isles 
With no genetic confirmation of the viral genome in rodent populations, and only a 
handful of reported human clinical cases (table 2), orthohantaviruses have historically not 
been considered enzootic to the British Isles. However, growing evidence of viral exposure 
has been obtained through serosurveillance studies conducted over the past 30 years, by 
detection of hantavirus-specific antibodies in both humans and rodents (Pether and Lloyd, 
1993; McKenna et al., 1994; Webster and Macdonald, 1995; McCaughey et al., 1996; 
Coleman, 2000; McCaughey and Hart, 2000). In 2013, a study conducted in the Yorkshire 
region reported a 7.6 % seroprevalence of orthohantavirus-specific IgG antibodies among a 
selected group of subjects expected to be at higher risk of acquiring an infection than the 
general population due to occupational exposure (Jameson et al., 2014). The observed 
prevalence of this study was comparable to levels found in other known endemic regions of 
Europe (Vaheri, Henttonen et al. 2013). 
  
                                                          
1 The taxonomic relationship between Saarema virus and DOBV has been much 
contested, with some groups considering them separate viral species and some 
considering Saarema virus a DOBV strain (i.e. DOBV-aa) (Plyusnin et al., 2006). In 
2016 Saarema virus was removed as a separate genus of the Hantaviridae by the 
ICTV, who have instructed it should be considered a DOBV strain.   
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Table 2. Published cases of domestically acquired orthohantavirus infection in the UK 
prior to 2012 
 
*Laboratory-acquired infection.  **11-month study  
 
In the current decade three novel orthohantaviral species have been isolated from 
rodents in the UK (Jameson, Logue, et al., 2013; Jameson, Taori, et al., 2013; Pounder et al., 
2013). In 2012 SEOV was detected in wild caught brown rats in the north-eastern region of 
England (Jameson, Logue et al. 2013). The investigation followed a case of severe acute 
kidney injury (AKI) in a patient from Yorkshire and the Humber, whom on serological testing 
presented with rising titers of orthohantavirus-reactive IgG antibodies. Phylogenetic studies 
Year Location Source # cases Strain Diagnositic 
modality 
Reference 
1977 Research 
laboratory, 
UK 
Wistar rat       
(r. norvegicus) 
immunocytom
as 
4* HNTV/SEOV IFA (Lloyd and 
Jones, 1986) 
1983 Scotland  Unknown 1 HNTV or 
related 
IFA (Walker et al., 
1985) 
1988 Glasgow Unknown 1 Unknown IFA (Kudesia et 
al., 1988) 
1991 Somerset Unknown 1 Unknown IFA (Pether et al., 
1991) 
1991 Somerset Unknown 1  - IFA (Phillips et al., 
1991)  
1991 Somerset Unknown 1 Unknown IFA (Pether et al., 
1993) 
1992 Somerset Unknown 25** Unknown IFA (Pether and 
Lloyd, 1993) 
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of the S and M genomic segments isolated from two rodents caught at the patient’s place 
of residence showed that the virus clustered closely with a previously described SEOV 
strain, IR146, a strain associated with laboratory-acquired SEOV infections in the UK and 
Belgium (Lloyd and Jones, 1986). The isolation of the Humber strain confirmed, for the first 
time, the presence of an orthohantavirus in wild rodents in the UK.  Not long after this 
initial discovery another case of AKI resulted in the detection of a related, yet genetically 
distinct SEOV among a colony of fancy pet agouti rats (Rattus norvegicus) (Jameson, Taori 
et al. 2013). The virus strain was named Cherwell. In addition to the original patient, two of 
three additional individuals that had been in contact with these rats were seropositive for 
hantavirus specific IgG antibodies, and one of them had been hospitalized some years 
earlier with an undiagnosed viral illness characterized by AKI and thrombocytopenia, both 
symptoms associated with HFRS. In a subsequent case of AKI in a pet rat owner in 2014, a 
partial viral sequence was recoverable form the patient’s serum that exhibited 100 % 
homology to the Cherwell strain (Duggan et al., 2017). Since these initial findings a further 
eight cases of HFRS with domestic origin have been diagnostically confirmed by the Rare 
and Imported Pathogens Laboratory (RIPL), Porton Down (table 3). In Sweden, SEOV was 
recently detected in a pedigree pet rat imported from England. Phylogenetic analysis 
revealed that the virus did not cluster with either of the newly described British strains, but 
with Belgium895, a strain previously isolated from wild rats in Belgium (Heyman et al., 
2009; Lundkvist et al., 2013).  
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Table 3. Cases of domestically acquired orthohantavirus infections diagnosed by RIPL 
2012-2015 
Year Age Sex Renal 
failure 
Animal 
exposure 
Species (titre) Reference 
2015 53 M   Rats SEOV (1:1000)  RIPL  
2015 22 M   Reptiles and 
rodents 
SEOV (1:100) RIPL 
2015 20 M + Rats SEOV/HNTV 
(1:10000) 
RIPL 
2015 28 F + Rats SEOV/HNTV 
(1:1000) 
RIPL 
2014 10 F + Rats SEOV/HNTV 
(1:3200) 
RIPL 
2014 41 M + Rats SEOV/HNTV 
(1:10000) 
RIPL 
2013 11 F   Rats HNTV (1:3200) RIPL 
2013 20 M +   SEOV/HNTV 
(1:10000) 
RIPL 
2012 28 M + Rats SEOV (1:10000) RIPL 
2012 59 M + Rats SEOV (1:10000) RIPL 
 
In addition to the above mentioned SEOV strains, a virus clustering with the 
Arvicolinae-associated orthohantavirus species was recently isolated form a single field vole 
(Micortus agrestis) in Cheshire in north western England (Pounder et al., 2013).The virus 
was named Tatenale, and subsequently a similar, but genetically distinct orthohantavirus, 
was found to be endemic in a field vole population in the Kielder Forest at the English - 
Scottish border (Thomason et al., 2017). The pathogenic potential to humans of these 
viruses remain unknown, as no cases of human disease have been associated with them. 
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The Arvicolinae-associated orthoantaviruses include the NE-causing PUUV species and 
TULV. Interestingly, in the mid 80’s, serosurveillance studies conducted in the UK reported 
a high prevalence of what was considered PUUV-specific antibodies, though without 
neutralization assays to verify, a determination of the specific viral species cannot be 
ascertained from these results (McCaughey and Hart 2000). In central and eastern Europe 
vole populations carry the Arvicolinae-associated TULV.  The species is generally considered 
to be non-pathogenic, but there exists serological documentation of subclinical human 
infection, and there are reports of TULV–associated HFRS cases from Switzerland and the 
Czech Republic (table 1) (Schultze et al., 2002; Heyman et al., 2011; Zelena et al., 2013).  
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1.2 Genomic structure and viral life cycle 
As is characteristic for Bunyaviruses, the Hantaviridae harbour a tri-segmented 
negative-sense, single-stranded RNA genome. The size of the total genome ranges from 
approx. 11, 8 kb to 12, 3 kb depending on the viral species. The three genomic segments 
are descriptively named small (S), medium (M) and large (L) based on their size, and each 
carries an open-reading frame that codes for the viral nucleoprotein (N), glycoprotein 
precursor (GCP) and RNA-dependent RNA-polymerase (RdRp) respectively. The open 
reading frames are flanked by non-transcribed regions at the 3’ and 5’ ends (Hepojoki, 
Strandin et al. 2012).  The terminal nucleotides of the non-transcribed regions are 
complementary and highly conserved among orthohantaviruses; 3’AUCAUCAUCUG (Meyer 
and Schmaljohn, 2000; Hussein et al., 2011). Through hydrogen bonding between the 3’ 
and 5’ termini the viral RNA forms panhandle structures (Mir et al., 2006). These structures 
are hypothesized to act as promoters, supported by observations that terminal deletions in 
the genomic segments correlate with decreased viral replication in persistently infected cell 
cultures (Meyer and Schmaljohn, 2000). 
1.2.1 L segment 
With approximately 2150 amino acid residues, and with a molecular mass of about 250 
kDa, the RdRp is the largest of the orthohantaviral proteins (Kukkonen et al., 2005). The 
role of the RdRp is to copy negative-sense viral RNA into positive-sense mRNA and 
complementary RNA intermediates for protein synthesis and genome replication 
respectively. The RdRp is a highly conserved protein, not only among the Hantaviridae, but 
all viruses harboring RNA genomes, and sequence comparisons of the RNA polymerase of 
RNA viruses indicate that certain amino acids are essential for expression of a functional 
polymerase (figure 1.2) 
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Figure 1.2 Schematic of conserved domains in ORF of Orthohantavirus L segment, 
adapted from (Kukkonen et al., 2005). The color code shows which domains are also 
conserved among other RNA viruses. Domain A and C are centered on conserved 
aspartates, B a conserved glycine and D a conserved lysine. p (pre-motif A) contains a 
conserved lysine and two arginines. 2 indicate two conserved residues, a glutamate and 
lysine, located between p and A. 4 contains three conserved glycines and one tyrosine. The 
N-terminal conserved domains contain two conserved residues each, and the C-terminal 
conserved domain contains acidic residues. ORF; open reading frame.  
1.2.2 M segment 
The GCP polypeptide, encoded by the M segment open reading frame, is not observed 
in infected cells, but is co-translationally cleaved by the cellular signal peptidase complex to 
the mature viral glycoproteins Gn and Gc (figure 1.3). These correlate to the amino 
terminus and carboxyl terminus of the GCP respectively, and the cleavage products have 
approximate sizes of 650 and 490 amino acid residues (Hepojoki, Strandin et al. 2012). The 
signal sequence WAASA has been experimentally demonstrated to be the cleavage site of 
the HTNV GCP (Lober et al., 2001). This motif is highly conserved among orthohantaviruses, 
and it adheres to specific sequence rules required for localization to and cleavage of cellular 
proteins at the endoplasmic reticulum (ER) membrane (Lober et al., 2001). This has marked 
it as a good candidate for a putative shared cleavage site of the Hantaviridae family. Gn and 
  32 
Gc form hetero-oligomers, and their co-expression seems to be a necessity for exit from the 
ER, and translocation to the Golgi (Hepojoki, Strandin et al. 2012). The orthohantaviral 
glycoproteins have a high frequency of cysteine residues in their amino acid sequence (4-7 
%), which gives them a propensity for forming disulfide bridges (Hussein et al., 2011). 
Disulfide bridges are molecular structures important for protein folding and maintenance of 
their tertiary structure outside of the cytoplasm.  
  
 
Figure 1.3. Schematic of the SEOV Cherwell GCP, created with SnapGene© Viewer using 
the Cherwell SEOV M segment sequence (3399bp). The SP (signal peptide) and WAASA 
sequences indicate cleavage sites within the GCP. Gn and Gc are the mature viral 
glycoproteins and correlate to the amino terminus and carboxyl terminus of the GCP 
respectively. GCP; glycoprotein precursor.  
The Hantaviridae glycoproteins are modified by N-linked glycans, all of which are 
endoglycosidase H sensitive, identifying them as high-mannose type glycans (Shi and Elliott, 
2004). This particular modification takes place at the cis-Golgi. N-glycans are commonly 
found attached to a nitrogen atom of an asparagine (Asn) residue which is present as part 
of the signal sequence Asn-X-Thr/Ser, where X is not a proline, threonine (Thr) or serine 
(Ser). By detecting this signal sequence it is possible to predict sites were N-linked glycans 
are likely to be present on a protein. Sequence analysis of the M segment open reading 
frame has revealed four conserved N-glycosylation sites for orthohantaviruses. On HTNV 
these are mapped to; Asn134, Asn347 and Asn399 on Gn, and Asn928 on Gc (Hepojoki et 
al., 2012). Utilizing site-directed mutagenesis it has been demonstrated that all of the 
conserved sites carry functional N-glycans on HTNV and PUUV(Johansson et al., 2004; Shi 
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and Elliott, 2004). In addition, a fifth N-glycosylation site specific for HTNV was identified on 
Gn at position Asn235 (Shi and Elliott, 2004). For PUUV, the presence of an O-glycan was 
identified on Gc at position Thr984 (Johansson et al., 2004). Introduction of mutation at the 
conserved N-glycan sites has dramatic effects on glycoproteins function, affecting the 
intracellular trafficking of the proteins, their ability to properly fold and form heterodimers, 
and impairs their antigenic properties (Shi and Elliott, 2004). 
The viral genome is contained within a particle that consists of a lipid envelope covered 
by spikes that protrude 10-12 nm from the surface. These spikes are made up of Gn:Gc 
hetero-oligomers (Cifuentes-Munoz et al., 2014). Ultrastructural analysis of HNTV and TULV 
by cryo-electron tomography has made it possible to elucidate the surface structure of the 
virions (Huiskonen et al., 2010; Battisti et al., 2011). These analyses have revealed square 
shaped surface spike-complexes exhibiting four-fold symmetry. Molecular mass estimations 
of these complexes correspond to the presence of four copies each of the Gn and Gc 
subunits. Some differences in spike densities between HTNV and TULV have been noted, 
but whether this represents an actual difference in the organization of the spike complexes, 
or are artifacts caused by the experimental procedure remains undetermined (Cifuentes-
Munoz et al., 2014).  
Members of the Bunyaviridae lack matrix proteins, proteins that for several other 
enveloped negative-sense RNA viruses are necessary for the interaction of envelope 
glycoproteins and ribonucleoproteins within the viral particle, facilitating assembly and 
budding of virions (Timmins et al., 2004). It has been suggested that the Gn and Gc of 
orthohantaviruses act as surrogate matrix proteins, as they have ribonucleoprotein-binding 
abilities, and the Gn cytoplasmic tail (GnCT) harbours a YxxL sequence (figure 1.3), a 
sequence resembling the so called late domain sequences found in matrix proteins 
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(Hepojoki et al., 2010; Wang et al., 2010; Strandin et al., 2013). In matrix proteins these 
sequences are responsible for recruiting host cell factors to the sites of viral budding.  
1.2.3 S segment 
The N protein is an un-glycosylated protein of about 430 amino acid residues, and with 
an approximate molecular mass of 50kDA (Hepojoki et al., 2012). Some viral species, 
specifically those carried by Cricetidae rodents, encode an additional non-structural protein 
in the S segment that overlaps the N protein open reading frame by +1 nucleotide 
(Jaaskelainen et al., 2007). The function of this protein remains to be fully elucidated, 
though the non-structural proteins of PUUV and TULV have been demonstrated to act as 
weak antagonists of interferon (IFN) induction in fibroblasts (Jaaskelainen et al., 2007).  In 
addition, the non-structural protein of TULV has been shown to interact with ACBD3, a 
protein involved in the structural maintenance of the Golgi apparatus (Rönnberg et al., 
2012)   
The N protein is the major structural component of the virus, and the most abundantly 
expressed protein in both virions and infected cells. Multiple functions have been ascribed 
to it, due to its interactions with both viral and host cell components (Kaukinen et al., 
2005). By binding to viral RNA at the panhandle structure the N protein encapsidates the 
genomic segments so that they exist as ribonucleoprotein complexes coupled to the RdRp 
within the virion (Mir et al., 2006; Hepojoki et al., 2012). The N protein is also able to bind 
cellular 5’mRNA caps and protect these from degradation, implicating it in the process of 
cap-snatching (Mir et al., 2008, 2010). This tactic is used by several RNA viruses and entails 
the use of cellular 5’ methylated-mRNA-caps as primers for the viral RdRp to initiate 
transcription (Decroly et al., 2011). Additionally, the N protein has been shown to be 
capable of functioning as an initiation factor for viral translation by replacing and taking on 
the function of the eukaryotic cellular initiation complex eIF4F (Mir and Panganiban, 2008).  
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1.2.4 The viral life cycle 
An important function of orthohantaviral surface glycoproteins is to mediate the 
interaction between the virion and cell membrane through specific binding to cell surface 
receptors. Several putative receptors have been identified through in vitro studies though 
none have been definitely validated in in vivo infection. Several lines of evidence point to 
integrins as essential cellular receptors for viral entry. It has been demonstrated that 
orthohantaviruses enter human endothelial cells by binding to β3-integrins, and 
transfection of unpermissive cells with human recombinant β3-integrins render them 
susceptible to infection (Gavrilovskaya et al., 1998, 1999; Mou et al., 2006). A specific 
domain of the β3-integrin subunit was identified as a possible binding site for 
orthohantaviruses (Raymond et al., 2005; Bondu et al., 2017). Interestingly Prospect Hill 
Virus, which is a non-pathogenic orthohantavirus, does not utilize the β3-integrin receptor 
for cell entry, but requires the presence of β1-integrin (Gavrilovskaya et al., 1998, 1999). 
The utilization by pathogenic and nonpathogenic viruses of different receptors, along with 
the role of β3-integrins in regulation of the vasculature, has led to speculations about the 
contribution integrins have as viral receptors in the pathogenesis of HFRS and HPS 
(Gavrilovskaya, Gorbunova et al. 2008, Wang, Zhang et al. 2012) CD55/DAF, a regulatory 
protein of the complement system, has also been demonstrated to facilitate viral infection 
by HTNV and PUUV, and SNV binds to this receptor with high affinity (Krautkramer and 
Zeier 2008, Buranda, Wu et al. 2010). A second protein involved in the complement system, 
gC1qR, was also shown to facilitate the entry of HTNV in human lung epithelial cells (Choi, 
Kwon et al. 2008). Likely, more than one receptor is involved in vivo, and other factors 
might also contribute. Depletion of cholesterol from lipid rafts in the plasma membrane 
lowers the susceptibility of cells to HTNV and ANDV infection (Krautkramer and Zeier 2008, 
Cifuentes-Munoz, Darlix et al. 2010).  
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The most common mode of cellular entry for orthohantaviruses seems to be by 
clathrin-mediated endocytosis, which has been demonstrated for HNTV, SEOV and Black 
Creek Canal virus (BCCV) (Jin et al., 2002; Ramanathan et al., 2007; Ramanathan and 
Jonsson, 2008). Intriguingly, ANDV does not rely on clathrin-mediated endocytosis to enter 
VeroE6 cells, but can use this mechanism to infect HMVEC-L cells (Ramanathan and 
Jonsson, 2008; Chiang et al., 2016). In both VeroE6 cells and HMVEC-L cells, ANDV could 
also enter cells by an uncharacterised clathrin-independent endocytic mechanism. This 
suggests that ANDV, possibly uniquely among orhtohantaviruses, has the ability to utilize 
different mechanisms for cellular entry depending on the target cell. Once in the cell the 
virus traffics along the endocytic pathway, before escaping into the cytosol by low-pH-
mediated fusion of the virion with the host-cell membrane (Jin et al., 2002; Buranda et al., 
2013). Gc of ANDV has been identified as a class II fusion protein, placing it in the same 
structural category as Gc of other Bunyaviruses (Garry and Garry, 2004; Plassmeyer et al., 
2005; Tischler et al., 2005; Cifuentes-Munoz et al., 2011; Halldorsson et al., 2016). A pH of 
4.0 - 5.8 is necessary to trigger the fusogenic activity of Gc, a pH-range indicative of the 
virus probably reaching late endosomes (pH 4.9-6.0) before it is released into the cytosol 
(Ogino et al., 2004; Cifuentes-Munoz et al., 2011; Huotari and Helenius, 2011; Acuna et al., 
2015). Trafficking to late endosomes is further supported by observations that shortly 
following infection HNTV localises with the late endosomal/lysosome marker LAMP-1 and 
UV-inactivated SNV localises with and activates the GTPase Rab7, also associated with late 
endosomes (Jin et al., 2002; Buranda et al., 2013).   
Intact cytoskeletal structures are essential for orthohantaviruses to complete their life-
cycle (Ramanathan et al., 2007; Ramanathan and Jonsson, 2008). Both old and new world 
orthohantaviruses require actin for efficient entry, as demonstrated by an inability of 
representatives of both species to replicate in permissive cells treated with an inhibitor or 
actin polymerisation one hour pre-infection. Seemingly however, only new world viruses 
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continue to require actin at later time points in the viral life cycle. ANDV seems especially 
reliant on an intact actin network, with loss of actin integrity almost completely inhibiting 
viral replication. BCCV, also a new world virus, experienced a 50 % reduction in viral yield 
under the same circumstances. The effect of disrupting actin at three hours and 12 hours 
post-infection with HNTV or SEOV was, on the other hand, negligible. The latter two viruses 
were conversely dependent on an intact microtubule network at these later time points, 
and while new world orthohantavirus replication was also negatively affected by 
microtubule dissociation, this was to a far lesser extent than for HNTV and SEOV. 
The specific sites of orthohantaviral assembly and budding are currently under 
investigation. Several lines of evidence point to the Golgi complex as the main site of viral 
maturation. The glycoproteins accumulate and are retained in the Golgi complex when both 
Gn and Gc are expressed together or during viral infection, and budding of virions is 
observed there (Goldsmith et al., 1995; Shi and Elliott, 2002; Kariwa et al., 2003; 
Spiropoulou et al., 2003; Deyde et al., 2005). The timing of glycoprotein accumulation in the 
Golgi coincides with the time infectious viral particles are detectable in cell culture, and 
treatment of orthohantavirus infected cells with Brefeldin A, an antiviral compound that 
inhibits the transport of proteins from the ER to Golgi, inhibits viral replication (Kariwa et 
al., 2003; Ramanathan et al., 2007; Ramanathan and Jonsson, 2008). Orthohantaviral N 
proteins are transported to the ER-to-Golgi intermediate compartment (ERGIC) following 
infection, and the integrity of this complex seems to be essential for viral replication 
(Ramanathan et al., 2007; Ramanathan and Jonsson, 2008). ANDV Gc, and to a lesser extent 
SNV Gc, can co-precipitate ERGIC-53, indicating a possible association of the glycoproteins 
with the ERGIC as well (Klaus et al., 2013). Golgi maturation is considered a hallmark of 
Bunyaviruses and is the site of maturation for for Rift Valley Fever virus, Bunyamwera virus, 
Crimean-Congo Haemorrhagic Fever virus and Uukuniemi virus (Jäntti et al., 1997; 
Haferkamp et al., 2005; Novoa et al., 2005; Carnec et al., 2014). However, assembly of 
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orthohantaviral glycoproteins and viral budding has also been reported to occur at the 
plasma membrane, with ANDV, SNV, BCCV and HTNV glycoproteins having been observed 
to aggregate there at late stages post-infection or –transfection (Spiropoulou et al., 2003; 
Ogino et al., 2004; Xu et al., 2007; Cifuentes-Munoz et al., 2011). Viral budding at the 
plasma membrane has been observed for SNV and BCCV (Goldsmith et al., 1995; Ravkov et 
al., 1997). Even budding of virions at the rough ER has been reported for a species of HNTV 
(Xu et al., 2007). These discrepancies in cellular trafficking and sites of maturation could be 
due to the use of different cell lines; HNTV glycoproteins do not assemble at the plasma 
membrane in P388D1 cells, but in VeroE6 and BHK cells, and SNV does not accumulate at 
the plasma membrane in NRK cells. The latter observation could, however, be a 
consequence of the timing of investigation rather than the cell line used. In the study,  NRK 
cells were only monitored at 12 hours post transfection due to cytotoxic effects of the 
vaccinia expression system used (Spiropoulou et al., 2003). As such it is possible to 
speculate that many studies have not observed glycoproteins at the plasma membrane 
because cells have not been monitored at late enough time-points for glycoprotein 
accumulation there. It is also possible that the sites of assembly are species-specific, or that 
orthohantaviruses can assemble at multiple sites in the cell.  
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1.3. Clinical course 
Clinically orthohantavirus infections generally manifest as HFRS in Eurasia and HPS in 
the Americas. Both syndromes primarily affect blood vessels and are characterized by 
altered barrier functions of the vascular endothelium, causing systemic vascular leakage. 
The major difference between the two syndromes is the primary afflicted organ. In HFRS 
this is the kidneys, whereas in HPS the lungs are targeted (Jonsson et al., 2010). Though the 
primary target organs differ, HFRS and HPS are both generalized infections with multi-organ 
involvement. Cardiopulmonary and neurological complications have been noted in NE, and 
pulmonary oedema in severe HTNV infection is not uncommon (Mustonen et al. 2013; Du 
et al. 2014). Though rare, there are reports of renal involvement in cases of HPS from North 
America, and in South America it has been reported that as many as 50 % of ARAV patients 
present with raised serum creatinine, indicative of renal dysfunction (Hjelle et al., 1996; 
Passaro et al., 2001; Campos et al., 2009). 
The outcome of infection ranges from subclinical sero-conversion through mild, 
moderate and severe disease, to death. The infecting viral species is a major determinant of 
expected disease severity. For HFRS-causing viruses, HTNV and DOBV are associated with 
severe disease (10% - 15% mortality rate), SEOV with moderate (1% - 5% mortality rate) 
and PUUV with the mild form known as NE (< 1% mortality rate). This, however, is also 
subject to variability on a case by case basis, and an individual PUUV case might be severe 
while a HTNV case can present with a mild clinical course (Jonsson et al., 2010). 
The classical course of HFRS is divided into five distinct phases: (1) febrile, (2) 
hypotensive, (3) oliguric, (4) polyuric, and (5) convalescence. Variations among patients are 
however common, and this nicely structured division of clinical symptoms can be difficult to 
spot (Jonsson et al., 2010). It has been noted that cases of SEOV infection display a less 
obviously staged disease course than HTNV, and this has been proposed to act as a 
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contributing factor to the relatively higher levels of initial misdiagnosis of SEOV cases 
(Zhang et al., 2011).  
The incubation period for HFRS is generally two – three weeks. The febrile phase that 
follows is sudden and characterized by development of quite indistinct flu-like symptoms, 
including fever, headache, backache and nausea. Typical laboratory findings during the 
hypotensive phase include thrombocytopenia, leukocytosis and increased C-reactive 
protein levels. The oliguric phase2 accounts for approximately half of all HFRS related 
deaths, which is often due to disseminated intravascular coagulation causing multi organ 
failure or kidney failure. Restoration of renal function occurs during the polyuric phase, 
which leads on to convalescence and recovery (Jonsson et al., 2010).  
The usual incubation period for HPS lasts approximately two weeks.  The course of 
disease progression, as well as laboratory findings, mirrors those of HFRS. A short febrile 
prodrome characterized by general symptoms of malaise transitions to an often severe, 
acute disease. Once respiratory symptoms manifest patients often rapidly deteriorate, and 
respiratory failure and cardiogenic shock ensues (Jonsson et al., 2010).   
In addition to variability in severity, the nature of clinical symptoms in both HRFS and 
HPS cases can differ between patients. Unspecific symptoms other than renal failure or 
pulmonary insufficiency can often dominate the clinical picture, complicating the diagnostic 
process (Vaheri et al., 2008).  Furthermore, typical laboratory findings in orthohantavirus 
infections are also symptomatic of other sepsis-causing infections. Leptospirosis is, due to 
its similar clinical presentation and epidemiology, often a differential diagnosis in cases of 
orthohantavirus infection (Gamage et al., 2011; Goeijenbier et al., 2014). Leptospirosis is a 
globally distributed spirochetal zoonosis, with highest associated morbidity rates occurring 
in tropical areas. It is increasingly being recognized as a cause of undifferentiated febrile 
                                                          
2 Oliguria is defined as urine output of less than 400 ml / day 
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illness in these regions (Costa et al., 2015).  As is the case for orthohantaviral disease, 
leptospirosis spans a broad clinical spectrum ranging from a mild self-limiting influenza-like 
disease through to Weil’s disease, which is the most severe manifestation of leptospirosis. 
Weil’s disease is associated with AKI, liver failure and pulmonary haemorrhage (Forbes et 
al., 2012). In the UK leptospirosis is a rare, but potentially fatal disease. Domestic exposure 
is predominantly environmental, through contact with bacterially contaminated soil or 
water during leisure or occupational activities. Asymptomatic rats and small rodents seem 
to be the main reservoirs of leptospira in the UK, and cases of disease acquired form 
domestic rats have occurred in this country (Forbes et al., 2012).  
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1.4 Pathogenesis and biomarkers of disease severity 
The pathogenesis of orthohantavirus-induced disease is not fully understood; direct 
virally- mediated mechanisms, indirect immune-mediated mechanisms and host genetic 
factors, are all likely to be involved in the highly variable clinical course.  
Orthohantaviruses exert no cytopathic effects in vitro or in vivo, rendering the cause of 
increased vascular permeability obscure.  There is evidence that the virus itself can induce 
functional changes in infected cells. Alteration in endothelial cell barrier function was 
demonstrated in human kidney cells infected with HTNV or PUUV, as observed by a 
redistribution and reduction of ZO-1, a protein marker of cell tight junctions (Krautkramer 
et al., 2011). Orthohantavirus infection has also been shown to sensitize and prolong the 
hyper-permeability response of human umbilical vein endothelial cells stimulated with 
VEGF and low doses of TNF-α, with no discernible effect on cell viability (Niikura et al., 
2004; Gavrilovskaya et al., 2008). Furthermore, ANDV and HTNV displayed on endothelial 
cell surfaces seem to mediate the adherence of quiescent platelets to endothelial cells 
through binding of β3 integrin (Gavrilovskaya et al., 2010). Microarray analysis of mRNA 
transcription in endothelial cells following orthohantavirus infection has revealed infection-
specific alternations (Geimonen et al., 2002; Khaiboullina et al., 2004). Geimonen et al 
found that one day following infection with the nonpathogenic Prospect Hill several genes 
were specifically upregulated, whereas the pathogenic strains HTNV and New York-1 virus3 
did not cause notable change in the transcription of the same genes. At a later time point, 
four days post infection, the number of upregulated genes for all three strains were similar. 
Interestingly, the early response noted for Prospect Hill virus included several IFN-specific 
genes (Geimonen et al., 2002). Orthohantavirus growth in cells is reduced by IFN 
pretreatment or early IFN addition, and it seems that the cytoplasmic tail of Gn of some 
                                                          
3 New York virus has as of the ICTV report of 2016 on Bunyavirales, been 
removed as a separate orthohantaviral species. It has been advised it should be 
considered a strain of SNV.  
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orthohantaviruses regulates the early induction of IFN, thus permitting viral replication in 
endothelial cells (Alff et al., 2006). The Gn cytoplasmic tail of PHV does not possess this 
ability, indicating that early inhibition of cellular IFN responses by Gn plays a role in 
determining the pathogenic potential of orthohantaviruses (Alff et al., 2006; Matthys et al., 
2014). In support of this is the observation that interferon regulatory factor 3 translocation 
to the nucleus, which is necessary for transcription of type I IFNs, is greatly reduced in cells 
infected with pathogenic orthohantaviurses as compared to non-pathogenic species (Shim 
et al., 2011). However, the ability of viruses to regulate early IFN responses does not fully 
explain why some orthohantaviruses causes human disease and some do not. TULV, also 
non-pathogenic, is in contrast to PHV capable of both replicating in human endothelial cells 
and regulating early IFN responses through its GnCT, like pathogenic orthohantaviruses do 
(Gavrilovskaya et al., 2008; Matthys et al., 2011). 
A strong innate immune response is launched in response to orthohantavirus infection, 
evident as highly elevated serum levels of pro-inflammatory cytokines, such as TNF-α, 
interleukin (IL)-6, IL-2 and IL-8 in acute infection. As disease progresses towards 
convalescence the levels of these cytokines fall (Borges et al., 2008; Sadeghi et al., 2011; 
Korva et al., 2013). Conversely, the anti-inflammatory cytokine TGF-β has the opposite 
kinetics, with marked increases in the late and convalescent stages of disease compared to 
acute, and a protective effect has been associated with the expression of this cytokine 
(Borges et al., 2008; Sadeghi et al., 2011; Korva et al., 2013). In rats and deer mice elevated 
levels of TGF-β have been implicated in the maintenance of persistent infections 
(Easterbrook et al., 2007; Schountz et al., 2012). Interestingly, IL-10, another cytokine 
associated with anti-inflammatory activity, follows the kinetic profile of the above 
mentioned pro-inflammatory cytokines. It thus seems that any mitigating effect that might 
be expected in the presence of IL-10 is absent.  
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Due to their high levels in acute infection, along with their pro-inflammatory effector 
functions, the role of TNF-α and IL-6 as mediators of pathogenesis, and their utility as 
prognostic biomarkers, have been investigated. Sadeghi et al found higher levels of pro-
inflammatory cytokines including IL-6 and TNF-α associated with higher maximum serum 
creatinine in PUUV infection (Sadeghi et al., 2011). These results corroborated previous 
findings linking high levels of IL-6 with the severity of AKI measured by serum creatinine 
levels in NE (Outinen et al., 2010). Takala et al, however, did not see the association of 
systemic inflammation with elevated serum creatinine in PUUV infection, though they did 
correlate it with other parameters reflecting disease severity (Takala et al., 2000). In a fatal 
case of HFRS caused by DOBV, persistently elevated levels of TNF-α were highlighted to 
contrast with the kinetics of this cytokine in patients who recovered (Korva et al., 2013). 
This study also noted that DOBV patients generally had higher levels of pro-inflammatory 
cytokines compared to PUUV patients, reflecting a stronger inflammatory response in the 
generally more severe clinical course of DOBV infections. Both IL-6 and TNF-α were found 
to be elevated among HPS patients, but only IL-6 seemed to be associated with disease 
severity, based on the finding that serum levels of IL-6 in two fatal cases were much higher 
than among survivors (Borges et al., 2008).  A genetic polymorphism involved in TNF-α 
production was later implicated as a genetic risk factor for development of fulminant HPS 
following ARAV infection. A hyper-secretor variant of the TNF-α allele (TNF-α2), in which a 
guanine at position -308 is substituted for alanine, was far more frequent among HPS cases 
(38 %) compared to a group of seroconverted individuals with no reported history of HPS (7 
%). Furthermore, the TNF-α2 allele was less frequent among the healthy seroconverted 
group compared to a seronegative control group. In the latter group the frequency of TNF-
a2 heterozygous individuals was similar to that observed among HPS patients (Borges et al., 
2010). The study did not detect any link between TNF-α2 and disease severity, in 
accordance with the authors’ previous observations (Borges et al., 2008). The TNF-α2 allele 
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is in high linkage disequilibrium with the HLA-B8 DRB1*3 haplotype, a HLA haplotype that 
has been associated with an increased risk of disease development and severe clinical 
course of NE in Finnish populations (Mustonen et al., 1996; Mäkelä et al., 2002). A trend 
was noted for TNF-α2 carriers to experience severe NE, however it was found not to be an 
independent risk factor, and the association was put down to the TNF-α2 polymorphism 
being a passive component of the extended HLA-B8 DRB1*3 haplotype (Mäkelä et al., 
2002).  
Analyzing the humoral response during the clinical course has provided conflicting 
results. High levels of neutralizing antibodies in the acute stage were reported to be 
protective in SNV infection, as mild disease was associated with high titres and severe with 
low titres (Bharadwaj et al., 2000). However, Terajima et al did not detect any difference in 
titres of neutralizing antibody between severe and moderate SNV patients (Terajima and 
Ennis, 2011). On the other extreme of the severity scale, Lindkvist et al observed markedly 
varying levels in antibody titre among NE patients, which did not provide any indication on 
the severity of the clinical course (Lindkvist et al., 2008). In contrast, Petterson et al found 
low admission IgG titres to correlate with severe NE prognosis (Pettersson et al., 2014). In 
both these studies the characterization of the humoral response was solely quantitative.   
Thrombocytopenia and leukocytosis are both common clinical findings in the early 
stages of an acute orthohantavirus infection, and both parameters have been suggested to 
have value as predictive markers for severe kidney injury in NE and HFRS caused by PUUV 
and HTNV respectively (Rasche et al., 2004; Kim et al., 2007; Libraty et al., 2012; Wang et 
al., 2013). However, results reporting the causality of thrombocytopenia and leukocytosis 
with the severity of subsequent AKI are conflicting. Using univariate analysis Rasche et al 
associated an admission platelet count < 60x10^9/L in NE patients with development of 
subsequent severe AKI and requirement for hemodialysis.  With a far lower cut-off value of 
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< 33x10^9/L, Wang et al found thrombocytopenia, especially nadir counts, predictive of AKI 
among HTNV infected patients.  They also noted several other adverse outcomes, including 
death, to only occur among patients in the < 33x10^9/L group. Librarty et al, however, did 
not associate thrombocytopenia with severity of AKI in NE patients. In contrast, they 
reported a correlation with  maximum leukocyte count, which on average occurred two 
days before max serum creatinine was reached (Libraty et al., 2012). In HFRS caused by 
HTNV, Kim et al found leukocyte count at admission predictive of development of AKI in the 
oliguric phase. They noted that the maximum leukocyte count and minimum platelet count 
were more sensitive markers of oliguric AKI than admission values, but concluded they 
were not useful as predictive markers as they coincided too closely with the development 
of oliguria (Kim et al., 2007). The way in which thrombocytopenia and leukocytosis manifest 
in HFRS means individual measurements are likely to be highly variable and will depend on 
for example when the patient presents at hospital. Furthermore, the complexity of 
pathogenesis following orthohantavirus infection means the use of any single biomarker is 
unlikely to be informative, though combinations of general and specific markers might be 
useful in both aiding diagnosis and predicting prognosis (Knust et al., 2012).  For HFRS, early 
clinical markers that might aid in identifying patients that are likely to experience kidney 
failure would be valuable. In addition, as AKI is a complication that can arises from a variety 
of clinical conditions and effective treatment is reliant on treating the underlying cause, 
being able to differentiate AKI caused by infection as compared to e.g. diabetes, would be 
useful for the prompt initiation of appropriate treatment.  
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1.5 Diagnostic methods 
Diagnosis of HFRS and HPS are based on clinical presentation and serological 
confirmation of infection. Obtaining background information from the patients about e.g. 
travel history, occupation and leisure activities can be important aids in the diagnostic 
process, in addition to providing valuable information for surveillance purposes.  
The diagnostic methods in use for Hantavirus infection are various serological assays, 
namely commercial or in-house immunofluorescence assays (IFAs), immunoblots and 
enzyme immunoassays. These methods are all based on indirect confirmation of infection 
by the detection of hantavirus-specific IgM and/or IgG in patient sera. In the case of IgG 
detection, a ≥ four-fold increase in titre from serially obtained samples are required for 
confirmation of acute infection, as simply the presence of IgG in serum could indicate a 
previously resolved infection. IFA, based on acetone-fixed hantavirus infected cells, was the 
first modality in use for diagnosis of HFRS in Europe and Asia (Vaheri et al., 2008). In the 
case of NE diagnosis by IFA a caveat to the method was the finding that due to the early 
antibody response and rapid seroconversion, many patients presented with already high, 
stable levels of IgG in the acute phase, and seroconversion or a ≥ four-fold increase in 
antibody titres from paired sera was not always possible to demonstrate (Niklasson and 
Kjelsson, 1988). In an effort to counter these complications, Finnish investigators developed 
an alternative method for discriminating between acute and previously acquired infections 
of PUUV. Fluorescence typing is based on a shift in functional affinity of IgG towards viral 
proteins during the course of infection, which can be visualized by IFA as characteristic 
fluorescence patterns corresponding to acute or old immunity. A granular staining pattern 
is associated with acute infection, while diffuse staining develops gradually with old 
immunity (figure 1.4). This method has allowed for IgG-based diagnosis from a single 
sample (Hedman et al., 1991; Kallio-Kokko et al., 2001).  
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Due to the safety aspects involved with handling whole live virus, the diagnostic 
antigens currently in use are most commonly derived from recombinant DNA methods 
(Jonsson et al., 2010). Though antibodies targeting all three structural proteins develop in 
the course of in vivo infection the nature of the N-targeted response and characteristics of 
the N protein makes it highly suitable as a diagnostic tool (Jenison et al., 1994; Yoshimatsu 
et al., 1996; Kallio-Kokko et al., 2001; Lindkvist et al., 2008). Recombinant N protein 
produced in various expression systems have been widely applied as diagnostic antigens 
(table 4) (Wang et al., 1993; Vapalahti et al., 1996; Billecocq et al., 2003; Meisel et al., 
2006). It is important to note that the type of expression system used impacts on the 
antigenicity of the protein being expressed. For instance, if glycosylation is required, an E. 
coli system should be avoided, as this system is not capable of glycosylation. For 
orthohantavirus N protein expression, lack of glycosylation is not an issue, as the protein is 
not glycosylated (Hepojoki et al., 2012). However, some antigenic sites on the N protein are 
conformation dependent, and protein conformation can also be affected by the expression 
system. It was observed that linear, group-specific epitopes on the HNTV N protein were 
recognised equally using both a Baculovirus (insect) and E. coli (bacteria) expression 
system, however sero-specific antigens on the HNTV N protein were only detected using 
the Baculovirus system (Yoshimatsu et al., 1996).  This discrepancy was likely due to the 
protein being expressed as a monomer rather than a multimer when using E. coli 
(Yoshimatsu et al., 1996; Yoshimatsu and Arikawa, 2014). Point-of care tests for PUUV and 
DOBV/HNTV are commercially available (Reagena, Toivala, Finland). These tests detect N 
protein-reactive IgM in acute serum, plasma or fingertip blood with sensitivities and 
specificities > 95 %.  Test formats can be species specific or multiparametric, i.e. 
simultaneous screening for two or more hantavirus species (Hujakka et al., 2001; Lederer et 
al., 2013). The advantage of the latter approach is removing the risk of missing infections 
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caused by viruses from across the major phylogenic clusters, which is especially important 
to consider in areas of co-circulation. It is also useful when diagnosing imported cases 
where disease is due to a non-endemic species, or in cases of suspected infection in an area 
where hantavirus-infections are emerging and a local species remains unknown.  
In 2012 the European Network for Diagnostics of Imported Viral Diseases organized an 
external quality assurance of European laboratories performing diagnosis of Hantavirus 
infection (Escadafal et al., 2012). In all, 27 labs from 20 European countries participated. 
Laboratories were evaluated on assay sensitivity, i.e. correct detection of IgG and IgM 
antibodies, and specificity, i.e. identification of the infecting virus. The quality assurance 
concluded that with regards to sensitivity, there was little qualitative difference between 
the diagnostic modalities in use. However, it was noted that performance differed between 
laboratories using the same techniques, highlighting a need for standardization of assay 
protocols. In the case of specificity, half of the participating laboratories did not include 
specification of species type as part of their test results, as they only tested for the 
presence or absence of antibodies.   
Identification of the infecting virus type is difficult to achieve by the conventional 
serological assays, as the immune response in the acute phase targets the highly cross-
reactive amino-terminal region of the N protein (Jenison et al., 1994; Yoshimatsu et al., 
1996; Lindkvist et al., 2008). Endpoint titration, i.e. determination of the reciprocal of the 
highest serial dilution that retains measurable antibody activity, can be informative for 
differentiating orthohantaviruses from different phylogenic clusters, though with more 
closely related species such as SEOV, HTNV and DOBV results often remain indeterminate 
(table 5) (Lederer et al., 2013).   
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Table 4. Expression systems used to produce recombinant N protein for diagnostic 
application 
 
 
 
 
Expression system Antigen Reactivity Reference 
E. coli N protein; PUUV, 
HTNV, SEOV 
Rat antisera (isotype 
not specified) 
(Wang et al., 1993) 
Baculovirus N protein; PUUV Human antisera 
(IgM/IgG) 
(Vapalahti et al., 
1996) 
Saccharomyces 
cerevisiae 
N protein; PUUV, 
DOBV 
Human antisera 
(IgG/IgA) 
(Meisel et al., 2006) 
BHK-21 N protein; PUUV Human antisera 
(IgM/IgG) 
(Billecocq et al., 
2003) 
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Table 5. 4 sera obtained from a serosurveillance study conducted by Public Health England in the period October 2013 – June 2014* that were positive 
for hantavirus-specific antibodies by a multiparametric IFA (Euroimmune, Lubeck, Germany) 
 
* personal correspondence 
**The infecting strain could be typed for three of four sera samples based on endpoint reactivity, while sample RP13000572 remained indeterminate at 
a 1:10,000 dilution.
Serum no. 1:100 1:1000 1:10,000 
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RP13000478 + - + + ++ + - - - - + - - - - - - - 
RP13000571 ++ + +++ +++ +++ ++ ++ - ++ ++ + + - - + - - - 
RP13000572** +++ ++ +++ +++ +++ +++ +++ + +++ ++ + + ++ - ++ + + - 
RP13000580 ++ - +++ + + - + - ++ + + - - - + - - - 
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The most sensitive method, and the gold standard for serotyping of orthohantaviruses, 
is the neutralisation assay, preferably on sera obtained at least one month post infection, 
as the neutralising antibody response of acute sera remains cross reactive (Lundkvist et al., 
1997). In addition to the necessity of using convalescent blood, the assay is laborious and 
slow, and must be conducted at biosafety level three facilities making it unsuitable for 
routine diagnostic use. An attractive alternative to the neutralization assay is the use of 
vesicular stomatitis virus (VSV) as a vector for the expression of the orthohantavirus 
glycoproteins. This so-called pseudovirus system consists of a replication-deficient VSV 
core, in which the VSV envelope glycoprotein has been replaced with a fluorescent reporter 
protein (VSVΔG). This system efficiently incorporates envelope proteins of foreign viruses 
(Ogino et al., 2003). It has been used to express Gn and Gc of HTNV, SEOV, PUUV and 
ANDV, and though neutralizing titres generally are somewhat lower, it has produced 
comparable results in detection of neutralizing antibodies and ability for viral 
differentiation to the conventional neutralization assay with native virus (Ogino et al., 2003; 
Ray et al., 2010; Higa et al., 2012). The method is faster and safer than the latter, with 
results obtained within a few days and circumventing the need for working in a 
containment laboratory. A proposed strategy for hantavirus diagnosis that is based on an 
initial screening utilizing the cross-reactive amino-terminal part of the N protein of 
pathogenic viral species spanning the three major rodent-associated phylogenic clusters, 
followed by serotyping with truncated N protein antigens retaining the sero-specific 
carboxyl-termini has been suggested as an alternative to the neutralization assay 
(Yoshimatsu and Arikawa, 2014). 
The level of detectable viremia varies greatly in orthohantavirus infections. Generally, 
species associated with severe disease lead to higher viral loads and prolonged measurable 
viremia than do moderate- and mild disease causing species (Korva et al., 2013). The viral 
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genome is detectable prior to the onset of clinical symptoms and the development of IgM 
antibodies, and an early high viral load seems to be associated with a severe prognosis 
(Evander et al., 2007; Ferrés et al., 2007; Korva et al., 2013). In all orthohantavirus 
infections, viremia declines rapidly with disease progression, and the earlier a clinical 
sample is obtained the greater the chances are of successfully extracting genetic material 
(Korva et al., 2013). RT-PCR has been successfully developed for both high and low 
virulence species, and is a valuable tool for early and rapid detection and identification of 
the infecting species, as well as providing information on viral load Importantly however, 
due to the often short and fluctuating levels of viremia seen with hantavirus infections, 
results of a PCR cannot be considered confirmative in a diagnostic setting and must be used 
in conjunction with other tests (Schilling et al., 2007; Oldal et al., 2014).  
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1.6 Clinical proteomics  
Proteomics is the study of proteins in a biological system, i.e. using state-of-the-art 
analytical tools to identify and quantify proteins, determine their structure and function or 
investigate protein interactions (Van Oudenhove and Devreese, 2013). A proteome can be 
defined as all expressed proteins, including post-translational modifications, produced by a 
cell or tissue. Unlike the genome, which remains essentially unchanged over time, the 
proteome is dynamic, and what is expressed varies depending on the specific condition the 
cell or tissue is experiencing at the time of investigation. The constituents of a proteome 
are also location specific, again in contrast to the genome, which is the same in any 
nucleated cell of an organism (Vizcaion, 2015). The field of clinical proteomics aims to 
answer questions of clinical significance using proteomic methods.   
The plasma proteome comprises the total expressed protein content of blood plasma. 
This is a highly heterogenic collection of proteins including the classical blood resident 
proteins that exert their function in plasma, tissue resident proteins that leak into the 
circulation, and proteins originating from commensal or infecting organisms (Anderson and 
Anderson, 2002). Plasma is the fluid fraction of whole blood which remains when platelets 
and red and white blood cells are removed. Plasma is collected in the presence of an anti-
coagulant, e.g.  ethylenediamineteraacetic acid (EDTA), heparin or citrate to inhibit clotting. 
When plasma is allowed to clot the liquid fraction remaining is referred to as serum. The 
content of the serum proteome is comparable to the plasma proteome with the exception 
of most clotting factors (Issaq et al., 2007). While the majority of the protein content of 
plasma and serum overlap, a comparison of EDTA plasma, heparin plasma and serum 
revealed that about 10 % of the total protein of each fraction was unique (Lan et al., 2018). 
In addition to discrepancies between detectable protein content, the absolute levels of 
many proteins differ in serum and plasma, and in plasmas collected with different anti-
coagulants, from the same individual (Tvedt et al., 2015). It is therefore important that 
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quantitative comparisons between serum and plasma, or plasma collected using different 
anti-coagulants, are avoided. Since the turn of the century, through the field of proteomics, 
thousands of proteins have been detected and identified in blood (Nanjappa et al., 2014). 
The dynamic range in concentration of the plasma and serum proteomes span more than 
10 orders of magnitude between albumin, the most abundant protein, and the rarest 
proteins that are clinically measurable (Anderson and Anderson 2002). This far exceeds the 
range that is concurrently measurable by current proteomic methods (Patel et al., 2011). In 
addition to its large dynamic range, extensive post-translational modifications and intra- 
and inter-individual variability of proteins contributes to the complexity of the proteomes, 
making both plasma and serum complicated samples to analyse (Nanjappa et al., 2014). 
Nonetheless, blood is relatively easy to obtain, in contrast to many other clinical specimens, 
and it is therefore a very important and much analyzed sample in clinical settings. 
Combined with the nature of its constituent proteins, this makes blood an attractive, and 
potentially rich source of biomarkers for various disease states (Zhang et al., 2007). Despite 
the difficulties faced with proteomic analysis, the ongoing efforts in optimizing workflows, 
and the identification of several potential plasma and serum biomarkers for a range of 
pathologies highlights the clinical importance of blood (Bauer et al., 2006; Kumar et al., 
2012; Dagonnier et al., 2017). Knowledge of relative and absolute concentrations of blood 
proteins in clinical samples can prove useful for monitoring and diagnosing disease, and an 
essential aspect of clinical proteomics is comparing the relative quantity of blood proteins 
in healthy and diseased conditions (Nanjappa et al., 2014). Proteomics has been used to 
investigate outcome in HPS caused by SNV. A study identified the protein plasminogen 
activator inhibitor 1, elevated expression of which is associated with impaired fibrinolytic 
function and thrombosis, as a potential prognostic marker for fatal outcome (Bondu et al., 
2015). Interestingly, the plasminogen activator inhibitor 1 gene has also been linked to 
disease severity among patients with NE (Laine et al., 2012).  
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In contrast to other conventional methods for identification and quantification of 
proteins such as western blot and ELISA, mass spectrometry is a high throughput method 
that allows for simultaneous quantification and identification of hundreds of proteins in a 
single experiment, with no need for a priori knowledge about specific proteins of interest 
(Nanjappa et al., 2014). Mass spectrometers measure the molecular weight of a sample, or 
more specifically, the mass-to-charge (m/z) ratio of charged ions. The basic components of 
a mass spectrometer are; an ion source that ionizes sample molecules, an analyzer that 
uses electromagnetic fields to separates ions based on their mass, and a detector that 
records the presence of ions. The results are plotted as a mass spectrum with m/z on the x-
axis and ion intensity on the y-axis, which, when searched against established databases 
predicts the identity of peptides and proteins in a sample (figure 1.4) (CE et al., 2010).  
 
Figure 1.4. The basic components of a mass spectrometer. Figure modified from 
(theforensicslibrary n.d)   
A commonly used strategy of mass spectrometry-based proteomics is the combination 
of 2D gel electrophoresis and mass spectrometry. With this method, proteins in a biological 
sample are separated by two gel-based techniques, firstly by charge using isoelectric 
focusing and secondly by molecular weight using SDS-PAGE.  The gel is then stained and 
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proteins are quantified by determining the staining intensities of selected protein spots. 
Spots of interest are excised from the gel, digested into peptides, and the protein(s) is/are 
identified by mass spectrometery. As an alternative to gel-based approaches, gel-free 
methods can be used. In the latter proteins are directly digested in solution prior to a 
separation step. The peptides produced by digestion are subsequently separated by liquid 
chromatography and finally analysed by mass spectrometry ( van Oudenhove et al 2013).  
Relative quantification of proteins can be achieved using either labelled or label-free 
strategies. A labelled approach entails labeling samples from different conditions with 
stable isotopes. This can be achieved either through metabolic labeling, where labels are 
incorporated into proteins by growing samples on media in which an element has been 
replaced with its corresponding stable isotope, or through chemical labeling, where, in an 
additional step following proteolysis, each sample is labeled with an unique isobaric tag. For 
the label-free approach protein abundance can be determined by spectral counting, a 
method in which the number of fragment-ion spectra acquired for peptides of a specific 
protein is counted and compared between samples. Alternatively it can be determined by 
measurement and comparison of ion intensities, which means comparing the 
chromatographic peak areas of corresponding peptides from different samples (figure 1.5) 
(Megger et al., 2013). Both labelled and label-free approaches have been utilized to 
investigate serum proteome profiles of infectious diseases (Patel et al., 2011; Kumar et al., 
2012).   
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 Figure 1.5. Relative quantification of proteins by label-free proteomics based on (left) 
spectral counting and (right) peptide-ion intensity, reprinted from Biochimica et Biophysica 
Acta (BBA) - Proteins and Proteomics, Megger et al, Label-free quantification in clinical 
proteomics, pp: 1581-1590, copyright (2013) with permission for reuse in a 
thesis/dissertation from Elsevier (license number: 4461341371341) (Megger et al., 2013). 
With spectral counting the peptide and protein abundance is estimated by the number of 
acquired peptide spectrum matches, whereas quantification by peptide-ion intensity is 
achieved by measuring and comparing the chromatographic peak areas of corresponding 
peptides. In this schematic the protein abundance is highest in state A. MS; mass 
spectrometry, MS/MS; tandem mass spectrometry. 
A major challenge for successful quantitative proteomics analysis is the requirement for 
reproducibility while performing a multi-step experimental workflow in which there is 
ample opportunity for introduction of error and bias. The different approaches all have 
their advantages and limitations. A major advantage of the 2D gel approach is the ability to 
visualize different isoforms of a protein, however the resolution of the method is relatively 
low (Lilley, 2015). When comparing label-free and labeled approaches, the depth of 
proteome coverage achieved by the former is greater. However, as samples are pooled in 
the latter, the reproducibility of labelled methods are more easily controlled (Li et al., 2012; 
Megger et al., 2013, 2014). Optimally, though not necessarily practically or financially 
feasible, using more than one approach would be beneficial, as comparative studies have 
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shown there to be significant complementarity between methods in regards to both 
proteins identified and the their relative quantities (Tian et al., 2009; Collier et al., 2011; 
Merl et al., 2012) 
  
  60 
Aims 
For this study label-free proteomics was utilized to investigate biomarkers of 
orthohantavirus infection and HFRS pathology in clinical human sera, and to study the 
cellular interactome of recombinant SEOV Cherwell glycoproteins in a human kidney cell 
line. 
Biomarkers of infection and pathology were explored by;  
1. Directly comparing the proteomes of a group of orthohantavirus-infected sera with 
non-infected sera to investigate differences in the abundance of specific proteins 
between the two groups that might be reflective of infection state. 
2. Analysing a longitudal set of serum samples from a single individual including a 
seronegative baseline, samples obtained during active HFRS, and a convalescent 
sample, to identify proteins with abundance changes that correlate with disease, 
thus shedding light on mechanisms involved in the pathology of HFRS.  
The interactome of SEOV Cherwell glycoproteins was analysed with the aim of 
discovering host proteins that associate with the viral proteins, thus establishing host 
factors that could be targeted to disrupt the function of the viral glycoproteins, and in 
extension inhibit the completion of the viral life-cycle.  
 
 
.   
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Chapter 2: Materials and methods 
2.1 Samples 
2.1.1 Ethical approval 
Ethical approval for use of residual diagnostic sera of acute orthohantavirus and acute 
leptospirosis was obtained from the NRESComittee East-Midlands HRA (appendix A).  
2.1.2 Human serum samples 
All human sera were provided by the Rare and Imported Pathogens Laboratory (RIPL), 
Public Health England (PHE), Porton Down. As a precautionary procedure all samples were 
heat-treated at 60 °C for 15 minutes prior to any experimental analysis, so as to inactivate 
any possible viral residue. Convalescent orthohantavirus samples and orthohantavirus-
seronegative samples were surplus sera previously obtained by PHE during a 2013-2014 
serosurveillance study done to ascertain the prevalence of orthohantavirus infections in 
presumed at-risk groups in the UK. Acute orthohantavirus infected samples and acute 
leptospirosis infected samples were residual archived sera originally received by RIPL for 
diagnostic purposes.  
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2.2. Immunodepletion of sera using spin columns 
Sera were depleted of the top 12 most highly abundant serum proteins (table 6) 
using a commercial immunodepletion kit (Pierce™ top 12 abundant protein depletion spin 
columns (Thermo Fisher Scientific)) according to the manufacturers’ protocol. 10µl of 
sample was added to the depletion spin column and incubated with end-over-end mixing 
for one hour. The eluate contained the depleted sample in a final volume of 500µl. For each 
sample a matched undepleted control (crude) was prepared as a 1:50 dilution in a final 
volume of 500µl dH2O.  Processed samples were kept at -80°C until required for 
downstream analysis. 
Table 6. Proteins depleted by Pierce™ Top 12 Abundant Protein Depletion Spin 
Columns. 
 
 
 
 
 
 
 
 
 
  
Protein 
α 1-acid glycoprotein 
α 1-antitrypsin 
α 2 -macroglubulin 
Abumin 
Apolipoprotien a-I 
Apolipoprotin A-II 
Fibrinogen 
Haptoglobin 
IgA 
IgG 
IgM 
Transferrin 
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2.3 BCA procedure for determining protein concentration 
Determination of serum protein concentrations were done by the BCA method, using a 
commercial kit following the manufacturer’s 96 well microplate protocol (Thermo Fisher 
Scientific).  25µl sample was transferred to each well and mixed with 200µl assay standard 
reagent (50:1 solution of reagents A: B) and incubated at 37°C for 30 minutes. Samples 
were measured in duplicate as undiluted (1:50 working concentration), 1:5 and 1:10. 
Absorbance was measured at 570nm on a microplate reader (TECAN).  Bovine serum 
albumin (BSA) provided in the kit was serially diluted in H2O and used to make a standard 
curve ranging from 0 to 2000µg/µl to which the unknown samples could be compared. 
Protein concentrations were calculated accordingly; 
(([undiluted + undiluted] /2) + ([1:5 + 1:5]/2) + ([1:10+1:10]/2) /3) = X µg/ml. 
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2.4 SDS-PAGE  
2.4.1 SDS electrophoresis 
Each sample was diluted to the appropriate protein concentration for antigen detection 
in dH2O. Proteins were denatured by addition of 5x SDS buffer to the sample mixture and 
heat-treated at 95°C for 10 minutes. Samples were then loaded on to a Tris-acrylamide gel 
of an appropriate acrylamide percentage for the required molecular weight resolution 
(table 7). The gel was immersed in 1x running buffer (0.25M tris-base / 1.92M glycine / 0.5 
% (w/v) SDS), and set to run at 150 V  - 200 V, 400mA until optimal resolution of the protein 
ladder was (Colour protein standard, Broad-range, 11-245 kDa P7712, New England Biolabs) 
achieved (45 – 90 minutes).  
Table 7. Recipe for tris-acrylamide SDS resolving and stacking gels 
Resolving Gel (10 ml) Stacking Gel (5 ml) 
% Gel 15% 12% 10% 7.5% % Gel 5% 
30% Acrylamide  5 ml 4 ml 3.3 ml 2.5 30 % Acrylamide  830 μl  
1.5M Tris-HCl 
pH8.8 
2.5 ml 2.5ml 2.5ml 2.5ml 1M Tris-HCl 
pH6.8 
630 μl 
H2O 2.3 ml 3.3 ml 4 ml 4.8 ml H2O 3.4 ml 
10% (w/v) SDS 100 μl 100µl 100µl 100µl 10% (w/v) SDS 50 μl 
10% (w/v) APS 100 μl 100µl 100µl 100µl 10% (w/v) APS 50 μl 
TEMED 10 μl 10µl 10µl 1 10µl TEMED 5 μl 
Resolution 
(Protein kDa) 
10-40 20-100 30-100 25-200 
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2.4.2 Sypro Ruby whole protein gel stain 
Whole protein visualisation of SDS-PAGE gels were done with SYPRO Ruby protein gel 
stain (Molecular probes, Invitrogen, cat: S-12000). Following SDS-PAGE the gel was 
incubated in fix solution (50 % (v/v) methanol / 7 % (v/v) acetic acid) for 2 X 30 minutes at 
room temperature with shaking.  The gel was then incubated in the dark with SYPRO Ruby 
gel stain overnight at room temperature. The following day the Sypro Ruby gel stain was 
discarded and the gel was incubated in the dark in wash solution (10 % (v/v) methanol / 7 % 
(v/v) acetic acid) for 30 minutes at room temperature with shaking. The gel was then rinsed 
in ddH20 for 2 X 5 minutes. The gel was imaged at 488 nm on the ChemiDoc Touch Imaging 
System (BioRad), or on a GENEFLASH imager (Syngene bio-imaging).  
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2.5 Western blotting 
2.5.1 Semi-dry blot procedure 
PVDF membranes (Immobilon® –P, cat.no; IPVH00010) with 0.45 um pore size, were 
activated in 100 % methanol for 30 – 60 seconds before being equilibrated in Towbin buffer 
(25mM tris-base / 192 mM glycine / 20 % (v/v) methanol). Two filter papers and the SDS-
PAGE gel itself were also soaked in Towbin buffer.  One square of filter paper was placed on 
the surface of the semi-dry blotter, with the membrane and SDS-PAGE gel placed on top. 
Finally, the second filter paper was placed on top of the gel, and the sandwich was soaked 
with Towbin buffer. The transfer was run at: 10V, 400mA, 30 minutes or 30V, 45mA, 90 
minutes up to 2 small gels, or 15V, 400mA, 60 minutes for three small gels or one large gel.  
After transfer the membrane was blocked in 5 % skimmed milk or 10 % skimmed milk for 
one hour at room temperature with shaking, or subjected to reversible whole protein 
staining as detailed in section 2.5.3 prior to blocking. Immobilized proteins were detected 
with the primary antibodies listed in table 9.  Primary antibodies were diluted (see table 9 
for antibody – specific dilutions) in TBS-T (0.25M Tris-base / 1.5M NaCl / 10 % (v/v) Tween 
20). The membranes were incubated with approximately 5ml primary antibody solution 
overnight at 4°C with shaking. Following primary antibody incubation, the membrane was 
washed 3 X 5 minutes in TBS-T. Primary antibodies were detected with HRP-conjugated 
secondary antibodies (table 10) diluted 1:1000 in 5 % skimmed milk TBS-T or 2.5 % 
skimmed milk TBS-T. The membrane was incubated with the secondary antibody for one 
hour a room temperature with shaking. Before imaging the membrane was washed 3 X 5 
minutes (when using mouse secondary antibody) or 4 X 5 minutes (when using rabbit 
secondary antibody) in TBS-T. Secondary antibodies were detected using enhanced 
chemiluminescence (ECL) and visualised on the ChemiDoc Touch Imaging System (BioRad). 
Relative densities of visualised bands were determined with FIJI  (Schindelin et al., 2012; 
Rueden et al., 2017) or with ImageLab 5.2.1 (BioRad).   
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2.5.2 Dry-blot procedure 
For the dry-blot procedure the Iblot® System (Thermo Fisher Scientific) was used 
according to the manufacturers’ protocol. The iBLOT Transfer Stack (Thermo Fisher 
Scientific) was assembled on the iBlot gel transfer device, with a BoltTM 4 %-12% Bis-Tris 
Plus pre-cast gel (Life Technologies), and pre-soaked filter paper was placed between the 
bottom and top stacks. The transfer was run at 20V for seven minutes. The nitrocellulose 
membrane was blocked for one hour with Blotto® (5 % (w/v) non-fat powdered milk / 
25mM Tris/ 150mM NaCl / pH 7.4 / 0.01 % Antifoam A / Kathon® anti-microbial agent, 
Thermo Fisher Scientific) at room temperature with shaking. The membrane was incubated 
overnight at 4 °C with primary antibody diluted (see table 9 for antibody-specific for 
dilutions) in TBS-T. Following overnight incubation the membrane was washed 3 X 5 
minutes in TBS-T, before being incubate with HRP-conjugated secondary antibody diluted 
1:1000 in Blotto®. Following incubation with the secondary antibody the membrane was 
washed 3 x 5 minutes in TBS-T. The secondary antibody was detected with ECL, and 
visualised on a G: box (Syngene). Relative densities of visualised bands were determined 
with FIJI / ImageJ2 (Schindelin et al., 2012; Rueden et al., 2017)or with ImageLab 5.2.1 
(BioRad).   
2.5.3 SYPRO Ruby blot stain 
To determine whole protein intensities, for use as normalisation reference and loading 
control, blots were reversibly stained with SYPRO Ruby blot stain. After semi-dry transfer 
the PVDF membrane was allowed to dry completely, before being activated in 100 % 
methanol for a few seconds. The membrane was then left to incubate in wash solution (10 
% methanol (v/v) / 7 % acetic acid (v/v)) for 15 minutes at room temperature. The 
membrane was rinsed in dH20 4 X 5 minutes, before being incubated in Sypro Ruby Protein 
Blot Stain (Bio Rad, cat: 1703127) for 15 minutes at room temperature, in a dark container. 
The membrane was rinsed in dH20 3 X 1 minute to remove excess stain, before being 
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visualised with the ChemiDoc iTouch imaging System at 488 nm. Following visualisation, the 
semi-dry western blot protocol was continued as detailed in section 2.5.1.  
2.5.4 Strip-blot procedure 
When probing a membrane for more than one protein, the membrane would be 
stripped after initial antibody detection using a Chemicon® Blot Restore Membrane 
Rejuvination Kit (Millipore, cat: 2520) according to the manufacturers’ protocol. Following 
visualisation of the secondary antibody used for the first antibody detection, the membrane 
was submerged in 10ml blot restore solution A and incubated on a shaker for 10 minutes at 
room temperature. Solution A was then discarded, and the membrane was submerged in 
10ml blot restore solution B and incubated on a shaker for 15 minutes at room 
temperature. Solution B was discarded, and the blot was blocked for 2 X 5 minutes in 5 % 
(w/v) skimmed milk TBS-T or 10 % (w/v) skimmed milk TBS-T, with shaking at room 
temperature. After blocking, the membrane was incubated with 5ml primary antibody at 
4°C, overnight with shaking. The membrane was then washed 3 X 5 minutes with TBS-T and 
incubated one hour with 5ml secondary antibody at room temperature with shaking. The 
blot was washed 3 or 4 X 5 minutes with TBS-T, before the secondary antibody was 
detected with ECL, and protein bands were visualised with the ChemiDoc Touch Imager 
System (Bio-Rad).  
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2.6 ELISA 
Detection and quantitation of galectin-3-binding protein was done using the Human 
90K/Mac-2BP Platinum sandwich ELISA (BM234 – Affymetrix eBiosciences) according to the 
manufactures protocol. Standards, ranging 200.0ng/ml – 12.5ng/ml, were provided ready 
for use in the kit. All buffers were brought to room temperature before beginning the 
assay. Samples were diluted 1:100 in the sample diluent (1x) provided in the kit. 100µl 
standard or sample was added to the wells in duplicate, blank wells contained 100µl sample 
diluent only.  After loading, the plate was incubated at 37°C for 45 minutes without 
shaking4. Following incubation wells were washed four times with the wash buffer (1x) 
provided in the kit. 100µl HRP-conjugate was then added to each well, and the plate 
incubated a second time at 37°C for 45 minutes, without shaking. Wells were washed four 
times and 100µl TMB substrate solution added to all wells. The plate was incubated at 
room temperature for 15 minutes protected from light. The enzyme reaction was stopped 
after 15 minutes by adding 100µl Stop solution to each well. Absorbance was measured at 
450nm on an Infinite® F50 (Tecan) microplate reader coupled with MagellanTM software, or 
a GloMax microplate reader (Promega).  
 
                                                          
4 OD values obtained without shaking may be lower than indicated in the manufacturers 
protocol but are still valid. 
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2.7 Mass spectrometry 
The steps described in the following section (section 2.7) were kindly done by Dr. Stuart 
Armstrong, Department of Infection Biology, Institute of Infection and Global Health, 
University of Liverpool.  
2.7.1 Tryptic digestion 
Depleted samples were precipitated by addition of an equal volume of ice-cold 30 % 
(w/v) trichloroacetic acid in acetone with incubation at 20°C for two hours. Samples were 
centrifuged at 12,000g for 10 minutes (4⁰C) to pellet proteins. Pellets were washed three 
times with ice-cold acetone and allowed to air dry. Protein pellets were re-suspended in 
50mM ammonium bicarbonate, 0.1 % (w/v) RapiGest SF (Waters). Samples were heated at 
80°C for 10 min, reduced with 3mM DTT at 60°C for 10 minutes, cooled, then alkylated with 
9mM iodoacetamide (Sigma Aldrich) for 30 minutes (room temperature) protected from 
light; all steps were performed with intermittent vortex-mixing. Proteomic-grade trypsin 
(Sigma Aldrich) was added at a protein: trypsin ratio of 50:1 and incubated at 37°C 
overnight. To remove RapiGest SF, the samples were precipitated using 1% (v/v) 
trifluoroacetic acid at 37°C for two hours and centrifuged at 12,000g for one hour (4°C).  
2.7.2 NanoLC MS ESI MS/MS analysis 
Peptides were analysed by on-line nanoflow LC using the Thermo EASY-nLC 1000 LC 
system (Thermo Fisher Scientific) coupled with Q-Exactive mass spectrometer (Thermo 
Fisher Scientific). Samples were loaded on a 50cm Easy-Spray column with an internal 
diameter of 75µm, packed with 2µm C18 particles, fused to a silica nano-electrospray 
emitter (Thermo Fisher Scientific). The column was operated at a constant temperature of 
35°C. Chromatography was performed with a buffer system consisting of 0.1 % formic acid 
(buffer A) and 80 % acetonitrile in 0.1 % formic acid (buffer B). The peptides were separated 
by a linear gradient of 3.8 % – 50 % buffer B over 157 min at a flow rate of 300nl/min. The 
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Q-Exactive was operated in data-dependent mode with survey scans acquired at a 
resolution of 70,000. Up to the top 10 most abundant isotope patterns with charge states 
+2, +3 and/or +4 from the survey scan were selected with an isolation window of 2.0Th and 
fragmented by higher energy collisional dissociation with normalized collision energies of 
30. The maximum ion injection times for the survey scan and the MS/MS scans were 250 
and 100ms, respectively, and the ion target value was set to 1E6 for survey scans and 1E4 
for the MS/MS scans. Repetitive sequencing of peptides was minimized through dynamic 
exclusion of the sequenced peptides for 20s. 
2.7.3 Protein Identification and Quantification 
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, Nonlinear 
Dynamics). Peaks were picked by the software using default settings and filtered to include 
only peaks with a charge state between +2 and +7. Spectral data were converted into mgf 
files with Progenesis LC–MS and exported for peptide identification using the Mascot 
(version 2.3.02, Matrix Science) search engine. Tandem MS data were searched against 
translated ORFs from the human genome (Uniprot release 2015_02; 20,367 sequences; 
11,398,732 residues) and the Hanta (Seoul) genome (NCBI Refseq 3 sequences; 3,713 
residues). The search parameters were as follows: precursor mass tolerance was set to 10 
ppm and fragment mass tolerance was set to 0.01Da. Two missed tryptic cleavages were 
permitted. Carbamidomethylation (cysteine) was set as a fixed modification and oxidation 
(methionine) set as variable modification. Mascot search results were further validated 
using the machine learning algorithm Percolator embedded within Mascot. The Mascot 
decoy database function was utilised and the false discovery rate was <1%, while individual 
percolator ion scores >13 indicated identity or extensive homology (p <0.05). Mascot search 
results were imported into Progenesis LC–MS as XML files. Relative quantification using 
non- conflicting peptides was calculated by Progenesis.  
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2.8 Data analysis 
Abundance was log2-transformed. Proteins were identified based on detection of at 
least two unique peptides, and differential abundances were considered significant if there 
was a minimum two-fold difference (1 log2) in abundance between comparative groups, 
and a q-value < 0.05. For clustering of longitudal mass spectrometry data the software 
GProX v.1.1.16 (Rigbolt et al., 2011) was used. Parameters for clustering were; minimum 
fold change ≥ 2, unique peptides ≥ 2 and q-value ≤ 0.05.  Functional annotation of identified 
proteins was done using Gene Ontology (GO) terms. Protein interactions and protein 
networks were determined using STRING© v.10.5 (Szklarczyk et al., 2017) and Reactome© 
(Croft et al., no date; Fabregat et al., 2016).  Profile contrasting was kindly done by 
Yongxiang Fang at the Centre for Genomic Research at the University of Liverpool. 
2.9 Statistical analysis  
Statistical analysis was done using SigmaPlot 13.0 or Excel for Mac 14.7.6. Significance 
was determined by t-test for parametric and Mann Whitney U test on Ranks for non-
parametric parameters. Kruskal-Wallis ANOVA on ranks was used to calculate significance 
for ELISA (G3BP). Determination of the correlation of protein abundances between 
individual healthy control samples was determined by calculating the Spearman’s Rank 
Correlation Coefficient.   P < 0.05 was considered significant findings.  
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2.10 Plasmids 
Vectors containing the full-length M segment of Seoul orthohantavirus, strain Cherwell 
(GenBank accession; KM948593.1) were produced by GeneArt Gene Synthesis (Invitrogen). 
The M segment was cloned into an eGFP-N1 plasmid (referred to as eGFP-N1-GCP) and 
eGFP-C1 (referred to as eGFP-C1-GCP) plasmid with kanamycin resistance.  The plasmids 
were codon optimized for homo sapiens.  
2.11 Large scale preparation of plasmid DNA 
2.11.1 Transformation 
Agar plates were prepared containing 50ug/ml of antibiotics by pouring approximately 
20 ml pre-prepared agar (32g (w/v) + ref) onto culture plates with kanamycin or ampicillin 
depending on the specific antibiotic resistance of the plasmid. The plates were left to set at 
room temperature, and then dried out at 37°C for approximately 30 minutes. Cell cultures 
for propagating plasmid DNA were set up by adding 2µl plasmid to 50µl competent cells 
(DH5α™ Competent Cells, Invitrogen, cat: 18265-017) and leaving them to incubate on ice 
for 30 minutes. The cells were then subjected to a 45 seconds heat-shock at 42°Cs, before 
being placed on ice for two minutes. 250µl room temperature SOC media (Sigma Aldrich, 
cat: S1797) was added to each tube and the cells were incubated at 37°C for one hour with 
shaking (140rpm). Following incubation, 40µl of the cell culture was spread on an agar 
plate. The plates were incubated overnight at 37°C. A positive control to determine the 
quality of the competent cells was set up alongside the plasmid DNA, in which 5µl pUC19 
was added to 50µl competent cells. Following overnight incubation, the plates were 
checked for colonies. At this point the plates could be stored at 4°C until further use. From 
each plate a single colony was picked using a pipette tip and placed in a 50ml Falcon tubes 
containing 5ml LB Broth with 0.1% (v/v) antibiotics. The tubes were incubated at 37°C with 
shaking (250rpm) for six – eight hours. 250µl of the pre-culture was then transferred to a 1L 
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Erlenmeyer tube containing 250ml LB Broth with 0.1% (v/v) antibiotics. The flask was 
incubated overnight at 37°C with shaking (200 rpm).   
2.11.2 Maxi-prep 
Following transformation plasmid DNA was extracted using a Qiagen plasmid maxi kit 
(QIAGEN®, cat: 12162) following the manufacturers’ protocol. Overnight bacterial cultures 
(see section 2.11.1) were harvested by centrifugation at 6000g for 15 minutes at 4°C. The 
supernatant was discarded and the bacterial pellet re-suspended in 10ml Buffer P1. 10 ml 
Buffer P2 was then added and the suspension was left to incubate at room temperature for 
5 minutes. Following incubation 10 ml chilled Buffer P3 was added and the solution was left 
to incubate on ice for a further 20 minutes. The solution was centrifuged at 10,000g for one 
hour at 4°C, and then re-centrifuged for an additional 30 minutes. A QIQGEN-tip was 
equilibrated by allowing 10ml Buffer QBT to flow through it, before the supernatant of the 
bacterial suspension was loaded onto the QIAGEN tip and allowed to enter the resin by 
gravity flow. The QIAGEN tip was then washed two times by adding 30ml Buffer QC and 
allowing it to move through the resin by gravity flow. Plasmid DNA was eluted by adding 
15ml Buffer QF to the Qiagen tip and collecting the eluate in a clean 50ml falcon tube. The 
DNA was precipitated with 10.5ml isopropanol at room temperature, and centrifuged at 
4000g for 75 minutes. The supernatant was discarded, and the DNA pellet washed with 5ml 
room temperature ethanol (70 % (v/v)), centrifuged again at 4000g for 30 minutes and 
discarding the subsequent remaining supernatant. The pelleted DNA was left to air-dry for 
10 minutes, before being re-dissolved in 300µl cold dH20 (4°C). DNA concentrations were 
determined on a NanoDrop™ 2000 (Thermo Fisher Scientific), and plasmids were stored at -
20°C or -80°C for downstream use.  
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2.12 Restriction digestion 
Agarose gel electrophoresis with SYBR safe staining was used for DNA visualisation and 
restriction enzyme digestion analysis of plasmid DNA. 1 % (w/v) agarose gels were prepared 
by melting 1g agarose (AGTC Bioproducts) in 100ml 1x TBE (890mM Tris-borate / 890MM 
boric acid / 20mM EDTA / pH 8.3). 5µl SYBR safe (Invitrogen, cat.no. S33102) was added to 
50ml cooled agarose, and the agarose was poured into a gel-casting tray with a comb and 
allowed to set. Restriction enzyme reactions for eGFP-C1-GCP and eGPF-N1-GCP were set 
up as follows:  
Component Volume 
dH2O To 50 µl 
10X CutSmart®(NEB) 5 µl 
DNA (1µg/µl) 1 µl 
Mix by pipetting – then add 
Restriction enzyme 1 µl 
Final volume 50 µl 
 
The restriction enzymes used were; NheI (NEB, cat: R0131S) and BamHI (NEB, cat: 
R136S) for eGFP-N1-GCP and XhoI (NEB, cat: R0146S) and BamHI for eGFP-C1-GCP. After 1 
hour incubation at the enzyme’s optimal temperature (37°C for all enzymes used) the 
reaction was stopped by a 20 minute heat-inactivation step at 65°C. The solution was 
loaded onto the agarose gel, and run for 100 minutes at 80V and 200mA, or until the 
loading buffer front reached the end of the gel.  
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2.11 Cell culture 
HEK293T cells (ECCAC) were maintained at 37°C with 5 % CO2. The cells were grown in 
Dulbecco’s modified eagle’s medium (DMEM) with 10 % (v/v) foetal bovine serum (FBS) and 
1% (v/v) penicillin-streptomycin. The cells were passaged when they reached approximately 
90 % confluence, every three - four days.  
2.12 Calcium phosphate transfection 
HEK293T (ECCAC) cells were seeded 24 hours before transfection in DMEM 10 % FBS 
without antibiotics. For downstream immunofluorescent staining, cells were seeded in a six 
well plate in which a cover slip, washed in 70 % ethanol and PBS had been placed (see 
section 2.15 for immunofluorescent staining procedure). Depending on the scale of the 
transfection and the size of culture dish/plate used, the amounts of reagents were scaled 
up or down accordingly (table 8). 24 hours after seeding, the confluency of the cells 
reached approximately 50 %. 2M CaCl2 and DNA were mixed with ddH20. This was added in 
a dropwise fashion to a separate tube of 2x HBS. This mixture was left to incubate for 30 
minutes at room temperature. The mixture was then added drop by drop onto the cells 
kept in transfection media.  The cells were left to incubate overnight (16- 24 hours) at 37°C 
with 5 % CO2. Fluorescence microscopy was used to visually determine whether 
transfections had been successful.  
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Table 8. Set-up for calcium phosphate transfections. 
Format 
Relative 
area 
Cells 
Culture 
media 
Transfection 
media 
2X HBS 2M CaCl2 DNA 
24 well 0.25x 
6 x 104 
each well 
500l 280l 18l 2.18l 0.36g 
12 well 0.5x 
1 x 105 
each well 
1ml 570l 36l 4.36l 0.71g 
6 well 1.2x 
2 x 105 
each well 
2ml 1.4ml 86l 10.5l 1.71g 
10cm 7x 
1.25 x 
106 
10ml 8ml 500l 61l 10g 
T25 3x 5.2 x 105 5ml 3.4ml 214l 25.8l 4.28g 
T75 9x 1.5 x 106 12ml 10ml 643l 184l 12.9g 
T175 21x 3 x 106 30ml 24ml 1500l 183l 30g 
500cm2 60x 8 x 106 100ml 68ml 4280l 523l 86g 
10cm 
dish 
 4 x 106 25ml 25ml 1280l 156.16l 25.6g 
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2.13 Protein extraction methods 
2.13.1 Protein extraction with RIPA buffer (for downstream western blotting) 
Cells were harvested 24 hours after calcium phosphate transfection. The transfection 
media was discarded from the plate. All wells were gently washed with 1ml PBS to remove 
traces of media. The PBS was discarded and RIPA buffer (10mM Tris-Cl pH 7.5 / 150mM 
NaCl / 5mM EDTA / 0.1 % SDS / 1 % Triton X-100 / 1 % Deoxycholate) with 1x Halt Protease 
Inhibitor (Thermo Fisher Scientific, cat: 78440) was added to each well. Approximately 
100µl RIPA with 1x protease inhibitor was added to each well (i.e. sufficient RIPA buffer to 
cover the wells completely). The plate was left to incubate for 15 minutes on ice. The cells 
were dissociated from the surface of the well/dish using a cell scraper, and the cells and 
buffer were transferred to a 1.5ml Eppendorf tube. This tube was centrifuged at 14000g at 
4°C for 10 minutes. Following centrifugation the supernatant was transferred to a new 
1.5ml Eppendorf tube and stored at –20°C or –80°C until needed for downstream analysis. 
The pellet was discarded or frozen for downstream western blotting. All reagents and 
materials used in the procedure were kept on ice throughout.   
2.13.2 Protein extraction with lysis buffer (for downstream immunoprecipitation 
and mass spectrometry) 
Cells were harvested 24 hours after calcium phosphate transfection. The cells were 
dissociated from the dish using a cell scraper. The cells and media were then transferred to 
a 50ml Falcon tube. The cells were spun down for 10 minutes at 1000g at 4°C. The 
supernatant was discarded, 10ml ice cold PBS was added on to the pellet, and the cells 
were spun for 10 minutes at 1000g at 4°C. This was repeated two more times. Following the 
third wash, the pellet was re-suspended in 200µl Lysis buffer (10mM Tris-CL, pH 7.5 / 
150mM NaCl / 0.5mM EDTA / 0.5 % NP-40 / 1x Halt Protease Inhibitor (Thermo Fisher 
Scientific)). The cells were left to incubate in lysis buffer for 30 minutes on ice. Every 10 
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minutes during the incubation the solution was pipetted up and down to aid re-suspension 
of the pellet.  After incubation the lysate was transferred from the falcon tube to a 1.5ml 
Eppendorf tube and spun down for 10 minutes at 14000g at 4°C. The supernatant was 
transferred to a new Eppendorf tube, and wash/dilution buffer (10mM Tris-Cl pH 7.5 / 
150mM NaCl / 0.5mM EDTA) with 1x Halt™ Protease Inhibitor (Thermo Fisher Scientific) 
was added to make a total volume of 1ml.  This was stored at – 80°C until used for the GFP-
trap procedure (section 2.14). Before freezing, 50µl of the diluted sample was taken off and 
used for western blotting. This fraction was considered the ‘input’ sample.   
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2.14 GFP-Trap 
Following protein extraction with lysis buffer (section 2.13.2), GFP-tagged proteins and 
proteins bound to GFP-tagged proteins were co-precipitated using GFP-Trap® (Chromotek, 
cat: gtm-20). 500µl wash/dilution buffer (10mM Tris-Cl pH 7.5 / 150mM NaCl / 0.5mM 
EDTA) with 1x Halt™ Protease Inhibitor (Thermo Fisher Scientific) was added to Eppendorf 
tubes. 25µl of GFP-trap beads were then added to the tubes.  The beads were washed three 
times by spinning them down for two minutes at 2500g at 4°C, discarding the supernatant 
and adding 500µl fresh wash/dilution buffer. Once the beads were washed the lysates 
obtained from the procedure of extracting proteins for immunoprecipitation (section 
2.13.2) were added to the tubes containing the beads, and left to incubate overnight at 4°C 
with end-over-end mixing. After overnight incubation, the tubes were centrifuged at 2500g 
for 2 minutes at 4°C, and the supernatant was discarded. The beads were re-suspended in 
500µl wash/dilution buffer, centrifuged at 2500g for two minutes at 4°C, and the resulting 
supernatant was discarded. This was repeated two more times. After the final washing 
step, 25µl 0.2M glycine pH 2.5 was added onto the beads. The content was left to incubate 
at room temperature for 10 minutes at 300rpm. They were then centrifuged at 2500g for 
two minutes at 4°C. Following centrifugation, the supernatant was transferred to a new 
Eppendorf tube and 2.5µl 1M Tris-base pH 10.4 was added. This step was repeated three 
more times, so that the final volume of the eluate was 100µl.  For down-stream western 
blotting, 15µl of the eluate was taken off. The remaining eluate was stored at -80°C until it 
was used in downstream mass spectrometry.  
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2.15 Immunofluorescence staining 
Immunofluorescence staining was done to visualise transfected protein localisation in 
HEK293T cells. Cells were fixed to cover slips 24 hours following calcium phosphate 
transfection (section 2.12). The cells were washed three times with 1ml PBS to remove any 
traces of media.  1ml 4 % paraformaldehyde was then added to each well, and the plates 
left to incubate at room temperature for 15 minutes. After incubation the 
paraformaldehyde was removed, and the cells were washed three times with 1ml PBS. 
Fixed cells could be left long-term in PBS at 4°C or proceed directly to downstream 
permeabilizing and staining.  
To permeabilize cells after fixation, 1ml PBS 0.1 % Triton was added to each well and 
the plate was left to incubate for 10 minutes at room temperature. The cells were then 
washed three times with 1ml PBS 0.5 % Tween. After the third wash the cells were 
incubated in PBS 10 % FBS for one hour at room temperature to block unspecific binding of 
the primary antibody. After blocking the cells were washed with PBS 0.5 % Tween before 
100µl of the primary antibody, diluted PBS 0.5 % Tween with 2 % FBS, was added directly 
onto the cover slips. The plate was left to incubate in the dark for one hour at room 
temperature. After incubation the cells were washed three times with PBS 0.5 % Tween 
before adding 100µl of the secondary antibody, diluted 1:200 in PBS 0.5 % Tween with 2 % 
FBS, directly onto the cover slips. The plate was again left to incubate in the dark for one 
hour at room temperature. The cells were again washed three times with 1ml PBS 0.5 % 
Tween.  The cover slips with fixed, stained cells were carefully removed from the wells 
using forceps, inverted and placed on glass slides spotted with 10µl - 20µl mounting media 
containing DAPI (Invitrogen) for visualisation of the cell nucleus. Mounted cover slips were 
sealed with nail varnish and kept at 4°C.   
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2.16 Immunofluorescence microscopy 
The cellular localisation of transfected proteins was visualised and determined using an 
Axio Imager.M2 microscope (Carl Zeiss Micoscopy GmbH, 2011) coupled with ZEN 2 (blue 
edition) software, and using a HXP 120 C light source. Images were captured at 20X and 63X 
magnifications.  Channels for capture of blue - (DAPI, excitation at 405 nm, emission at 
470nm), green – (GFP, excitation at 488 nm, emission at 510 nm), and red fluorophores 
(ALEXA 546, excitation at 488 nm / 532 nm, emission at 573 nm, or ALEXA 568, excitation at 
568 nm, emission at 603 nm) were selected.  
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Table 9. Primary antibodies 
 
 
 
 
 
 
 
 
 
       Table 10. Secondary antibodies 
 
  
Target Vendor WB dilution IF dilution Cat. number 
Afamin R and D 
systems 
1:1000 - MAB8065 
Albumin Sigma 
Aldrich 
1:10 000  - A6684 
Calnexin Abcam - 1:1000 Ab22595 
C-reactive 
protein 
Sigma 
Aldrich 
1:200 - C1688 
GAPDH Abcam 1:2000 - Ab8245 
GFP Sigma 
Aldrich 
1:2000 - 11814 460 001 
Giantin Abcam - 1:500 Ab80864 
TOM70 Santa Cruz - 1:50 sc26495 
Antigen Species Fluorophore Vendor Cat. number 
Rabbit Donkey Alexa 546 Life 
technologies 
A-10040 
 
Mouse Goat Alexa 568 Life 
technologies 
A-11004 
Mouse Goat - Sigma 
Aldrich 
A4416 
Rabbit Goat - Sigma 
Aldrich 
A6154 
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Chapter 3: Discovery and evaluation of afamin as a biomarker of 
orthohantavirus infection in human sera 
3.1 Introduction 
Understanding how orthohantaviruses and similar infections impact humans can be 
evaluated by the severity of clinical symptoms, but also through changes in the proteome of 
tissues. Blood is a commonly used tissue for diagnostic purposes, due to its ease of 
sampling in a clinical setting.  Blood can be fractionated depending on how the sample is 
taken and stored.  These fractions include; whole blood, plasma and serum.  Plasma is the 
liquid fraction of blood remaining once blood cells have been removed through 
centrifugation, while serum, which is very similar in composition to plasma, lacks both 
blood cells and clotting factors.  The constituents of the serum proteome, including serum 
resident proteins and tissue-derived proteins leaking into the circulation, along with 
proteins originating from both commensal and infecting organisms, make it an attractive 
source for the putative detection of biomarkers for various disease states (Anderson and 
Anderson, 2002; Zhang et al., 2007). Serum biomarkers for various pathological conditions, 
including  stroke, autoimmune disorders and infectious disease, have been investigated, 
using proteomic methods such as label-free and labelled MS and protein microarrays (Bauer 
et al., 2006; Kumar et al., 2012; Dagonnier et al., 2017). Proteomics has also been used to 
investigate factors determining outcome in orthohantavirus infection. In a retrospective 
analysis of plasma from 14 hantavirus cardiopulmonary syndrome (HPS) patients with 
serologically proven Sin Nombre virus (SNV) infection, 2D gel electrophoresis coupled with 
mass spectrometry was used to identify plasminogen activator inhibitor type 1 as a 
potential prognostic marker of fatal outcome (Bondu et al., 2015). For the study the 
patients were divided into three classes depending on severity of illness and outcome; class 
I were patients experiencing mild-moderate disease, (i.e. did not experience 
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cardiopulmonary failure and did not need mechanical ventilation), class II covered patients 
who required extracorporeal membrane oxygenation due to cardiac insufficiency and 
ultimately recovered from illness, while class III patients required extracorporeal membrane 
oxygenation but had fatal outcomes. Samples from 10 healthy individuals were used as 
controls.  For class I patients, admission day samples were analysed, while for class II and III 
patients’ serial samples for up to five days from admission were examined.  Among the fatal 
cases in the study (n = four, approximately 28 %) the abundance of plasminogen activator 
inhibitor type 1 was highly elevated imminent to death, as compared to healthy controls 
(Bondu et al., 2015). Interestingly, a genetic polymorphism in the plasminogen activator 
inhibitor type 1  gene has also been associated with more severe renal impairment, 
measured as maximum creatinine levels, in Finnish nephropathia epidemica (NE) patients 
(Laine et al., 2012) .  
Translating proteomic discoveries into clinically viable assays is a long and complex road. 
Several aspects relating to the study design, sample acquisition,  handling and analysis must 
be carefully considered (Kearney et al., 2018). The initial step of this pipeline is the use of 
high-throughput methods to analyse proteomes of clinical interest.  These discovery phase 
analyses will usually yield datasets consisting of hundreds of protein hits. Systems biology 
approaches are therefore used to make an informed selection of candidate biomarkers for 
further evaluation (Micheel et al., 2012; Kearney et al., 2018). Once a selection is made, the 
behaviour of candidate biomarkers are verified for consistency in an independent sample 
cohort. If an independent sample set is not possible to obtain, verification must be done on 
a subset of the original discovery set. Importantly, if a subset of the original sample cohort 
is used, this subset should not have been included in the initial analyses (Micheel et al., 
2012). When the aim of proteomic research is the development of a clinical assay, the next 
step of the process is the validation phase, which involves defining the clinical test method, 
analytical validation of the test and finally biological validation on a blinded sample set. If 
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the assay is successfully validated at this point, it can be brought to the final stages of 
evaluation in a clinical trial setting (Micheel et al., 2012). Only a few proteomic assays have 
so far been introduced (Kearney et al., 2018) PreTRM is a selected reaction monitoring mass 
spectrometry-based assay, which was approved for use in the USA in 2015. The test has 
been validated for use in the 19th and 20th week of pregnancy, to predict the risk of 
spontaneous pre-term birth through evaluating the relative ratio of two proteins; insulin-
like growth factor-binding protein 4 and sex hormone-binding globulin (Saade et al., 2016; 
Kearney et al., 2018). In the field of infectious disease, various biomarker panels have been 
evaluated for the diagnosis of Hepatitis C virus- induced fibrosis (Castera, 2012; Schiavon et 
al., 2014). Patented panels available for this indication include FibroTestTM (Biopredictive, 
France) and ELFTM (iQur, Southampton, UK), two assays that measure a combination of 
serum proteins to evaluate the degree of fibrotic damage (Poynard et al., 2004, 2007; 
Rosenberg et al., 2004; Parkes et al., 2010). In practice a combination of non-invasive 
methods, such as biomarker algorithms complemented by imaging techniques, have 
produced more accurate results than biomarkers alone for diagnosing fibrosis in Hepatitis C 
virus (Castera, 2012) Importantly, while the incorporation of non-invasive methods could 
reduce the need for liver biopsies among Hepatitis C virus patients, which is the current 
diagnostic gold standard, there are still several caveats to their use in clinical practice, such 
as their general low accuracy for discriminating early stages of fibrosis, and confounding due 
to co-morbidities (Castera, 2012; Schiavon et al., 2014). 
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3.1.1 Hypothesis 
SEOV infection causes measurable alterations in the human serum proteome that are 
indicative of viral infection and renal pathology.  
This hypothesis was explored by comparing the proteomes of five orthohantavirus-
seropositive (one x acute and four x convalescent) and five orthohantavirus-seronegative 
serum samples using label free mass spectrometry, to investigate whether there were 
differences in the abundance of specific proteins between the two groups that might be 
reflective of infection state. 
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3.2 Results 
3.2.1 Establishing an experimental pipeline for detection of serum proteins by 
label free mass spectrometry in healthy human sera 
The dynamic protein abundance range in serum samples taken for proteomic analysis 
can span more than ten orders of magnitude between the most abundant protein, which is 
serum albumin (34-54 mg/ml), and the lowest abundant proteins that are detectable, e.g. 
cytokines such as interleukin (IL)-6 with an approximate abundance of < 0.000000005 
mg/ml in healthy individuals (Anderson and Anderson, 2002; Nanjappa et al., 2014).  
Additionally, a few highly abundant proteins dominate the bulk mass of blood and these 
effectively mask detection of lower abundance proteins by proteomic methods. In an effort 
to increase the depth of coverage of mass spectrometric analysis, sera were depleted of the 
top 12 most highly abundant proteins as detailed in chapter 2.2 (table 6) using 
immunodepletion spin coloumns (Thermo Fisher Scientific). Following depletion, the 
protein concentrations of depleted samples and their undepleted (crude) counterparts 
were determined by BCA. Two biological and two technical replicates of orthohantavirus 
seronegative sera were depleted to test the efficiency of the immunodepletion spin 
columns. After depletion the average decrease in protein concentration from crude to 
depleted was 91.1 %. As the orthohantavirus infected sera provided by RIPL (see chapter 
2.1.2) had been heat-inactivated at 60°C for 15 minutes as a precautionary procedure to 
inactivate any possible residual virus in the sera, the effect of this treatment on protein 
quality and detection was investigated on an orthohantavirus seronegative control sample. 
This sample was split into two equal parts, of which one aliquot was heat-treated as 
described above and one was left untreated. The samples were then depleted and 
compared as depleted and crude specimens by BCA, and then whole protein stain of SDS-
PAGE separated extracts.  Western blot was used to visualise albumin, a high abundance 
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protein targeted for depletion by the immunodepletion spin columns (see chapter 2.2). 
Subjecting sera to heat-inactivation did not have any discernible effect on the parameters 
measured (figure 3.1). After triplicate measurements of depleted and crude sera by BCA, 
the average protein concentration of the heat-inactivated specimen was 2.38μg/μl before 
and 0.48μg/μl after depletion. For the specimen that had not been subjected to heat-
inactivation the average protein concentrations of crude and depleted sera were 2.27μg/μl 
and 0.42μg/μl respectively. The percentage decrease in protein content for the heat-
inactivated and non-heat-inactivated specimens in depleted compared to crude samples 
were 79.8 % and 81.5 % respectively.  
 
Figure 3.1. A, SYPRO ruby stain (whole protein stain) comparing non-heat-inactivated 
and heat-inactivated sera. B, western blot for albumin comparing non-heat inactivated and 
heat-inactivated sera. 12 ug protein was loaded in each lane. The experiment was repeated 
three times, and protein concentrations were calculated as the average concentration of 
three technical replicates.  NC; negative control, C; crude, D; depleted.  
To determine the baseline variability that could be expected when analysing sera by 
mass spectrometry and have an indication of the depth of proteome coverage to expect 
following immunodepletion, two healthy control sera samples were analysed by mass 
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spectrometry and compared (figure 3.2). In total, 202 proteins were identified across the 
two samples by mass spectrometry. Following removal of contaminants, i.e. keratins and 
non-human proteins introduced to the samples through use of upstream experimental 
reagents containing non-human protein constituents, along with removal of any protein 
only identified in one of the samples and all proteins identified by < 2 unique peptides, 124 
proteins were common to the two samples tested. The label-free quantification (LFQ) 
intensities, which is a measure of the normalised, summed peptide intensities of identified 
proteins, were compared for the 124 proteins common to the two samples analysed (Cox et 
al., 2014). The spearman correlation coefficient (rho= 0.97) between the samples was 
significant, p < 0.000 
Figure 3.2. Label free quantification (LFQ) intensities for the 124 commonly detected 
proteins in two healthy (read orthohantavirus seronegative) control samples analyzed by 
mass spectrometry (sample 1 and sample 2). The Spearman correlation coefficient rho = 
0.97 when comparing the LFQ intensities of the two samples. Rho was significant, p < 
0.0001.  Each tick on the x-axis represents one individual protein of the 124 proteins 
detected in both sample 1 and sample 2, ranked in ascending order of abundance for 
sample 1 (orange line). Selected proteins are highlighted: hepatocyte growth factor 
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activator (HGFAC), proteoglycan 4 (PRG4), lipopolysaccharide-binding protein (LBP), 
carboxypeptidase B2 (CPB2), complement C1q subcomponent subunit A (C1QA), 
apolipoprotein D (APOD), leucine-rich alpha-2-glycoprotein (LRG1), thrombospondin-1 
(THBS1), complement component C7 (C7), complement C1r subcomponent (C1R), protein 
AMBP (AMBP), alpha-2-macroglobulin (A2M), C4b-binding protein alpha chain (C4BPA), 
serum albumin (ALB).  
3.2.2 Preparing orthohantavirus infected samples for proteomic analysis 
With the objective of investigating if a measurable difference in the abundance of 
specific proteins in orthohantavirus-infected and non-infected sera could be detected, the 
proteomes of five orthohantavirus seropositive (four x convalescent, one x acute) and five 
orthohantavirus seronegative controls were compared. Each sample was depleted of the 
top 12 abundant serum proteins as described in chapter 2.2. The decrease in protein 
concentrations in individual samples from crude to depleted following immunodepletion 
ranged from 87.3 % - 96 %. The reduction was visualised by comparing crude and depleted 
specimens side by side on a SDS gel stained with a whole protein stain (figure 3.3A). To 
further validate that the process of immunodepletion had the desired effect, western blots 
were done in which depleted and crude samples were compared side by side for 
abundance of albumin (normal range: 34-54 g/L) and C-reactive protein (CRP) (normal 
range: <0.003 g/L). In depleted samples the detectable amount of albumin was reduced 
compared to crude, while the detectable amount of CRP was enriched in depleted samples 
as compared to crude (figure 3.3B), indicating that the depletion process enhanced the 
detection of lower abundance proteins relative to the detection of high abundance 
proteins.  
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Figure 3.3 Changes in protein abundance before (lane marked C for crude) and after 
immunodepletion (lane marked D for depleted). The figure shows the crude and depleted 
specimens of two representative samples; one orthohantavirus seronegative (-) and one 
orthohantavirus seropositive during acute disease (+a). A, changes in protein pattern 
before and after depletion, visualized with Sypro ruby whole protein gel stain, and B, 
western blot showing reduced detection of albumin and enrichment of CRP in depleted 
samples compared to crude. 2.5μg protein was loaded per well. CRP; C-reactive protein. 
3.2.3 Comparing orthohantavirus seronegative and seropositive samples by 
label-free mass spectrometry 
Following immunodepletion and determination of protein concentrations, the protein 
content of the samples were determined and quantified by mass spectrometry, as detailed 
in chapter 2.7. In total, 381 proteins identified by a minimum of two unique peptides were 
common to all 10 samples analysed (appendix B.1). Using threshold values of q < 0.05 and a 
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minimum fold change of 1 log2, a total of 74 proteins were revealed to be differentially 
abundant between the two groups (figure 3.4). 20 proteins were increased in abundance in 
the seropositive group compared to controls and 54 proteins were decreased in abundance 
in the seropositive group compared to seronegative controls (table 11). Among the 20 
proteins with increased abundance, STRING© network analysis (version 10.5) showed 
enrichment of several biological process gene ontology (GO) terms such as regulation of 
hydrolase activity, regulation of complement activation, cell adhesion and regulation of 
angiotensin levels in blood (figure 3.5, table 11). Among the proteins with decreased 
abundance a large number of immunoglobulin fragments were identified with biological 
process GO terms relating to complement activation and immune regulation. Most of the 
Ig-fragments were not recognised by the STRING© software, so GO term annotation was 
found by searching their UniProt entries. STRING© analysis of the remaining proteins in the 
decreased abundance group revealed functional associations relating to regulation of body 
fluid levels, lipid transport, localization and regulation of hydrolase activity (figure 3.5, table 
11).  
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Figure 3.4. Differences in protein abundances between a group of five seropositive 
samples (four x convalescent and one x acute) and five seronegative controls.  Serum 
proteins were identified and quantified by label-free mass spectrometry using Progenesis.  
Abundance was expressed as the mean log2 of positive/negative samples. Proteins were 
identified based on detection of at least two unique peptides, and significant findings had a 
minimum fold difference of 1 log2 in abundance between the positive and negative group 
and a q-value < 0.05.  74 proteins (highlighted red) were found to be significantly 
differentially abundant in seropositive samples compared to seronegative controls. 
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Figure 3.5. STRING© version 10.5 network analysis of 74 proteins with differential 
abundance in seropositive samples (n = five) compared to seronegative samples (n = five). 
A, 20 proteins with increased abundance in seropositive samples compared to seronegative 
samples. Green; regulation of complement activation, red; regulation of hydrolase activity, 
blue; regulation of angiotensin levels in blood, purple; cell adhesion. B, 29 proteins with 
decreased abundance in seropositive samples compared to seronegative samples. Several 
of the Ig-fragments (see table 11) were not recognised by STRING© and are therefore 
missing from the protein network. Red; regulation of body fluid levels, blue; lipid transport, 
green; regulation of hydrolase activity, yellow; localisation.   
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Table 11. Proteins with significantly different abundance in the seropositive group 
compared to the seronegative group. 
 Increased in seropositive 
Description Gene FC log2 q value Accession GO term 
Thrombospondin-4   THBS4 2.7 0.01 P35443 Cell adhesion 
78 kDa glucose-
regulated protein  
HSPA5 2.4 0.001 P11021 Regulation of 
hydrolase activity 
Vinculin  VCL 2.3 0.015 P18206 Cell adhesion 
Spectrin beta chain, 
erythrocytic  
SPTB 1.8 0.019 P11277 Actin filament 
capping 
Aminopeptidase N ANPEP 1.5 0.019 P15144 Regulation of 
angiotensin levels 
in blood 
Xaa-Pro dipeptidase  PEPD 1.5 0.046 P12955 Metabolic process 
Inter-alpha-trypsin 
inhibitor heavy chain 
H3  
ITIH3 1.4 0.005 Q06033 Regulation of 
hydrolase activity 
Neural cell adhesion 
molecule 1  
NCAM1 1.4 0.046 P13591 Cell adhesion 
Complement 
component C8 gamma 
chain  
C8G 1.4 0.005 P07360 Regulation of 
complement 
activation 
Heparin cofactor 2  SERPIND1 1.3 0.007 P05546 Regulation of 
hydrolase activity 
Alpha-1-
antichymotrypsin  
SERPINA3 1.3 0.002 P01011 Regulation of 
hydrolase activity 
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Complement 
component C8 alpha 
chain  
C8A 1.1 0.017 P07357 Regulation of 
complement 
activation 
Complement factor B  CFB 1.1 0.004 P00751 Regulation of 
complement 
activation 
Complement 
component C9  
C9 1.1 0.022 P02748 Regulation of 
complement 
activation 
Angiotensinogen  AGT 1.1 0.034 P01019 Regulation of 
angiotensin levels 
in blood / cell 
adhesion 
Inter-alpha-trypsin 
inhibitor heavy chain 
H4  
ITIH4 1.1 0.011 Q14624 Regulation of 
hydrolase activity 
Complement C2  C2 1.0 0.005 P06681 Complement 
activation 
Collagen alpha-3(VI) 
chain   
COL6A3 1.0 0.001 P12111 Regulation of 
hydrolase activity 
/ cell adhesion 
Protein AMBP  AMBP 1.0 0.023 P02760 Regulation of 
hydrolase activity 
/ Cell adhesion 
Thyroxine-binding 
globulin  
SERPINA7 1.0 0.007 P05543 Regulation of 
hydrolase activity 
 Decreased in seropositive 
Description  FC log2 q Value Accession Go term 
Ig lambda chain V-II IGLV2-11 -4.9 3.76E-03 P01707 Regulation of 
  98 
region TRO  immune response 
LRP2-binding protein LRP2BP -4.5 0.011 Q9P2M1 Protein binding 
Ig kappa chain V-III 
region VH (Fragment)  
-* -4.5 0.001 P04434 -* 
Ig kappa chain V-I 
region CAR  
IGKV1-5 -4.2 0.009 P01596 Regulation of 
immune response 
Ig gamma-2 chain C 
region  
IGHG2 -4.0 0.0002 P01859 Complement 
activation 
Ig gamma-3 chain C 
region  
IGHG3 -3.7 0.001 P01860 Complement 
activation 
Platelet glycoprotein Ib 
alpha chain  
GP1BA -3.5 0.002 P07359 Regulation of 
body fluid levels 
Ig gamma-4 chain C 
region  
IGHG4 -3.5 0.002 P01861 Complement 
activation 
Afamin  AFM -3.5 0.0007 P43652 Localization 
Properdin  CFP -3.4 0.005 P27918 Regulation of 
protein 
processing 
Ig lambda chain V-III 
region LOI  
IGLV3-21 -3.4 0.0002 P80748 Regulation of 
immune response 
Ig lambda chain V 
region 4A  
IGLV7-43 -3.4 0.004 P04211 Regulation of 
immune response 
Coagulation factor XIII 
B chain 
F13B -3.3 0.004 P05160 Regulation of 
body fluid levels 
Immunoglobulin 
lambda-like 
polypeptide 5  
IGLL5 -3.3 0.001 B9A064 Localization 
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Ig heavy chain V-II 
region WAH  
IGHV4-39 -3.3 0.011 P01824 Regulation of 
immune response 
Ig gamma-1 chain C 
region  
IGHG1 -3.2 0.001 P01857 Complement 
activation 
Ig lambda-7 chain C 
region  
IGLC7 -3.1 0.001 A0M8Q6 Regulation of 
immune response 
Ig heavy chain V-III 
region GA  
IGHV3-30 -3.1 0.022 P01769 Regulation of 
immune response 
Ig heavy chain V-III 
region BUT 
IGHV3-53 -3.1 0.001 P01767 Regulation of 
immune response 
Ig heavy chain V-III 
region WEA 
IGHV3-48 -3.0 0.001 P01763 Regulation of 
immune response 
Apolipoprotein M  APOM -3.0 0.0005 O95445 Lipoprotein 
metabolic process 
Ig kappa chain V-III 
region IARC/BL41 
IGKV3-20 -2.9 0.004 P06311 Regulation of 
immune response 
Serum amyloid A-4 
protein  
SAA4 -2.8 0.001 P35542 Localization 
Ig lambda chain V-III 
region SH  
IGLV3-19 -2.7 0.004 P01714 Regulation of 
immune response 
Ig alpha-2 chain C 
region  
IGHA2 -2.7 0.003 P01877 Complement 
activation 
Ig alpha-1 chain C 
region  
IGHA1 -2.6 0.002 P01876 Complement 
activation 
Ig kappa chain C region  IGKC -2.6 0.002 P01834 Regulation of 
immune response 
Lumican  LUM -2.6 0.0002 P51884 Extracellular 
matrix 
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organization 
Ig heavy chain V-III 
region VH26  
IGHV3-23 -2.5 0.005 P01764 Regulation of 
immune response 
Ig heavy chain V-I 
region HG3  
IGHV1-46 -2.4 0.005 P01743 Regulation of 
immune response 
Apolipoprotein C-IV  APOC4 -2.4 0.023 P55056 Lipid transport 
Striated muscle 
preferentially 
expressed protein 
kinase  
SPEG -2.3 0.011 Q15772 Negative 
regulation of cell 
proliferation 
SH3 and multiple 
ankyrin repeat 
domains protein 1  
SHANK1 -2.2 0.001 Q9Y566 Localization 
Serum albumin ALB -2.0 0.023 P02768 Regulatio of body 
fluid levels / Lipid 
transport 
Ig kappa chain V-III 
region VG (Fragment)  
IGKV3-11 -2.0 0.004 P04433 Regulation of 
immune response 
Apolipoprotein A-II APOA2 -2.0 0.001 P02652 Regulation of 
hydrolase activity 
/ lipid transport 
Ig kappa chain V-III 
region B6 
IGKV3-20 -1.9 0.004 P01619 Regulation of 
immune response 
Ig kappa chain V-I 
region HK102 
(Fragment)  
IGKV1-5 -1.9 0.03 P01602 Regulation of 
immune response 
Vitamin K-dependent 
protein C  
PROC -1.8 0.001 P04070 Regulation of 
body fluid leves / 
localization 
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Serine/threonine-
protein 
kinase/endoribonuclea
se IRE1  
ERN1 -1.8 0.025 O75460 Regulation of 
hydrolase activity 
Ig kappa chain V-IV 
region Len  
IGKV4-1 -1.7 0.019 P01625 Regulation of 
immune response 
Vitamin D-binding 
protein 
GC -1.5 0.002 P02774 Regulation of 
body fluid levels 
Apolipoprotein C-II APOC2 -1.5 0.037 P02655 Regulation of 
hydrolase activity 
/ Lipid transport 
Myomegalin  PDE4DIP -1.4 0.006 Q5VU43 Cellular protein-
containing 
complex assembly 
Apolipoprotein E  APOE -1.3 0.025 P02649 Lipid transport 
Apolipoprotein A-I  APOA1 -1.3 0.035 P02647 Regulation of 
hydrolase activity 
/ Lipid transport / 
Regulation of 
body fluid levels 
Alpha-1-antitrypsin  SERPINA1 -1.3 0.037 P01009 Regulation of 
hydrolase activity 
/ Localization / 
Regulation of 
body fluid levels 
Coagulation factor XII  F12 -1.3 0.023 P00748 Regulation of 
body fluid levels / 
Regulation of 
protein 
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processing 
Beta-2-glycoprotein 1 APOH -1.2 0.011 P02749 Regulation of 
hydrolase activity 
/ Lipid transport / 
Regulation of 
body fluid levels 
Tetranectin  CLEC3B -1.2 0.041 P05452 Regulation of 
protein 
processing 
Leucine-rich alpha-2-
glycoprotein  
LRG1 -1.1 0.03 P02750 Positive 
regulation of TF-β 
receptor signalling 
pathway 
Fibulin-1  FBLN1 -1.1 0.037 P23142 Regulation of 
body fluid levels / 
Regulation of 
hydrolase activity 
Protein FAM186A  FAM186A -1.1 0.017 A6NE01 - 
Histidine-rich 
glycoprotein  
HRG -1.0 0.009 P04196 Regulation of 
hydrolase activity 
/ Localization / 
Regulation of 
body fluid levels 
*obsolete uniport entry, deleted from the database in 2016 
Afamin was identified among the top 10 proteins with decreased abundance in seropositive 
samples, with a q < 0.0007 and a fold change of log2 = -3.5. Afamin was also highlighted 
when analysing the mass spectrometry-acquired dataset by a correlation analysis in which 
the seropositive and seronegative group was contrasted against each other (figure 3.6). It 
was therefore selected as a protein of interest for further investigation as a potential 
marker infection.  
  103 
 
Figure 3.6. Profile contrasting of the seronegative (n = 5, white) and seropositive (n = 5, red) 
groups in a correlation analysis using raw mass spectrometry data.  
To verify that afamin was decreased in the orthohantavirus seropositive samples 
compared to seronegative controls, a western blot was run probing specifically for the 
presence of afamin in the samples analysed by mass spectrometry (figure 3.7).  The relative 
intensities (RI) of the bands were determined using the image processing software FIJI. A 
control sample of pooled seronegative sera was loaded on both gels to act as a reference to 
which the other samples of interest could be compared (figure 5, lane 1; GR). The average 
RI of afamin in seropositive samples was 0.56, and the average RI of seronegative was 0.48 
(table 12).  There was no statistically significant difference between the seropositive and 
seronegative groups, but notably the single acute disease sample of the seropositive group 
had the lowest measured relative intensity of all 10 samples investigated, with a RI = 0.10 
(table 12, figure 3.7; seropositive lane 6).   
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Table 12. Relative intensities of afamin in seropositive and seronegative samples. 
Seropositive Seronegative 
Lane Relative intensity Lane Relative intensity 
1 1 1 1 
2 0.54 2 0.20 
3 0.65 3 0.80 
4 0.68 4 0.41 
5 0.40 5 0.16 
6 0.10 6 0.32 
Average 0.56 Average 0.48 
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Figure 3.7. Verification of mass 
spectrometry and profile contrasting 
results for afamin by western blotting. 
5μg protein was loaded per well. All 
samples were analyzed crude. GR; gel 
reference (a pool of 5 independent 
seronegative samples). For analysis of 
relative intensities across gels this 
band was arbitrarily set to a value of 1. 
NC; negative control (loading buffer 
only). - ; seronegative, +c ; seropositive 
convalescent, +a; seropositive acute. 
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3.2.4 Afamin abundance in patients with acute orthohantavirus infection 
compared to healthy controls  
A described above, western blotting indicated that the abundance of afamin was lowest 
in the single acute disease sample in the discovery cohort. Furthermore, the fold change for 
afamin remained above the set threshold level for significance when disregarding the 
seropositive convalescent samples and only comparing the seropositive acute sample to the 
seronegative controls, log2 = -4.3. It was therefore deemed appropriate to not follow up in 
convalescent samples, but only to consider acute disease samples compared to 
orthohantavirus-seronegative controls for the validation phase. To validate whether afamin 
was consistently decreased in acute orthohantavirus infection compared to healthy 
controls, an independent cohort of eight seronegative and eight acute disease samples 
were investigated for relative abundance of this protein by western blot (figure 3.8A).  The 
median abundance of afamin in the seropositive group (median = 0.137) versus the 
seronegative groups (median = 0.181) was not found to be statistically significant in this 
cohort, p < 0.463 (figure 3.8B).   
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Figure 3.8. Validation of afamin abundance in an independent cohort of acute 
orthohantaviurs seropositive and orthohantavirus seronegative sera. A, Western blots. 5μg 
protein was loaded per well, with 5 ng rGFP spiked into each sample prior to protein 
denaturing. The rGFP acted as a loading control, and as a parameter to normalize afamin 
measurements against. NC; negative control (H20 + loading buffer only), GR; gel reference 
(a seronegative sample loaded onto both gels to act as a reference value). The intensity if 
this band was arbitrarily set to value of one for relative intensity calculation. +*; the well 
was loaded with 2.5 μg protein. This sample was excluded from subsequent statistical 
analysis due to low protein load. B, comparison of the relative intensities of afamin 
measured by western blotting of the acute seropositive group (left) and the seronegative 
group (right). Relative intensities were measured using ImageLab (BioRad) and statistical 
analysis was done with SigmaPlot 13.0. The median quantity of the acute group = 0.137 
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(left box) and the seronegative group = 0.181 (right box). In the seropositive group there 
was one missing value). There was no significant difference in medians between acute and 
seronegative groups by Mann- Whitney Rank Sum test, p < 0.463.   GFP; green fluorescent 
protein.  
3.2.5 Afamin abundance measured on sequential days of hospitalisation in a 
patient with HFRS 
Protein abundance changes in relation to pathological conditions often occur within 
relatively short timeframes. Elevation of several plasma cytokines were observed within a 
week of admission in patients with dengue haemorrhagic fever (Jadhav et al., 2017). Within 
24 hours, abundance changes in Nt-proBNP, troponins and inflammatory mediators were 
demonstrated following myocardial infarction, and changes in serum vasopressin was 
observed within minutes of reperfusion of liver grafts (Keegan et al., 2010; van Diepen et 
al., 2016). As such, having the opportunity to look at temporal proteome changes within a 
single individual could more accurately capture biological changes in response to infection. 
If the abundance of afamin fluctuated during the course of HFRS, the results from the 
above investigated, single time point samples, might not accurately reflect proteome 
changes in response to disease, as the time points during illness at which these samples 
were collected was unknown. Afamin abundance was therefore additionally investigated in 
six sequential serum samples obtained from one individual who had been hospitalised with 
HFRS during pregnancy. The samples from the hospitalised pregnant patient consisted of 
one x orthohantavirus seronegative sample (prior to seroconversion), four x 
orthohantavirus seropositive samples obtained during acute illness and one x 
orhtohantavirus seropositive convalescent sample (see chapter 4).  Changes in serum 
afamin abundance were evident in this individual when comparing levels of the healthy 
seronegative baseline, through acute disease, to convalescence (figure 3.9). Notably, 
afamin abundance was lowest in the earliest obtained acute disease sample (day three) and 
rose on sequential days of illness.  
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Figure 3.9. The average afamin abundance of sequential samples from a patient 
hospitalised with HFRS. Afamin abundance dropped to its lowest point during acute 
disease. Afamin levels rose on sequential days of illness. In the convalescent sample afamin 
abundance exceeded that of the patients’ seronegative baseline. Day three – day seven 
equates days of clinical symptoms. Error bars are 2X standard error of the mean of triplicate 
measurements. LFQ; label free quantification 
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3.3 Discussion  
In this study the aim was to use label-free mass spectrometry as an exploratory method 
for discovery of novel biomarkers of orthohantavirus infection in human sera. For the initial 
discovery phase the seropositive sample cohort consisted of both acute and convalescent 
sera. This made true infection related links difficult to make, as a convalescent sample is 
likely to closely resemble that of an uninfected healthy control. Interestingly however, 
there were several proteins found to be differentially abundant in the seropositive 
compared to the seronegative group, despite most of the samples within the seropositive 
group originating from convalescent, presumably healthy, individuals. Whether the 
observed difference represents a true difference due to some chronic sequelae of a 
resolved infection or represents the variation in serum protein abundance for specific 
proteins that must be expected when looking at a random selection of healthy individuals 
with unknown medical histories, remains speculative, as follow up experiments of this 
study focused on differences between acutely ill patients and healthy controls.  The 
question of whether orthohantavirus infections can cause long-term complications remains 
unresolved. In a five year follow up of Finnish NE patients there was evidence of higher 
glomerular filtration rate, increased proteinuria and hypertension among former patients 
compared to seronegative controls (Mäkelä et al., 2000). However at a 10-year follow up of 
the same cohort, these differences between patients and controls were no longer 
significant (Miettinen et al., 2006). In a large study in northern Sweden, in which 1600 
people participated, no association was found between seropositivity for PUUV and 
increased incidence of hypertension or increased glomerular filtration rate, or of a higher 
risk of diabetes, heart attack or stroke (Bergstedt Oscarsson et al., 2016). Similarly, no 
association was found between orthohantavirus seropositivity and chronic renal failure in a 
Czech multi-centre study (Pejcoch et al., 2010).Interestingly, while the long-term outcome 
for renal and hypertensive complications following HFRS and NE seems favourable, in a 
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prospective study of HPS survivors, 50 % met the National Kidney Foundation’s criteria for 
chronic kidney disease (Pergam et al., 2009). There is also evidence that suggests patients 
who have recovered from HFRS and NE are at an increased risk of developing hormonal 
deficiencies (Stojanovic et al., 2008; Makela et al., 2010). It would be interesting to further 
investigate the apparent differences discovered in convalescent samples compared to 
seronegative in this study, to look at the potential for chronic complications associated with 
SEOV. This could initially be explored by comparing the incidence of pathological conditions 
in individuals with resolved SEOV infections to that of an orthohantavirus naïve cohort. 
Such a study would be greatly complicated by the fact that it would require access to a 
substantial number of long-term follow-up sera from individuals with proven exposure to 
SEOV, sampled at specified time-points following acute infection, along with samples from 
a demographically matched control group. 
The decision to progress the study only comparing acute and seronegative samples was 
based on the observation that the acute seropositive specimen of the seropositive group 
presented with seemingly more outlying values than the convalescent ones for a specific 
protein of interest, i.e. afamin. Additionally, it was believed there would be a greater 
chance of identifying true differences by comparing more obviously phenotypically 
different conditions, especially considering the small sample size available for analysis.  
Because the abundance of afamin was significantly decreased in the seropositive group 
by mass spectrometric measurement and highlighted as a protein of interest through a 
profile contrasting correlation analysis, it was selected for further investigation. Afamin is a 
highly glycosylated member of the albumin family, predominantly expressed in the liver 
and secreted into the bloodstream, but found in other extravascular fluids and tissues as 
well (Dieplinger and Dieplinger, 2015). The biological functions of afamin remain largely 
unknown. In vitro afamin binds vitamin E, and the concentrations of afamin and vitamin E 
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correlate in follicular and cerebrospinal fluid, though not in plasma. Notably, the two 
former fractions do not contain the proteins most closely associated with vitamin E 
transport in plasma, linking afamin to vitamin E transport in fluids were the lipoprotein 
system is lacking or insufficient (Jerkovic et al., 2005). Absolute afamin levels seem to 
remain relatively stable across a range of parameters such as circadian rhythm, gender and 
age (Dieplinger et al., 2013). It has been found to have altered abundance in various 
pathological conditions such as cancer, neurodegenerative disease and infection, however, 
its actual clinical relevance and utility remains questionable with results remaining 
unvalidated or controversial (Dieplinger and Dieplinger, 2015). Moderately decreased levels 
of afamin have been associated with ovarian cancer, inversely correlated with FIGO stage5 
and distant metastasis. Afamin did not, however add any significant value to the 
performance of cancer antigen 125, the most commonly used biomarker currently available 
for ovarian cancer, in differentiating ovarian cancer patients from healthy controls or 
benign gynaecological diseases (Dieplinger et al., 2009). In a clinical study on therapy 
response in ovarian cancer, post-therapeutic afamin levels ≥ 48 mg/l was associated with 
increased survival (Melmer et al., 2013). However, in another retrospective study no 
correlation between afamin and disease stage before intervention was seen, or with any 
measurements of therapy response and outcome (Aktas et al., 2013). In a small study 
looking at prognostic biomarkers for the development of familial Alzheimer’s disease, 
increased levels of afamin in cerebrospinal fluid were found in presymptomatic individuals 
carrying two high-risk gene mutations linked to the development of Alzheimer’s compared 
to non-carriers of these mutations (Ringman et al., 2012). Compared to healthy controls, 
significantly decreased plasma levels of afamin have been demonstrated in patients with 
                                                          
5  A staging system for ovarian cancer established by the International 
Federation of Gynecological Oncologists. The system has 4 stages with stage 1 
denoting a tumor limited to the ovaries or fallopian tube, and stage 4 denoting 
metastasis to another organ. 
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pneumonia and sepsis, but not in patients with chronic pathologies such as chronic 
obstructive pulmonary disease or chronic renal disease (Dieplinger et al., 2013). A common 
denominator for cancer, neurodegenerative disease and acute infections is the induction of 
reactive oxygen species (Liu et al., 2017; Yang and Lin, 2017).  The role of vitamin E as a 
potent antioxidant and afamin’s vitamin E-binding ability could implicate afamin in 
mechanisms associated with a response to oxidative stress during various pathological 
conditions. Afamin has also been implicated as a negative acute phase response protein, 
due to findings of an inverse relationship with CRP and IL-6 (Dieplinger et al., 2013). While 
afamin was not decreased in abundance during orthohantavirus infection compared to 
controls in the validation phase of this study, the protein did follow some interesting 
kinetics in a sequential sera set from a patient with acute HFRS due to SEOV. In the 
sequential sera from this patient afamin was decreased in the earliest acute disease sample 
of the set compared to all the other samples from the patient but increased over the next 
few days of illness. The observation that afamin was higher in the convalescent sample than 
the seronegative, could be explained by the patient’s pregnancy at the time of disease, as 
afamin increases almost two-fold during the course of an uncomplicated pregnancy 
(Hubalek et al., 2014). Possibly, this could also account for the slightly higher abundance of 
afamin on acute day seven compared to the seronegative specimen. As it was observed in 
the sequential sera that afamin levels were altered during illness, it is difficult to say if the 
findings of no difference in the formerly analysed cohort was due to there being no 
biologically effect on afamin abundance in response to orthohantavirus infection, or that 
the acute disease samples used in this study were taken at time points of disease 
progression at which afamin had already returned to normal levels. Possibly, measuring the 
relative intensity of afamin using a semi-quantitative technique such as western blotting, 
might not be an accurate enough method in this case. To progress the findings of this study, 
investigating the absolute, rather than relative abundance of afamin using an afamin-
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specific ELISA, could possibly provide more conclusive answers, as afamin levels could then 
be seen in relation to a normal range rather than an arbitrary normalisation value. 
For HFRS it would be clinically useful with biomarkers that could aid in early 
identification of patients that are likely to experience acute kidney injury (AKI) and 
requirement for renal replacement therapy.  Biomarkers of AKI have been investigated in 
both blood and urine in several settings (Alge and Arthur, 2015; Wasung et al., 2015). Urine 
derived markers have showed most promise as accurate early diagnostic and prognostic 
markers. This is possibly because kidney function and damage can be better evaluated by 
detecting what the kidneys do or do not secrete during diseased compared to normal 
conditions. In combination, urinary tissue inhibitor of metalloproteinases-2 and insulin-like 
growth factor-binding protein 7 have demonstrated a very good ability to accurately predict 
the development of AKI within 12 hours of measurement (Kashani et al., 2013; Bihorac et 
al., 2014) As such, looking at urine samples from HFRS patients might provide more direct 
evidence of renal dysfunction than through analysing sera. In the case of HFRS, however, 
markers indicative of severe AKI might not necessarily be kidney specific. Exposure to 
inflammatory factors and immune cells induces endothelial activation, which in turn can 
can be a driver of renal disease (Imig and Ryan, 2013). Elevated levels of soluble 
thrombomodulin, a marker of endothelial injury, has been associated with development of 
AKI in septic and critically ill patients in the absence of urinary markers (Katayama et al. 
2017; Bouchard et al. 2015). While AKI is a hallmark of HFRS, HFRS is predominantly a 
disease of the vascular endothelium (Krautkrämer et al., 2013). If AKI is a consequence of 
infection-induced endothelial activation, early markers predictive of severe outcome, i.e. 
AKI, might be vascular rather than kidney specific.  
In addition to biomarkers associated with the severity of AKI, it would also be beneficial 
with biomarkers capable of differentiating orthohantavirus infections from bacterial causes 
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of AKI, as leptospirosis is one of the most common differential diagnoses for HFRS (Gamage 
et al., 2011; Goeijenbier et al., 2014). Such biomarkers could possibly aid in the reduction of 
the use of provisional antibiotics. While it would be ideal with markers that could 
specifically point to a certain infection, in actuality this is quite unlikely, as similar 
symptoms generally mean similar pathologies and host responses on a clinical level. 
However, the intensity of the responses might differ, or certain shared factors may be more 
or less prominent depending on the infectious agent. As such, panels of biomarkers viewed 
in relation to each other and with well-defined thresholds could be informative for 
discriminating infections of different aetiologies. From the above datasets it would be 
interesting to look at several of the other proteins identified in addition to afamin. 
Angiotensinogen was found to be slightly elevated in infected samples. This protein is a 
competent of the renin-angiotensin system which regulates blood pressure, body fluid and 
electrolyte homeostasis, and it is a regulator of kidney function. Considering the pathology 
of HFRS this protein would be a very interesting candidate for further investigation, both in 
terms of acute disease and chronic complications. In addition, immune-function-associated 
proteins like properdin, a regulator of the alternative pathway of the complement system, 
and lumican, which mediates extravasation of neutrophils, would be very interesting to 
follow-up on(Hayashi et al., 2010). Both these proteins were found to be decreased in 
seropositive samples compared to seronegative ones, indicating they might be involved in 
processes that are activated in the human response to orthohantavirus infection.  
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3.4 Conclusion 
In the above study label free mass spectrometry complimented by immunological 
validation techniques were used to investigate putative novel biomarkers of 
orthohantavirus infection in human sera.  While the incorporation of convalescent sera at 
the discovery phase was not an optimal starting point for infection-related biomarkers, it 
did result in an interesting finding; the possibility of chronic changes in the serum proteome 
following a resolved orthohantavirus infection. While this would be fascinating to follow up, 
it could prove difficult because of the many possible confounders associated with long-term 
observations of populations, and the large numbers required for confident results.  
 The glycoprotein afamin was investigated as a putative biomarker for orthohantavirus 
infection. Whether or not the abundance of this protein was altered in response to 
infection remains inconclusive. In a cohort of eight acute disease samples compared against 
eight seronegative samples there was no measurable difference in afamin abundance. 
However, in a sequential set of sera from a single patient with HFRS, afamin abundance was 
decreased during acute disease compared to both a seronegative sample obtained pre-
infection and a convalescent sample from the same patient. Certainly, having access to 
more longitudinal samples such as the one used in this study, would increase the ability of 
detecting relative abundance changes with biological relevance.  In addition, considering a 
larger panel of proteins as biomarker candidates, and seeing them in relation to other 
infectious causes of AKI, especially leptospirosis, would provide stronger clinical relevance. 
Finally, it might be informative both in relation to rapid diagnosis of AKI and as an indication 
of the pathophysiology underlying AKI in HFRS, to consider changes in the urine proteome 
in response to orthohantavirus infection in addition to sera.    
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Chapter 4: Serum proteins associated with orthohantavirus 
infection in a pregnant patient 
4.1 Introduction 
One of the difficulties in studying the course of any infection in humans is gathering 
longitudinal samples.  This is particularly with regards to obtaining a sample prior to 
infection that can act as a base line comparator. In this study the serum proteome from a 
pregnant patient was analysed at the time of orthohantavirus infection.  Uniquely, a serum 
sample had been taken several months prior to both clinical symptoms and the positive 
diagnosis of orthohantavirus infection, and samples were also taken during acute infection 
and after the patient had recovered. This allowed for an unique analysis of temporal 
changes in protein abundance in her serum during and after disease, using the pre-infection 
seronegative specimen as a reference sample.   
Proteomics has not previously been applied to the analysis of the serum proteome 
during pregnancies complicated by any species of orthohantavirus. While orthohantavirus 
infections have previously been analysed by proteomic means in the context of hantavirus  
cardiopulmonary syndrome (HPS), this is the first temporal analysis of proteome changes 
during a case of haemorrhagic fever with renal syndrome (HFRS) (Bondu et al., 2015). 
Proteomic investigations of obstetric complications is an active area of research, with a 
focus on identifying biomarkers at an early screening stage that can predict later adverse 
pregnancy outcomes (Klein et al., 2014; Kolialexi et al., 2017). Proteomic investigations into 
infectious causes of obstetric complications mostly target amniotic fluids and placental 
tissue for analysis, as this is the site from which the most common infectious causes of 
adverse pregnancy outcomes stem from, such as Toxoplasma gondii infection and microbial 
invasion of the intra-amniotic cavity (Tambor et al., 2013; Jiao et al., 2017). 
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In this study the proteomes of the sera taken at different stages of infection were also 
compared to the serum proteomes from further patients taken either during acute 
orthohantavirus infection or when they were convalescent or from controls negative for 
orthohantavirus– specific antibodies.  These control patients were not detectably pregnant, 
and in contrast to the sequential samples from the pregnant patient, only a single sample 
was available for each individual control patient. The data identified changes in the serum 
proteome that could be correlated with pregnancy and viral infection. The data also 
provided information on the underlying phenotypic changes caused by the infection 
including evidence of cellular stress, disruption of haemostasis and activation of the acute 
phase response.  
4.1.1 Hypothesis 
Comparing the serum proteomes from a single individual prior to seroconversion, 
during active disease due to SEOV infection, and following recovery will reveal specific 
proteins with altered abundance levels as a result of clinical disease, shedding light on 
mechanisms involved in the pathology of HFRS.  
4.1.2 Case report 
A 28-year-old woman was admitted to hospital in July 2015 with a two-day history of 
pyrexia and malaise, for which she had received empirical cefalexin for a presumed urinary 
tract infection.  She was 25 weeks pregnant and had no significant past medical history. Her 
temperature was 39.6° C, heart rate 129 beats per minute and blood pressure 112/72. She 
remained pyrexial despite receiving empirical meropenem.  She had thrombocytopenia 
(nadir 49 x 109/L), raised transaminase levels (ALT 112 iu/L; normal <35) and raised serum 
creatinine, and was transferred to a tertiary obstetric unit on day four of illness with a 
diagnosis of possible HELLP syndrome (Hemolysis, Elevated Liver enzymes, and Low Platelet 
count) or acute fatty liver of pregnancy.   At this point she was apyrexial and was 
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normotensive but had marked pitting oedema.  She received dexamethasone 12 mg IM to 
induce fetal lung maturity in case urgent delivery was required. Investigations on day four 
of illness showed:  haemoglobin 104 g/L (normal 118-148), platelets 78 x 109/L (150-400), 
serum creatinine 234 µmol/L (50-130), serum ALT 122 iu/L (<35) and C reactive protein 157 
mg/L (<5).  Urine protein:creatinine ratio was raised at 76 mg/mmol (<45).  Bacterial 
cultures of blood and urine were sterile. Abdominal ultrasound scans showed no renal or 
liver abnormalities and there was normal fetal growth appropriate for gestation, with no 
features of uteroplacental insufficiency.   The patient mentioned that she kept and bred 
rats and suggested doing tests for leptospirosis and hantavirus. Paired serology was 
negative for leptospirosis but was strongly positive for Seoul (SEOV) and Hantaan virus 
(HNTV) IgG with titres of 1:1000 on day three of illness rising to 1:3200 on day five and a 
peak of 1:10000 on day 22, compared to negative results in the antenatal booking bloods 
taken 16 weeks previously.  There was weaker cross reactivity at lower titres with Puumala 
virus (PUUV), Dobrava virus (DOBV), Sin Nombre virus (SNV) and Saarema virus (all 1:1000). 
The patient was managed conservatively, and her laboratory parameters improved over the 
following five days and had normalised by day 22. Her pregnancy proceeded uneventfully.  
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4.2 Results  
4.2.1 Preparing serum samples for proteomic analysis 
To enhance protein identification and quantification from these field samples (table 13), 
and to enrich detection of lower abundance proteins, the longitudinal samples from the 
pregnant female were depleted of the most common high abundance serum proteins as 
detailed in chapter 2.2. This resulted in an approximate 75% decrease in total protein 
concentration for each sample.  This was visualized by SDS-PAGE where the crude and 
depleted samples were compared side by side (figure 4.1A). Depletion of high abundance 
proteins and concomitant enrichment of lower abundant proteins was confirmed by 
western blot, comparing human serum albumin (normal range; 34-54 g/L) and C-reactive 
protein (CRP) (normal range < 0.003 g/L) in crude and depleted samples (figure 4.1B). The 
comparative non-pregnant samples had been previously processed in the same manner 
(see chapter 3.2.2).  
Table 13. Sequential sera from a pregnant woman with HFRS 
Sample 
identifier Serostatus 
Date of 
sampling 
Total number of 
proteins 
identified by MS 
Proteins 
identified by a 
single peptide 
Negative Seronegative 06.03.2015 534 173 
Acute day 3 Seropositive 03.06.2015 561 196 
Acute day 4 Seropositive 04.06.2015 564 197 
Acute day 5 Seropositive 05.06.2015 553 187 
Acute day 7 Seropositive 07.06.2015 557 193 
Convalescent Seropositive 27.06.2015 549 186 
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Figure 4.1. Total protein stain and western blot analysis of patient sera confirming 
depletion of high abundance proteins. A, SYPRO Ruby total protein stain of the sequential 
sera sample set, n = 6. Numbers 3-7 denotes day of clinical symptoms. For each sample 
an undepleted (lane marked C for crude) and a depleted (lane marked D for depleted) 
specimen was loaded next to each other on the gel to visualize the difference in protein 
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concentration before and after immunodepletion. Each lane was loaded with 2.5 µg 
protein. B, Western blot for albumin (75 kDa) left, and CRP (24kDa) right, of one 
representative sample (day five of clinical symptoms) from the sequential sera set. By 
western blotting the detection of a high abundance protein (albumin) and a low abundance 
protein CRP in a single sample before (C) and after (D) immunodepletion could be 
compared. Each lane was loaded with 2.5 µg protein. CRP; C-reactive protein. 
4.2.2 Protein identification and quantitation by label free-mass spectrometry 
Proteins in the immunodepleted samples were identified and quantified by label-free 
mass spectrometry as detailed in chapter 2.7.  Filtering the results for contaminants and  
proteins identified by a single unique peptide left a total of 357 proteins common to all the 
samples taken from the pregnant female and 381 proteins common to all the samples taken 
from the non-pregnant control group (appendix B.2 and appendix B.1, see chapter  3.2.3). 
4.2.3 Analysis of protein abundance in the longitudinal sample set taken from a 
SEOV positive pregnant female 
In order to derive meaningful functional information from the longitudinal samples the 
proteome was clustered using GproX (Rigbolt et al., 2011). Using this software, proteins 
with similar patterns of abundance change with time could be grouped together (figure 4.2, 
appendix B.3). Thus five clusters of distinct temporal regulation were identified. Clustered 
proteins were assigned membership values to their cluster ranging from 0-1. This value 
indicated the goodness of fit of the specific protein entry to a cluster, with higher 
membership values equating better fit. From the five clusters all proteins with high 
membership values (≥ 0.6) were extracted to investigate if there were any functional links 
associated with the patients' pregnancy and disease status that emerged from the 
regulatory patterns. Cluster 1 had a pattern of relatively low abundance at the seronegative 
time-point followed by sustained elevation in protein abundance from day one acute 
through to convalescence (figure 4.2). In this cluster 22 proteins had membership values ≥ 
0.6, and of these 22 proteins 13 were specifically associated with pregnancy. Two blood 
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coagulation factors, fibrinogen alpha chain and coagulation factor VII, were also identified in 
cluster 1 (appendix B.3).  
  
Figure 4.2. Clustering of proteins identified by the proteomics analysis into similar 
patterns of temporal changes in abundance. Unsupervised clustering by the Fuzzy C-means 
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algorithm was done using GProX software version 1.1.16. 357 proteins, filtered for human 
ID and ≥ 2 unique peptides, were included in this analysis. Of the 357 proteins, 31 were 
grouped in a cluster in which no proteins reached a membership value above 0.6. This 
cluster was therefore excluded from further analysis, leaving a total of 326 proteins. 
Proteins were included in a cluster if they reached a minimum fold change in abundance 
between highest and lowest state = 2 and a q-value < 0.05.  Cluster 0 contained 108 
proteins that did not reach these set filter thresholds, leaving a total of 218 proteins across 
clusters 1 - 5.  The x-axis numeric 3-7 equates day of clinical symptoms. Neg; seronegative 
sample; Con; convalescent sample (22nd day of illness). 
4.2.4 The pregnancy-associated protein hCG did not conform to the kinetics of 
cluster 1 
The pregnancy-associated protein choriogonadotropin subunit beta variant 1 (hCG) was 
detected in the patient’s sera, as would be expected in pregnancy sera, as this protein is 
produced by the embryo and placenta early following conception. The longitudinal analysis 
showed that hCG did not, however, follow the temporal regulatory pattern of other 
pregnancy-associated proteins identified in cluster 1. Rather, it scored a 0.6 membership 
value to cluster 4 (figure 4.2, appendix B.3), a cluster dominated by antibody subunits and 
associated with a decrease in abundance during acute disease. The abundance of hCG was 
highest in the seronegative sample and declined during acute disease (figure 4.3). 
Compared to the acute samples the abundance of hCG was elevated in the convalescent 
specimen, though at this time point remained lower than the level measured at the 
seronegative baseline.  
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Figure 4.3. Heatmap of selected pregnancy-associated proteins from cluster 1 and 
choriogonadotropin  subunit beta. The heatmap was made in Perseus ver. 1.5.1.6, using the 
k-means algorithm. hCG does not follow the temporal abundance pattern of the other 
pregnancy-associated proteins identified in cluster 1 but decreases during acute disease 
and subsequently increases somewhat in the convalescent sample.  
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4.2.5 Proteins in cluster 2 were elevated during illness and contained putative 
markers for orthohantavirus infection  
Proteins in cluster 2 were elevated in abundance during illness compared to the 
seronegative and convalescent specimens (figure 4.2). This cluster contained 41 high 
membership proteins (i.e. proteins scoring > 0.6). Of these several were immune response-
associated proteins. Of the 41 proteins, eight proteins were classified as positive acute 
phase reactants (appendix B.3). The cluster also contained two innate immunity pattern 
recognition receptors, five receptors facilitating migration and adherence of immune cells to 
the vasculature, as well as proteins involved in angiogenic activity and proteasome subunits 
suggestive of increased proteolytic activity (appendix B.3). To identify proteins with 
abundance changes that might be specifically related to the patient’s viral infection, high 
membership protein hits from cluster 2 were compared with an independent dataset of n = 
10 single time-point serum samples. This comparison revealed 11 proteins present in both 
datasets with elevated abundance in acute samples compared to seronegative and 
seropositive convalescence samples (figure 4.4).  
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Figure 4.4. Log2 transformed abundance levels of 11 selected proteins identified in 
cluster 2 (acute phase cluster) of the longitudinal dataset (n = six) with membership scores ≥ 
0.6. These 11 proteins were additionally identified in an independent sample cohort of n = 
10 individual samples, following the same trend of abundance change as the acute phase 
cluster. In both datasets protein abundance was increased in the acute disease samples 
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compared to seronegative and seropositive convalescent specimens. The independent 
sample set consisted of 10 single time point; one x acute hantavirus infection sample, four x 
seropositive convalescent for hanta-antibodies and five x hantavirus seronegative samples. 
Fibrinogen gamma chain (FIBG), galectin-3-binding protein (G3BP), plastin-2 (PLAS), 
lipopolysaccharide binding protein (LBP), inter alpha trypsin heavy chain H3 (ITIH3), 
scavenger receptor cysteine-rich (SCAV), vascular adhesion molecule 1 (VCAM), proteasome 
subunit alpha type-6 (PA6), proteasome subunit beta type-1 (PB1), c-reactive protein (CRP), 
serum amyloid a-1 (SAA). A, log2 abundance levels of the 11 selected proteins in the 
sequential samples from the pregnant patient. AVG acute = the average value of four acute 
disease samples obtained in sequential days of hospitalization. Convalescent = sample taken 
approx. three weeks after the patient recovered. Seronegative = sample taken approx. three 
months prior to the patient was hospitalized and seroconverted. Error bars indicate 1 x 
standard error. B, log2 abundance levels for the 11 selected proteins in the independent 
single time point sample cohort. The convalescent and seronegative values are the average 
values of four and five individual samples respectively, while the acute measurement is the 
value of a single sample. Error bars indicate 1 x standard error.   
 
To investigate whether these results could be replicated in a larger sample cohort, an 
ELISA was done to quantify galectin-3-binding protein (G3BP) concentrations in an 
independent cohort of eight hantavirus seronegative, eight hantavirus seropositive 
convalescent and seven acute hantavirus-infected samples that had not previously been 
analysed by mass spectrometry (figure 4.5A). In the pregnant woman the abundance of 
G3BP was elevated in all four samples taken during her hospitalisation with HFRS as 
compared to the seronegative baseline and the convalescent sample from three weeks after 
hospitalisation (figure 4.4). G3BP was chosen for initial validation because increased levels 
of this protein has been associated with acute orthohantavirus infection previously 
(Hepojoki et al., 2014). The median G3BP abundance concentration of the acute 
seropositive samples (53.9 ng/ml) was higher than both the seronegative and seropositive 
convalescent sample medians (42.9 ng/ml and 32.4 ng/ml respectively). Individual 
concentration measurements were variable in all groups, especially in the seropositive 
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acute group (interquartile range; 42.4ng/ml - 87.1 ng/ml).  The difference between the 
groups was not found to be statistically significant by an ANOVA on ranks (p = 0.06). The 
highest concentration of G3BP was measured in an outlier of the seronegative group (99.4 
ng/ml, interquartile range; 35.7ng/ml – 45.1ng/ml).  To establish whether elevated G3BP 
was a generic response to infection or a specific response to orthohantavirus infection, 
levels of G3BP in acute orthohantavirus infected sera were compared to levels measured in 
acute leptospirosis infected sera.  Leptospirosis was chosen because this bacterial disease is 
a common differential diagnosis for HFRS, due to its similar epidemiology and clinical 
presentation (Forbes et al., 2012). The levels of G3BP were higher in leptospirosis-infected 
sera than in orthohantavirus infected sera, though not significantly so (median; 79.9 ng/ml 
and 31.7 ng/ml respectively, p = 0.06) (figure 4.5B). There was, however, a significant 
difference between acute leptospirosis and the healthy control samples (p < 0.05) while this 
was not the case when comparing acute orthohantavirus with healthy controls.  
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Figure 4.5 A, Galectin-3-binding protein (G3BP) concentrations in orthohantavirus -
seronegative and orthohantavirus-seropositive human sera. G3BP concentrations were 
measured in eight seronegative (green), seven seropositive acute (red) and eight 
seropositive convalescent (orange) samples by a sandwich ELISA (Affymetric eBiosciences). 
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These 23 samples were independent of both mass spectrometry analysed datasets. Optical 
densities were measured at 450 nm. Standards and samples were measured in duplicate. 
Medians, 25 % - and 75 % - quartile ranges for the groups were, seronegative; 42.9 ng/ml, 
35.7 ng/ml, 45.1 ng/ml, seropositive acute; 53,9 ng/ml, 42.4 ng/ml and 87.1 ng/ml, 
seropositive convalescent; 32.4 ng/ml, 29.3 ng/ml and 42.9 ng/ml.  Kruskal-Wallis ANOVA 
on ranks p-value = 0.06. B, concentrations (of G3BP in orthohantavirus-seronegative (n = 
four, green), acute orthohantavirus (n = seven, red) and acute leptospirosis (n = seven, 
burgundy). Optical densities were measured at 450nm. Standards and samples were 
measured in duplicate. Medians and interquartile ranges for the groups were, seronegative; 
22.6 ng/ml, 25%; 20.5 ng/ml, 75%; 30.5 ng/ml, acute orthohantavirus: 31.7 ng/ml, 25%; 
20.3 ng/ml, 75%; 55.5 ng/ml, acute leptospirosis; 79.9 ng/ml, 25%; 49.8 ng/ml, 75%; 135.4 
ng/ml. There was a significant difference in median values of seronegative and acute 
leptospirosis samples by Kruskal-Wallis one way ANOVA on Ranks with Dunn’s multiple 
comparison, p = 0.017 
 
4.2.6 Temporal regulatory patterns consistent with infection and consumption of 
clotting factors 
Clusters 3 and 4 contained proteins associated with an activated immune or 
inflammatory response (figure 4.2, appendix B.3). Cluster 3 peaked at day two of 
hospitalisation and contained 19 proteins with membership values ≥ 0.6. 14 of these high 
membership proteins were functionally associated with a response to oxidative stress and 
neutrophil activity. Cluster 4 mainly contained Ig-subunits (25 of 37 high membership 
proteins), but also three common negative acute phase reactants, i.e. proteins that are 
generally reduced in blood during acute infection. Cluster 5 decreased in abundance at day 
one followed by a steady increase back to pre-infection levels at the convalescent time-
point. Of 28 proteins with membership values ≥ 0.6, 18 were proteins associated with 
platelet activation and blood coagulation pathways. A few proteins involved in platelet 
activation were also present in cluster 2 (appendix B.3). Platelets become activated when 
encountering damaged endothelium or in response to pro-inflammatory mediators (Esmon, 
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2005). In contrast to inactive platelets that are repelled by the healthy endothelium, 
activated platelets become adhesive and attached to the endothelium and form aggregates. 
The platelets secrete the contents of their granules, which contain pre-formed pro-
coagulative, pro-inflammatory mediators and factors promoting aggregation (Esmon, 2005; 
Van Hinsbergh, 2012). As identified for cluster 4, cluster 5 also contained some negative 
acute phase reactants. 
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4.3 Discussion 
In this study label-free mass spectrometry was used to investigate temporal abundance 
changes in the serum proteome of a pregnant patient before, during and following an 
incidence of HFRS. The proteome data could be grouped into five discrete clusters 
associated with time of infection and biological function.  The identification in cluster 1 of 
pregnancy-associated proteins with a temporal abundance pattern consistent with an on-
going pregnancy provided a qualitative and quantitative assurance that the method used 
was able to detect expected abundance changes in clinically relevant proteins. For instance, 
chorionic sommatomammotropin, is a hormone expressed exclusively during pregnancy 
(Walsh and Kossiakoff, 2006). Pappalysin-1 is expressed at high levels in the placenta and 
serum, with levels rising throughout pregnancy. It directly interacts with bone marrow 
proteoglycan, levels of which also increase in placenta and serum during pregnancy 
(Overgaard et al., 1999). All three of these proteins had membership values of 0.9 to cluster 
1.  The detection of coagulation factors in the cluster is consistent with haemostatic changes 
that occur during the course of a normal pregnancy, as the concentration of fibrinogen and 
several coagulation factors increase, peaking around term (Brenner, 2004). Of interest, the 
pregnancy-associated protein hCG, though detected in the sera of the pregnant patient, did 
not follow the same regulatory pattern of other pregnancy-associated proteins identified in 
the dataset. hCG is a hormone important for maintaining a functional corpus luteum, an 
endocrine structure necessary for establishing and maintaining pregnancy. The abundance 
changes observed in the longitudinal dataset studied here could possibly be a reflection of 
the natural progression of hCG levels during an uncomplicated pregnancy, as the levels of 
this hormone rises drastically during early pregnancy, peaking around 10 weeks, after which 
it declines and reaches a stable level that is maintained until birth (Rull and Laan, 2005). 
However, the relatively lower hCG abundance during acute disease could also be caused by 
a direct or indirect suppressing effect that the viral infection had on abundance levels of this 
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hormone. As the seronegative specimen was taken around nine weeks of pregnancy, and 
the patient fell ill at 25 weeks, it is likely that the former scenario has been observed in this 
case (Nelson-Piercy 2014 , personal communication). It is important to add that the 
abundance changes observed for Cluster 1 may have been impacted by variable levels of 
depletion, especially with regards to the seronegative sample which was less efficiently 
depleted than the other samples of the set (figure 4.1A). This inconsistency may have 
resulted in a greater observed difference between the seronegative sample and the rest of 
the data set than is actually the case, due to a higher concentration of high abundance 
proteins sill present in the former. Though a rare occurrence, there are a few clinical reports 
of pregnancies complicated by PUUV, DOBV and Seoul virus (SEOV) infections from Europe, 
SNV infections from America, and Haantan virus (HNTV) infections from Asia (Howard et al., 
1999; Kim and Choi, 2006; Hofmann et al., 2012; Macé et al., 2013). SNV infection during 
pregnancy has resulted in both maternal and foetal mortality, while for HNTV there are no 
reports of maternal mortality, though a few cases resulting in the death of the infant. From 
Europe there are no reports of orthohantavirus infections during pregnancy that have 
ended with fatal outcomes for either mother or child. In all reported cases with positive 
outcomes for both mother and child, there is no evidence of vertical transmission of the 
virus or other adverse outcomes for the newborn infant.  
 
From cluster 2 several proteins linked to an acute infection were identified. Acute phase 
reactants are proteins produced and secreted by the liver in response to inflammatory 
signals, such as cytokines (Murphy, 2012). Orthohantavirus infection is known to elicit a 
strong immune response, characterized by a so-called «cytokine-storm» with high levels of 
pro-inflammatory cytokines produced during acute disease and elevated CRP is a common 
clinical finding for HFRS (Borges et al., 2008; Jonsson et al., 2010; Sadeghi et al., 2011; Korva 
et al., 2013). As the temporal pattern of this cluster was such that increased protein 
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abundance was maintained at a relatively stable level throughout the patient’s 
hospitalisation, these proteins were deemed appropriate candidates for comparison to non-
sequential samples. This comparison revealed 11 proteins with corresponding patterns of 
abundance change in both datasets. Among these 11 proteins G3BP was identified, and in a 
cohort of n = 23 independent samples the same trend of elevated abundance during acute 
orthohantavirus infection was again observed for G3BP. Though a statistically significant 
difference could not be demonstrated between the groups in this latter cohort, the majority 
of the acute seropositive samples did have abundance levels of G3BP exceeding those 
observed for the two other groups. It is necessary to investigate changes in G3BP linked to 
orthohantavirus infection in larger cohorts of HFRS-diagnosed patients, as a major drawback 
of this study was the small sample size, which impacts on statistical power. G3BP is a 
secreted glycoprotein with pleiotropic functions associated with infection, inflammation, 
developmental regulation and cancer (Than et al., 2015; Desmedt et al., 2016). The binding 
partner of G3BP, galectin-3, has also been linked to both acute and chronic renal 
pathologies and infectious and inflammatory disorders of the female reproductive tract 
(Than et al., 2015; Desmedt et al., 2016). G3BP is linked to integrin function, which is 
notable considering that in vitro integrins act as essential cellular receptors for 
orthohantaviral entry to unpolarised host cells (Gavrilovskaya et al. 1999; Gavrilovskaya et 
al. 1998; Mou et al. 2006). Infection of human umbilical vein endothelial cell with the 
orthohantaviral species PUUV, Prospect Hill virus  and Tula virus have been demonstrated to 
induce G3BP expression in these cells (Hepojoki et al., 2014). In vivo, G3BP was increased in 
the serum of macaques experimentally infected with PUUV (Klingstrom et al., 2002; 
Hepojoki et al., 2014), and G3BP was also elevated in sera of patients with acute PUUV 
infection compared to convalescence and correlated to clinical symptoms of NE (Hepojoki et 
al., 2014). G3BP has additionally been found to be elevated in the sera of patients with 
dengue fever, as well as in HIV positive individuals where its source has been postulated to 
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be latently infected T cells (Yang et al., 2014; Liu et al., 2016). In this study, by comparing 
acute orthohantavirus samples with acute leptospirosis samples it was demonstrated that 
G3BP, in addition to being elevated in orthohantavirus infection, was elevated in sera from 
individuals with an acute leptospirosis infection. The levels of G3BP were higher in acute 
leptospirosis sera than in acute orthohantavirus infected sera. Seeing as G3BP is elevated in 
several infections, it is likely involved in a generic response to infection. G3BP has been 
shown to be a stimulator of the proinflammatory cytokine interleukin (IL)-6 in cancer, and 
has been positively correlated with increased IL-6 production in cultured human peripheral 
blood mononuclear cells (Kalayci et al., 2004; Silverman et al., 2012). In a murine model, 
G3BP and its ligand galectin-3 contributed to venous thrombosis through a 
proinflammatory, IL-6 dependent, mechanism (Deroo et al., 2015). IL-6 is elevated in both 
orthohantavirus and leptospirosis infections, as a factor of the “cytokine storm” (Borges et 
al., 2008; Sadeghi et al., 2011; Korva et al., 2013; Haake and Levett, 2015). Elevated levels of 
IL-6 have been linked to disease severity in both NE and HPS (Borges et al., 2008; Sadeghi et 
al., 2011). The serum levels of G3BP differed quite substantially between the two infections 
investigated in this study, possibly a reflection of difference in disease severity between 
individual patients. Alternatively, it could be a reflection of a pathogenic mechanism, that 
though not specific for any of the infections, differs on a quantitative level. As the samples 
investigated were residual sera from diagnostic testing, and the length of storage of the 
samples before analysis was unknown, this could also have affected the quality and 
measurable levels of G3BP in individual samples. Putatively, better knowledge of the 
absolute and relative levels of this protein in acutely ill patients could contribute to 
differentiate infections of orthohantavirus from leptospirosis, or give insight into 
mechanisms of pathology and host response in illnesses characterized by haemorrhagic 
complications.  
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Cluster 3 contained several proteins related to oxidative stress and neutrophil function. 
The temporal pattern observed for this cluster was consistent with an acute infection, in 
which a rapid innate immune response is launched. The proteins identified for cluster 4 
seemed to reduce in abundance throughout acute illness. Possibly this reflected a 
measurable consumption of orthohantavirus-specific antibodies, though this would indicate 
a very rapidly developed humoral response. Such a rapid humoral response is a possible 
scenario, as orthohantavirus-specific antibodies can be detectable very early on following 
infection, and in some cases high, stable levels of IgG are already detected when a patient 
presents acutely ill at hospital (Niklasson and Kjelsson, 1988). 
 
Several blood clotting factors were identified in cluster 5, with a steep decrease in 
abundance at the first day of hospitalisation followed by a gradual increase in abundance on 
sequential days, reaching pre-infection levels at convalescence. Clinical orthohantavirus 
infections are characterized by altered barrier functions of the vascular endothelium, 
causing systemic vascular leakage in the absence of cytopathic effects (Jonsson et al., 2010). 
Damage to the vasculature, inflammatory mediators and an endothelium responding to 
vasoactive agents are all triggers of the blood coagulation cascade (Esmon, 2005; Van 
Hinsbergh, 2012). While changes to the vasculature would be expected during an 
orthohantaviral infection, it is necessary in this case to consider that pregnancy causes a 
state of hypercoagulation, and as such could confound findings of vascular disturbance in 
the context of a haemorrhagic illness such as HFRS (Brenner, 2004). A putative mechanism 
for increased vascular leakage in orthohantavirus- infected HUVECs involves activation of 
the plasma kallikrein-kinin system and increased production of bradykinin, a peptide that 
promotes vasodilation and increased vascular permeability (Taylor et al., 2013). Successful 
treatment of a near fatal PUUV infection with ictibant, a bradykinin receptor antagonist, 
supports the finding that increased bradykinin activity might play a role in orthohantavirus 
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pathogenesis (Antonen et al., 2013). Plasma kallikrein was identified in cluster 5 with a 
membership value to the cluster of one, indicating its involvement during acute disease in 
the case of the pregnant patient analysed in this study. Possibly the dramatic fall in 
abundance measured at the first day of hospitalisation, could be due to an increased 
consumption of this protein as a result of an activated plasma kallikrein-kinin system. The 
end product of this system, bradykinin, was however not detected in this dataset.  
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4.4 Conclusion 
Using label-free mass spectrometry to measure temporal changes in the serum 
proteome of a pregnant patient with concomitant HFRS and using GProX to group proteins 
with similar patterns of temporal regulation, functional changes associated with an on-
going pregnancy, an activated immune response, cellular stress and vascular disturbance 
could be identified. The fact that the investigated longitudinal sample set contained a pre-
infection specimen was beneficial, as it allowed a direct comparison of the patient’s 
diseased state with her own healthy baseline. This meant the difficulty of comparing the 
highly variable serum proteomes of random individuals could be circumvented. 
Conveniently, the pregnancy-associated proteins could also be viewed as an internal quality 
control for the proteomic approach. A number of specifically disease related proteins were 
identified as elevated during acute disease in a comparative analysis in which the 
longitudinal dataset was compared to a second proteomic dataset of non-sequential sera. 
The identification of the glycoprotein G3BP in this group of elevated proteins was notable, 
as it is a protein that has been demonstrated to be elevated and associated with disease 
severity in orthohantavirus infections by others. In this study, G3BP was additionally found 
to be elevated in an independent group of acute orthohantavirus infected sera compared to 
convalescent and seronegative controls. The protein was also elevated in sera from acute 
leptospirosis patients, with higher levels measured in acute leptospirosis compared to 
orthohantavirus infections. G3BP has both pro-inflammatory and pro-coagulant properties 
and has been associated with a range of pathological conditions in which inflammation, 
infection and vascular activation is involved. The results of this study further support its role 
as a factor that is involved in the host response to acute infections in which an activated 
vascular endothelium is a characteristic feature. Regarding the clotting factors identified in 
the longitudinal analysis, it is difficult to extrapolate these findings to other non-pregnant 
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orthohantavirus infected patients, due to the fact that pregnancy is a state that dramatically 
alters the equilibrium of haemostatic processes, which could confound the results.    
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Chapter 5: Interactome of Seoul Cherwell orthohantavirus 
glycoproteins in HEK293T cells 
5.1 Introduction 
The Hantaviridae genome consists of three genomic segments; small (S), medium (M) 
and large (L).The L segment encodes a RNA-dependent RNA-polymerase, the M segment 
the glycoprotein precursor (GCP) and the S segment the nucleoprotein (N)  (Hepojoki et al., 
2012). The GCP is co-translationally cleaved at a conserved site to form the two mature 
viral glycoproteins; Gn and Gc (Lober et al., 2001). On the viral envelope Gn and Gc form 
spike complexes made up of hetero-tetrameric associations of the two proteins (Huiskonen 
et al., 2010; Battisti et al., 2011). These complexes facilitate viral entry into host cells 
through interactions with cellular surface proteins. In vitro, integrins, CD55/DAF and gC1qR 
have all been implicated as viral receptors (Gavrilovskaya et al., 1998, 1999; Mou et al., 
2006; Choi et al., 2008; Krautkramer and Zeier, 2008).  Interestingly, pathogenic and non-
pathogenic orthohantaviruses rely on different host receptors for infection of human 
endothelial cells, with pathogenic strains binding to β3-integrins, while non-pathogenic 
species require the presence of β1-integrins (Gavrilovskaya et al., 1998, 1999). Inside the 
cell, orthohantaviral glycoproteins interact with both viral and host proteins. Interactions 
between the glycoproteins, N protein and viral RNA is speculated to be the mechanism by 
which viral envelope proteins and ribonucleoproteins combine, facilitating assembly of 
virions in the absence of matrix proteins found in other viruses with negative strand RNA 
genomes (Hepojoki et al., 2010; Wang et al., 2010). The Gn cytoplasmic tail (GnCT) of new-
world orthohantaviruses has been implicated as a virulence factor, with the ability to 
regulate the early anti-viral response. GnCT can interact with the cellular host protein TNF 
receptor associated factor 3 (TRAF3), an essential component of the signalling cascade 
leading to transcription of type-I interferon (IFN) in response to viral infections. Both viral 
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infection and expression of the GnCT alone inhibits the ability of TRAF3 to interact with 
TANK-binding kinase 1 (TBK1), an interaction which is necessary for downstream IFN 
production (figure 5.1) (Alff et al., 2008). However, removal of the TRAF3 binding element 
of GnCT does not abrogate the proteins’ ability to regulate IFN responses, indicating that 
TRAF3 binding alone is not sufficient to explain how this regulation occurs (Matthys et al., 
2014).  
 
Figure 5.1. Type I IFN induction by viral infection through RLR and TLR3 signaling, adapted 
from www.invitrogen.com Copyright © 2011-2016 InvivoGen. The RLRs (MDA5, LGP2 and 
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RIG-I) and TLR3 initiates type I IFN production in response to viral infection. The GnCT of 
orthohantaviruses inhibits the interaction of TRAF3 and TBK1, thus abrogating downstream 
signaling events.  MDA-5; melanoma differentiation associated gene, 5 LGP2; laboratory of 
genetics and physiology 2, RIG-I; retinoic acid inducible gene 1, IPS-1;interferon-β promoter 
stimulator 1, TRAF; TNF associated factor, NAP1; NF-κB–activating kinase-associated 
protein 1, TBK1; TANK-binding kinase 1, IKK; Inhibitor of  nuclear factor kappa-B kinase, 
TANK; Traf family member-associated NF-κB activator, IRF; interferon regulatory factor, 
ISRE; interferon sensitive response element, IFN; interferon, TRIF; TIR domain-containing 
adaptor protein inducing interferon-β, TLR3; toll-like receptor 3, ECM; extracelluar matrix. 
 
The sites of viral assembly and budding have not been definitely defined for 
orthohantaviruses. Like other Bunyaviruses they predominantly seem to assemble and 
mature at the Golgi complex (Shi and Elliott, 2002; Kariwa et al., 2003; Spiropoulou et al., 
2003; Deyde et al., 2005). However, aggregation of glycoproteins and viral budding has also 
been observed at the plasma membrane and endoplasmic reticulum (ER) for certain 
orthohantaviral species (Goldsmith et al., 1995; Spiropoulou et al., 2003; Ogino et al., 2004; 
Xu et al., 2007).   
In their natural hosts, orthohantaviruses actively replicate and persist in the absence of 
disease (Easterbrook et al., 2007; Schountz et al., 2012; Vaheri, Strandin, et al., 2013). As 
clinical disease in humans is believed to be, at least partially, a consequence of the host 
response, more insight into how the virus interacts with host factors might shed light on 
pathogenic mechanisms underlying clinical symptoms. In addition, understanding how the 
virus interacts with, and utilizes the cellular machinery to its advantage could provide novel 
drug target candidates. The current treatments for haemorrhagic fever with renal 
syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HPS) are symptomatic. A 
clinical trial run in the mid 1980’s demonstrated positive effects of ribavirin administration 
in Chinese HFRS patients, with reported lower case-fatality rate and decreased occurrence 
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of oliguria6 among ribavirin-treated patients (Huggins et al., 1991). These results have, 
however, not been convincingly replicated, and ribavirin has not shown efficacy in the 
treatment of HPS or nephropathia epidemica (NE) (Chapman et al., 1999; Mertz et al., 
2004; Rusnak et al., 2009; Malinin and Platonov, 2017).  Administration of human immune 
sera has shown promise as a treatment of Andes virus (ANDV), and there are in vitro and in 
vivo indications that drugs that antagonise the increased vascular permeability induced by 
orthohantavirus infection might have value as clinical treatments (Gorbunova et al., 2011; 
Antonen et al., 2013; Vial et al., 2015).  
For this study label-free proteomics was used to study the interactome of recombinant 
SEOV Cherwell glycoproteins in HEK293T cells, a human embryonic kidney cell line. The 
objective of this investigation was to gain further insights into cellular mechanism involved 
in the processing of the viral glycoproteins through host cells, and the cellular proteins they 
associated with. Future work could be focused on disrupting these protein:protein 
interactions to e.g. reduce the viral load. 
5.1.1 Hypothesis 
Orthohantaviral glycoproteins play a role in both the processing and assembly of the 
virus within cells and can act as a virulence factor with the ability to modify the cellular 
response to infection. By investigating the interactome of SEOV Cherwell glycoproteins, 
host proteins that interact with the viral proteins can be identified, providing insights into 
host factors that can be targeted in an effort to disrupt the function of the viral 
glycoproteins.   
 
                                                          
6 Oliguria is defined as urine output of less than 400 ml / day 
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5.2 Results 
5.2.1 Production of plasmids carrying the full-length GCP of SEOV Cherwell 
Several studies have demonstrated that proper trafficking of the viral glycoproteins 
through cells require that they are co-expressed, either through a single plasmid encoding 
the full-length GCP or through co-transfection of separate plasmids encoding Gn and Gc  
respectively (Shi and Elliott, 2002; Spiropoulou et al., 2003; Deyde et al., 2005)  As such, 
plasmids expressing the full length M segment open reading frame of Seoul virus (SEOV) 
Cherwell (GenBank accession; KM948593.1) were produced by GeneArt Synthesis 
(Invitrogen). Using the NCBI BLAST® tool, the sequence of the SEOV Cherwell GCP was 99% 
identical at the protein level and 95% identical at the nucleotide level to the SEOV 
glycoprotein reference sequence (SEOV 80-39, NCBI reference sequence; NP_942557.1). 
The inserted gene in the eGFP-C1 vector was 3419bp, making the entire plasmid (vector + 
insert) 8097bp, and in the eGFP-N1 vector the inserted gene was 3416bp, making the entire 
plasmid 8074bp. Following large scale production of plasmid DNA stocks, the size of the 
gene inserts were confirmed by restriction digestion. 
5.2.2 Transfection of HEK293T cells with plasmids containing the SEOV Cherwell 
GCP.  
To express viral glycoproteins for downstream analysis, HEK293T cells were seeded in 
six well plates and transfected with either eGFP-C1 as a positive control, eGFP-N1-GCP, 
eGFP-C1-GCP or were mock transfected. To establish that the procedure had been 
successful, cells were visualised under fluorescent microscope 16-24 hours following 
transfection. Cells transfected with the eGFP-N1-GCP plasmid exhibited high expression 
levels of GFP-tagged proteins, while cells transfected with the eGFP-C1-GCP plasmid 
exhibited a much lower transfection efficiency (figure 5.2A). As the GCP is co-translationally 
cleaved into Gc and Gn, this indicated good expression of Gc but poor expression of Gn 
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following transfection with plasmids encoding the full-length M segment open reading 
frame. The GCP of SEOV Cherwell has a molecular weight of approximately 125kDa, while 
Gn and Gc have approximate weights of 65-75kDa and 55kDa respectively. To further 
validate appropriate protein expression, the cells were lysed and proteins were extracted 
and subsequently visualised by western blotting using a GFP-specific antibody (figure 5.2B). 
GFP-tagged Gc was detected at with an expected molecular weight of approximately 
80kDa, while the GFP-tagged Gn protein, with an expected combined molecular weight of 
approximately 95kDa, was not detected. This corroborated what had been observed by 
fluorescent microscopy. Due to these results, subsequent experiments were conducted 
using only the eGFP-N1-GCP plasmid.    
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Figure 5.2 A, fluorescent microscopy visualizing GFP-tagged viral protein-expression 24 
hours following calcium phosphate transfection of HEK293T cells. The expression of eGFP-
N1-GCP was good (N1, bottom left), while the expression of eGFP-C1-GCP was poor (C1, 
bottom right). B, western blot for GFP-tagged Gn and Gc using a GPF-specific antibody. 
GAPDH was used as a loading control. The expected mw for GFP-Gc was 80kDA (55kDA + 
27kDa). For GFP-Gn a band was expected, but not detected, at 95kDa (65kDa + 27kDa). The 
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high mw bands detected on the top of the blot could be heterodimers of Gn and Gc or 
possible multimers of one of the proteins. These unspecific high mw band could 
alternatively be IgG from the beads, as IgG has an approximate mw of 150kDa. Sn; 
supernatant, P; pellet, M; mock. GFP; GFP transfected, N1; eGFP-N1-GCP transfected, C1; 
eGFP-C1-GCP transfected, NC; negative control, GFP; green fluorescent protein, SEOV; 
seoul virus.  
 
5.2.3 12 cellular proteins form associations with Gc 
To elucidate cellular interacting partners of Gc, HEK293T cells were seeded in 10cm 
dishes and transfected with either eGFP-C1, eGFP-N1-GCP, or were mock transfected. For 
each condition, transfections were performed in triplicate. Following successful 
transfection, as determined by fluorescent microscopy, the cells were lysed, and proteins 
were extracted and co-immunoprecipitated using GFP-trap (Chromotek) as detailed in 
chapter 2.14. Expression of the GFP-tagged Gc protein was validated by western blotting 
(figure 5.3), before the lysates were analysed by mass spectrometry (see chapter 2.7.2 and 
2.7.3). 
  149 
 
Figure 5.3. Western blot for Gc using a GFP-specific antibody. The expected band for Gc 
(with GFP-tag) was 80kDa. Transfections were done in triplicate, and protein extractions 
were performed with non-denaturing lysis buffer. GAPDH was used as a loading control. R1-
R3; replicate one-three. GFP; GFP transfected. N1; eGFP-N1-GCP transfected. M; mock 
transfected. NP; negative control. GFP; green fluorescent protein, SEOV; seoul virus.  
 
 By mass spectrometric analysis 233 proteins were commonly identified across the 
three conditions. Filtering of the results to include only those proteins identified by ≥ 2 
unique peptides left 211 proteins (appendix B.4). In a comparison of eGFP-N1-GCP and 
eGFP-C1 pulldowns, 12 proteins, excluding the viral glycoprotein itself, exceeded the 
threshold levels for fold change (FC) and p-value (FC > 2 and p-value < 0.05) required to be 
considered interacting partners of Gc (table 13, figure 5.4). Based on GO annotations the 12 
identified proteins were functionally associated with mRNA processing, ER-translocation, 
  150 
glycosylation, mitochondrial electron transport, ER-to-Golgi vesicular transport, and cell 
movement.  
 
Figure 5.4. 12 cellular proteins co-immunoprecipitated Gc by GFP-trap. The point 
highlighted in blue is the viral glycoprotein. 12 proteins (in red and labelled) were identified 
as interactors of Gc. Thresholds for association were set at FC > 2 and p-value < 0.05.  
DDOST; Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit , 
SNRPD2; Small nuclear ribonucleoprotein Sm D2, SDF2L1; Stromal cell-derived factor 2-like 
protein 1, SSBP1; Single-stranded DNA-binding protein, mitochondrial,  MARCKS; MARCKS-
related protein, COX5B; Cytochrome c oxidase subunit 5B, mitochondrial, SFXN1; 
Sideroflexin-1, SOD1; Superoxide dismutase [Cu-Zn], NDUFA7; NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 7, STIP1; Stress-induced-phosphoprotein 1, 
SRPRB; Signal recognition particle receptor subunit beta.  
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Table 14. All proteins that co-immunoprecipitated with Gc 
Protein names Gene GO term Accession FC -log(P-
value) 
Small nuclear 
ribonucleoprotein Sm 
D2 
SNRPD2 mRNA processing 
factor 
P62316 4.5 2.93 
Dolichyl-
diphosphooligosaccha
ride--protein 
glycosyltransferase 48 
kDa subunit 
DDOST Glycosyltransferase P39656 4.0 2.77 
Stromal cell-derived 
factor 2-like protein 1 
SDF2L1 Mannosyl-
transferase activity 
Q9HCN8 4.5 2.74 
Single-stranded DNA-
binding protein, 
mitochondrial 
SSBP1 DNA binding 
protein 
Q04837 3.1 2.48 
MARCKS-related 
protein 
MARCKS Non-motor actin 
binding protein; 
Signaling molecule; 
Structural protein 
P49006 
 
5.1 2.39 
Sideroflexin-1 SFXN1 Cation transporter; 
Transfer/carrier 
protein 
Q9H9B4 3.7 2.38 
Superoxide dismutase 
[Cu-Zn] 
SOD1 Oxidoreductase P00441 3.9 2.37 
Transmembrane 
emp24 domain-
containing protein 10 
TMED10 Transfer/carrier 
protein; Vesicle 
coat protein 
P49755 2.6 2.27 
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Cytochrome c oxidase 
subunit 5B, 
mitochondrial 
COX5B Oxidase P10606 3.9 2.05 
SEOV 80-39 SEOVsMgp1 Glycoprotein 
precursor 
NP_942557.1 6.3 1.79 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 7 
NDUFA7 Mitochondrial 
electron transport 
O95182 2.7 1.66 
Stress-induced-
phosphoprotein 1 
STIP1 Chaperon P31948 3.7 1.48 
Signal recognition 
particle receptor 
subunit beta 
SRPRB Receptor Q9Y5M8 3.1 2.30 
 
5.2.4 The cellular location of Gc corresponds with the ER  
To further validate the interaction of the identified host proteins with the viral 
glycoprotein, the intracellular location of Gc was investigated by immunofluorescent 
microscopy.  By visual inspection the location of Gc was found to corresponded largely with 
that of the ER marker calnexin (figure 5.5), and to some extent with the Golgi marker 
giantin (figure 5.6). This correlated well with the functional annotation of several of the 
identified associated host proteins; Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit (DDOST), Signal recognition particle receptor subunit 
beta (SRPRB) and Stromal cell-derived factor 2-like protein 1 (SDF2L1) are all ER-resident 
proteins, while Transmembrane emp24 domain-containing protein 10 (TMED10) is a 
protein involved in vesicular trafficking between the ER and Golgi complex, and Stress-
induced-phosphoprotein 1 (STIP1) can also localize to the Golgi (Honore et al., 1992; 
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Fukuda et al., 2001; Potter and Nicchitta, 2002; Bonnon et al., 2010; Roboti and High, 
2012). However, by quantitative analysis using the Coloc2 plugin for FIJI to calculate the 
Pearson’s correlation coefficient (PCC) of two probes (red / green and red / blue) there was 
good correlation of the GFP signal with the ER marker calnexin but only weak correlation 
between GFP and giantin (figure 5.8 and figure 5.9).  Calnexin/GFP PCC = 0.76 and 
giantin/GFP PCC = 0.37. For both markers the PCC was close to 0 (i.e. no correlation, 1 = 
perfect correlation) with DAPI (table 15)(Schindelin et al., 2012). By visual examination 
there seemed to be no significant overlap between expression of the viral glycoprotein and 
the mitochondrial marker TOM70 (figure 5.7), even though four (COX5B, NDFUA7, SDXN1 
and SSBP1) of the 12 interactors identified by mass spectrometry were mitochondrial 
proteins.  The PCC for TOM70/GFP was however 0.55, which indicated stronger correlation 
between GFP and TOM70 than between GFP and giantin (figure 5.10, table 15).  However, 
as the PCCs for both TOM70 and giantin were in an intermediate range, it is difficult to 
make conclusions on the true correlation of GFP with these markers based on the above 
results.  
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Figure 5.5. Immunofluorescent microscopy of transfected or mock transfected HEK293T 
cells. Cells were stained with DAPI for visualisation of the nucleus. Expression of the viral 
protein was determined by visualisation of GFP. Cells were co-stained with calnexin (ER 
marker). A, eGFp-N1-Cherwell-transfected cells at 20X at 63X magnification. B, eGFP-
transfected cells at 20X and 63X magnification. C, mock-transfected cells at 20X and 63X 
magnification. GFP; green fluorescent protein. 
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Figure 5.6. Immunofluorescent microscopy of transfected or mock transfected HEK293T 
cells. Cells were stained with DAPI for visualisation of the nucleus. Expression of the viral 
protein was determined by visualisation of GFP. Cells were co-stained with giantin (Golgi 
marker). A, eGFp-N1-Cherwell-transfected cells at 20X at 63X magnification. B, eGFP-
transfected cells at 20X and 63X magnification. C, mock-transfected cells at 20X and 63X 
magnification. GFP; green fluorescent protein.  
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Figure 5.7. Immunofluorescent microscopy of transfected or mock transfected HEK293T 
cells. Cells were stained with DAPI for visualisation of the nucleus. Expression of the viral 
protein was determined by visualisation of GFP. Cells were co-stained with TOM70 
(mitochondrial marker). A, eGFp-N1-Cherwell-transfected cells at 20X at 63X magnification. 
B, eGFP-transfected cells at 20X and 63X magnification. C, mock-transfected cells at 63X 
magnification. GFP; green fluorescent protein.  
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Figure 5.8. Immunofluorescence microscopy of eGFP-N1-Cherwell transfected HEK293T 
cells stained with Calnexin (ER marker) and DAPI (nuclear marker) at 63X magnification. 
Images were quantitatively analysed with the Coloc2 plugin for FIJI. The PCC for 
Calnexin/GFP = 0.76 and the above threshold PCC for Calnexin /DAPI = 0.23. GFP; green 
fluorescent protein. 
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Figure 5.9. Immunofluorescence microscopy of eGFP-N1-Cherwell transfected HEK293T 
cells stained with giantin (Golgi marker) and DAPI (nuclear marker) at 63X magnification. 
Images were quantitatively analysed with the Coloc2 plugin for FIJI. The above threshold 
PCC for giantin/GFP = 0.37 and the above threshold PCC for giantin/DAPI = 0.01. GFP; green 
fluorescent protein. 
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Figure 5.10. Immunofluorescence microscopy of eGFP-N1-Cherwell transfected HEK293T 
cells stained with TOM70 (mitochondrial marker) and DAPI (nuclear marker) at 63X 
magnification. Images were quantitatively analysed with the Coloc2 plugin for FIJI. The 
above threshold PCC for TOM70 /GFP = 0.55 and the above threshold PCC for giantin/DAPI 
= 0.18. GFP; green fluorescent protein. 
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Table 15. Pearson's correlation co-efficient of GFP and DAPI with ER, Golgi and mitochondrial markers 
 
 
5.2.5 Proteins of interest 
As the above results most strongly supported ER localisation of Gc, initial proteins of 
interest among the 12 identified interactors were postulated to be ER resident proteins 
based on GO annotation and network analysis using Reactome© 2017 and STRING© 
version 10.5. 
5.2.5.1 Endoplasmic reticulum  
DDOST and SRPBP (table 14) are both involved in the process of signal receptor particle 
(SRP) – dependent co-translational translocation of polypetides from the cytosol to the ER 
lumen (figure 5.8). DDOST is a component of the ER resident translocon complex TRAP, 
which facilitates the transport of polypeptides to the ER lumen(Potter and Nicchitta, 2002). 
SRPBP acts upstream of TRAP, binding a complex consisting of the signal receptor particle in 
association with ribosomal proteins that are in the process of translating mRNA (Potter and 
Nicchitta, 2002). DDOST also has an essential role in N-linked glycosylation, as a subunit of 
the N-oligo-saccharyl transferase complex (OST), a complex that catalyses the transferee of 
high mannose oligosaccharides to the N-glycan associated signal sequence Asn-X-Ser/Thr 
Protein pairs Pearson’s correlation co-efficient 
Giantin / GFP 0.37 
Giantin / DAPI 0.01 
Calnexin / GFP 0.76 
Calnexin/ DAPI 0.23 
TOM70 / GFP 0.55 
TOM70 / DAPI 0.18 
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(Roboti and High, 2012).   SDF2L1 (table 14) is also linked to the process of glycosylation. It 
is a component of the dolychyl-phosphate mannosyltransferase (figure 9B). Dolychol-
phosphate mannosyltransferase subunit 1, a catalytic subunit of this complex embedded in 
the ER, was also identified in the dataset, though not in association with Gc (appendix B.4). 
In addition to glycosylation, SDF2L1 is also involved in the unfolded protein response (figure 
5.9B).  
 
Figure 5.11. Above, overview of the pathway leading to co-translational translocation of 
proteins to the ER lumen. Boxes with yellow highlights represent complexes/components of 
the pathway for which identifiable proteins were present in the cell lysates analysed by 
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mass spectrometry. Below, detail of ER-specific part of the pathway. Orange boxes mark 
the protein-complexes of which SRPBP (SRP receptor) and DDOST (Translocon:TRAP) are 
components. (May, B, Gopinathrao,G (2008). Image for “SPR-dependent cotranslational 
protein target to membrane” pathway. Reactome© 2017. StableID: R-HSA1799339.).  
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5.3 Discussion 
In this study the interactome of SEOV Cherwell glycoproteins in HEK293T cells were 
investigated. 12 proteins were found to associate with the Gc subunit of the GCP, and GO 
annotation revealed that several of these proteins were functionally associated with 
cellular processes already known to be involved in orthohantaviral glycoprotein trafficking 
and maturation  (Shi and Elliott, 2002; Spiropoulou et al., 2003; Deyde et al., 2005).  Both 
DDOST and SDF2L are proteins involved in the process of glycosylation and might 
speculatively be cellular factors required for the proper glycosylation and assembly of 
orthohantaviral proteins in the ER prior to exit. In particular the link between DDOST and 
the N-glycan sequence motif Asn-X-Ser/Thr marks this protein as an interesting protein for 
follow-up. Orthohantaviral glycoproteins contain several of these conserved  motifs (Shi 
and Elliott, 2004). N-glycosolation is essential for the proper functioning of orthohantaviral 
glycoproteins, with site specific mutations of these conserved N-glycan signal motifs 
resulting in proteins without the ability to form heterodimers or traffic through the cell, and 
that exhibit impaired antigenic properties (Shi and Elliott, 2004). Furthermore, DDOST and 
SDF2L1 have both previously been reported to associate with ANDV glycoproteins (Klaus et 
al). DDOST is a component of the TRAP translocon, a protein complex that facilitates 
transport of proteins to the ER lumen. Silencing of SEC61B, also a component of TRAP, 
reduced the detection of La Crosse Virus in HEK293T cells by approximately 25 % (Zhang et 
al., 2017). La Crosse Virus is also a Bunyavirus, and like members of the Hantaviridae genus 
carries a genomic segment that codes for two glycoproteins in a single open reading frame 
(Pekosz et al., 1995). SEC61B did not bind to SEOV Gc in our study (appendix B.4), but as 
DDOST and SRPBP are both involved in the same pathway as SEC61B, it is possible to 
speculate that inhibition of components of this pathway could have the same effect on the 
turn-over of orthohantaviruses as was observed for La Crosse Virus. 
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Localisation of the viral glycoproteins at the ER was observed to a much greater extent 
in this study than that reported by others (Shi and Elliott, 2002; Kariwa et al., 2003; 
Spiropoulou et al., 2003; Deyde et al., 2005). It is possible that this observation was due to 
an unfolded protein response, which would cause retention of the proteins in the ER.  This 
scenario was supported by the interaction of Gc with SDF2L1, which is involved in the 
unfolded protein response pathway. It is also feasible that Gc was retained in the ER due to 
a lack of interaction between Gc and Gn, because of inefficient expression of Gn or its rapid 
degradation. Interaction between Gc and Gn is necessary for their transport away from the 
ER (Shi and Elliott, 2002; Spiropoulou et al., 2003; Deyde et al., 2005). TULV infection of 
VeroE6 cells seemingly induces the unfolded protein response, and there is evidence that a 
certain amount of viral glycoproteins are retained in the ER following orthohantaviral 
infection;  Gn tends to form high molecular weight aggregates, and the high mannose 
glycosylation of Gn and Gc  and their association with calnexin and calreticulin  points to a 
failure of passing the ER-control for properly folded proteins (Shi and Elliott, 2002; 
Spiropoulou et al., 2003; Li et al., 2005). It has been reported that expression of the viral N 
protein, or S segment RNA, rescues SNV Gn expression following transfection, raising the 
possibility that the accumulation of N protein induces a switch from Gn degradation to Gn 
accumulation (Ganaie and Mir, 2014). HNTV Gc has also been reported to traffic differently 
when expressed by transfection compared to infection, and co-transfection of   the N 
protein and Gc results in a trafficking pattern that more closely resembles that observed 
following natural infection (Shimizu et al., 2013). As such, it is possible that the absence of 
N protein in the above study resulted in impaired Golgi trafficking. It would be interesting 
to investigate if co-expression of the N protein with the glycoproteins would impact on the 
cellular localisation of the latter. The low levels of correlation between the Golgi marker 
giantin and GFP could also possibly be explained by the fairly low expression level of GFP, 
which as seen in figure 5.6 and 5.8, is only expressed in a low number of cells. Additionally, 
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in figure 5.3, it can be observed that the expression of the GFP-tagged viral protein was 
inconsistently expressed across replicates. Finally, it is possible that SEOV Cherwell 
glycoproteins aggregate to a greater extent at the ER membrane than is the case for other 
species of orthohantaviruses. Studies considering the trafficking and maturation of 
glycoproteins have not been performed using this particular strain of orthohantavirus 
before, and viral budding at the ER has previously been observed in VeroE6 cells for a 
specific species of HNTV (Xu 2017).  
Four mitochondrial proteins were found to bind Gc.  However, the results of 
immunofluorescence analysis were inconclusive for mitochondrial localisation of the viral 
protein, with an intermediate value obtained for quantitative analysis. This discrepancy 
could possibly be explained by the interaction of Gc with the protein SOD1. This protein is 
involved in the turn-over of toxic radicals produced by the mitochondria, and reportedly 
associates with COX5B, PRDX1 and NDUFA7 (figure 9C). Possibly the identification of these 
mitochondrial proteins does not reflect a direct interaction with Gc, but rather an 
association between them and another protein that interacts with Gc, i.e. SOD1. It’s also 
possible that these interactions are the result of non-specific interactions with the viral 
protein or the associated GFP-tag. It is possible these mitochondrial proteins have been 
released into the cytosol and become available for unspecific binding as a result of the 
stress put on the cells during the experimental procedures. 
To progress the above findings, the next step would be reverse pull-downs, i.e. 
determine if the viral proteins will reciprocally bind to the cellular proteins if the latter are 
used as the GFP-tagged bait proteins in immunoprecipitation. The initial focus would be on 
validating the interactions with the ER resident proteins, as these are the cellular structures 
the viral protein localised to. In addition it would be necessary to reimage the cells with 
better optimised parameters, so that further statistical tests could be reliable utilised, 
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providing stronger evidence for potential correlation and co-occurrence. As the PCC is less 
sensitive to differences in mean intensities between the probes and is less dependent on 
threshold values than the Manders split coefficients, the PCC was deemed the most 
appropriate coefficient to use for the images analysed above.  
It is necessary to address the question of why the viral protein was poorly expressed 
from the plasmid in which the GFP-tag was linked to the Gn region of the GCP (eGFC-C1-
GCP), while it was efficiently expressed from the plasmid in which the GFP-tag was linked to 
the Gc region (eGFP-N1-GCP). As Gn and Gc are both expressed from the same gene 
segment, and they need to form hetero-oligomeric interactions to traffic to cellular 
assembly sites and be expressed on the viral envelope, the intuitive assumption would be 
that they are expressed at similar levels in the cell. It is not possible from the above 
investigation to determine if the observed difference in Gc and Gn expression was a 
consequence of an inherently lower production of Gn, Gn being degraded to a larger 
degree than Gc, or if it was due to the GFP-tag interfering with protein expression when 
located at the N-terminus of the viral GCP.  As sequencing was not done following large-
scale production of viral DNA stocks, it is also possible that mutations occurred in the aa 
sequence of the viral protein at this step of the process, resulting in an aberrant viral 
protein. In a study looking at the cellular processing of Sin Nombre virus (SNV) 
glycoproteins, Gn was similarly detected at lower levels than Gc following transfection with 
a plasmid encoding the GCP (Spiropoulou et al., 2003). It is possible that the reduced 
expression of Gn is a consequence of a selective degradation of this protein in the cell, and 
that this is a tactic for the virus to specifically control Gn turn-over for efficient viral 
replication. In HeLa cells the autophagosome machinery degrades SNV Gn, and SNV 
replication in HUVECs is dramatically reduced when either formation of autophagosomes or 
their degradative pathway is inhibited (Hussein et al 2012). Inhibition of the 
autophagosome machinery has, conversely, no effect on the expression of Gc. SNV Gn also 
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seems to aggregate in Lamp-1 containing cellular compartments when expressed from GCP 
or following viral infection (Spiropoulou et al., 2003). LAMP-1 is a late-endosomal/lysosmal 
marker and this co-localisation has been postulated to represent lysosomal degradation of 
Gn. LAMP-1 co-localises with the autophage marker LC3 when autophage maturation is 
induced, and as such these results could be consistent with the former observations of 
autophagic clearance of Gn (Spiropoulou et al., 2003; Jackson et al., 2005).  
Autophagosomes are involved in several aspects of immunity, e.g. direct clearance of 
microbes, responding to inflammation, secretion of immune mediators, and antigen 
presentation (Deretic et al., 2017). As such it is unsurprising that infecting pathogens have 
developed ways of circumventing their activity. For instance, several positive-sense RNA 
viruses seem to utilize the autophagosomal machinery for their benefit (Jackson et al., 
2005; Richards and Jackson, 2013; Shi et al., 2016). In vitro, inhibiting the formation of 
autophagasome-like vesicles negatively affect the yield of poliovirus, rhinovirus and 
coxsacivirus B3. 
It would be interesting to compare the findings of this study with the interactome of 
SEOV Cherwell glycoproteins in a second cell line. HUVECs would be ideal, as they are 
frequently used in studies of orthohantavirus infection, and as an endothelial cell line 
represent the major target cell for orthohantaviruses (Gavrilovskaya et al., 2008). It would 
also be interesting to compare the interactome of SEOV, a cause of moderate HFRS in 
humans, with that of PUUV (NE), DOBV/HNTV (severe HFRS) and SNV/ANDV (HPS). Finally, 
comparing the interactome of SEOV in human and rat cell lines could possibly give insights 
into cellular factors that explain why human infection results in illness and viral clearance, 
while rats become persistently infected in the absence of clinical symptoms.   
  
  168 
5.4 Conclusion 
In this hypothesis generating study, 12 cellular proteins were identified as interacting 
partners with recombinant SEOV Cherwell Gc in HEK293T cells. Using immunofluorescent 
microscopy, recombinant Gc was predominantly observed at the ER . This cellular 
localisation of Gc proved to be in line with the functional annotation of several of the 
identified binding proteins, of which three were ER resident. It still remains to further 
validate these protein interactions before more specific conclusions can be drawn.  
Speculatively, some of the associations described in this chapter could be indicative of 
cellular mechanisms involved in the maturation of the viral glycoproteins. In addition to 
advancing this work by validating the above results, this study has raised questions about 
the processing of the two viral glycoproteins that would be of interest to pursue further. 
The different turn-over of Gc and Gn has been reported by others, and it would be 
interesting to follow up the discrepancies in protein expression observed for the two 
different plasmids used in this study, in an effort to shed more light on mechanisms 
involved in the regulation of the viral life cycle.  
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Chapter 6: Conclusion 
The aims of this thesis were to use label-free proteomics to analyse 
orthohantavirus- positive human sera in an effort to discover biomarkers of HFRS infection 
caused by SEOV, and to investigate the cellular interactome of recombinant SEOV Cherwell 
glycoproteins, with the aim of gaining further insights into the mechanism involved in the 
processing of the viral proteins and the cellular protein interactions they formed.  
Two strategies were used to examine the first of these aims:   
1. Directly comparing the proteomes of a group of orthohantavirus-infected sera with 
non-infected sera and select biomarker candidates from among the proteins with 
significant differences in abundance between the two groups.  
2. A proteomic case study in which abundance changes in the proteome of a single 
individual was followed during the course of a clinical HFRS infection and subsequently 
compared with a seronegative and convalescent sample obtained from the same individual, 
to identify proteins with abundance changes that correlated with disease. 
 By using a proteomic method to analyse changes in the serum proteome unique 
insights into protein alterations in response to orhtohantavirus infection have been made. 
The analysis of the longitudal sample set has allowed for novel insights into real-time 
changes during the course of active disease and recovery. These findings can be built on to 
gain a better understanding of the pathogenesis underlying HFRS. The glycoprotein afamin 
was investigated as a biomarker candidate based on initial findings of decreased abundance 
in seropositive samples compared to controls, though validation attempts of this finding 
produced conflicting results. No difference in afamin abundance was observed in a 
validation cohort of seven seropositive against eight seronegative samples. However, the 
relative abundance of afamin was observed to fluctuate in a temporal analysis of 
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longitudinal sera, with observed abundance changes temporally coinciding with disease 
progression. These discrepancies warrant further investigation into the response, or lack 
thereof, of afamin to acute orthohantavirus infection. Ideally this would be investigated in 
samples with well-defined times of sampling relative to infection, so as to take into account 
the transient nature of the abundance changes observed in the longitudinal sera. Galectin 
3-binding protein was also investigated as a biomarker candidate, based on temporal 
analysis of sequential sera from a single individual. In addition to afamin, it would be very 
interesting to widen the investigation to include other proteins identified in this study, e.g. 
angiotensinogen which is intricately linked to hemostastis and kidney function, and 
properdin and lumican, which are proteins involved in the immune respons. It would also 
be interesting to further investigate the apparent differences discovered in convalescent 
samples compared to seronegative in this study, to investigate the potential for chronic 
complications associated with SEOV. Chronic complications are not an extensively studied 
area of orthohantavirus infections, and the results of studies looking at long term sequalae 
are controversial.   
The increased abundance of G3BP in orthohantavirus infection was successfully 
validated in a larger, independent sample cohort.  G3BP has been associated with PUUV 
infection and clinical symptoms of NE by others, and our results further support its 
relevance to orthohantaviral disease.  We also found that leptospira-infected sera 
presented with elevated abundance of G3BP compared to controls, implicating G3PB in a 
generic response to infection The results of this study further support G3BPs role in the 
host response to acute infections in which an activated vascular endothelium is a 
characteristic feature. As mentioned above for afamin, it would be interesting to further 
investigate some of the other proteins identified in addition to G3BP.  HNTV infection of 
endothelial cells has been shown by others to induce VCAM. This protein was, like G3BP, 
found to be elevated in the sera of the pregnant patient during acute disease and in the 
  171 
single acute sample from the single-time-point cohort. VCAM mediates cell:cell adhesion, 
and as such it can be hypothesised that its alteration in response to orthohantavirus 
infection plays a direct role in the systemic vascular leakage characteristic of HFRS and HPS.  
For both afamin and G3BP, larger sample numbers would be required to confidently validate 
whether consistent abundance changes in relation to acute orthohantavirus infection occur, 
before speculations about their clinical utility could be further investigated.   
The second part of the thesis focused on exploring the interactome of the SEOV 
Cherwell glycoprotein in a human kidney cell line.  Using immunoprecipitation, mass 
spectrometry and cellular localisation studies, eight cellular proteins were identified as 
potential interacting partners of SEOV Gc in HEK293T cells. Functional annotation and 
network analysis revealed that several of these potential binding partners were involved in 
processes known to be required for the maturation of orthohantaviral proteins.  A final 
validation step determining the specificity of the identified interactions, using reverse co-
immunoprecipitation, remains to be done. If these findings are successfully validated, 
further studies could be pursued looking into the functional and biological relevance of 
these interactions and their associated pathways, by e.g. disrupting protein:protein 
interactions. 
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East Midlands - Nottingham 1 Research Ethics Committee  
The Old Chapel  
Royal Standard Place  
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University of Liverpool  
Institute of Infection and Global Health  
Department of Infection Biology  
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Dear Ms Bar-Yaacov,   
  
Study title:  Proteomic comparison of acute kidney injury due to Hantavirus 
infection and acute kidney injury due to leptospirosis   
REC reference:  17/EM/0074  
Protocol number:  NA  
IRAS project ID:  201621  
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Thank you for your letter of 22 February 2017, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation.  
  
The further information has been considered on behalf of the Committee by the 
Chair.   
  
We plan to publish your research summary wording for the above study on the 
HRA website, together with your contact details. Publication will be no earlier than 
three months from the date of this opinion letter.  Should you wish to provide a 
substitute contact point, require further information, or wish to make a request to 
postpone publication, please contact hra.studyregistration@nhs.net outlining the 
reasons for your request.  
Confirmation of ethical opinion  
  
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application form, 
protocol and supporting documentation as revised, subject to the conditions 
specified below.  
  
Conditions of the favourable opinion  
  
The REC favourable opinion is subject to the following conditions being met prior 
to the start of the study.  
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Management permission must be obtained from each host organisation prior to the 
start of the study at the site concerned.  
  
Management permission should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance 
arrangements. Each NHS organisation must confirm through the signing of 
agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise).   
Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and 
referring potential participants to research sites ("participant identification 
centre"), guidance should be sought from the R&D office on the information it 
requires to give permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in 
accordance with the procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of management 
permissions from host organisations  
  
Registration of Clinical Trials  
  
All clinical trials (defined as the first four categories on the IRAS filter page) must 
be registered on a publically accessible database within 6 weeks of recruitment of 
the first participant (for medical device studies, within the timeline determined by 
the current registration and publication trees).    
  
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment.  We will audit the 
registration details as part of the annual progress reporting process.  
  
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory.  
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If a sponsor wishes to request a deferral for study registration within the 
required timeframe, they should contact hra.studyregistration@nhs.net. The 
expectation is that all clinical trials will be registered, however, in exceptional 
circumstances non registration may be permissible with prior agreement from the 
HRA. Guidance on where to register is provided on the HRA website.    
  
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site 
(as applicable).  
  
Ethical review of research sites  
  
NHS sites  
  
The favourable opinion applies to all NHS sites taking part in the study, subject 
to management permission being obtained from the NHS/HSC R&D office prior to 
the start of the study (see "Conditions of the favourable opinion" below).  
  
Approved documents  
  
The final list of documents reviewed and approved by the Committee is as 
follows:  
Document    Version    Date    
Covering letter on headed paper [Cover letter]   1   18 December 2016  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) 
[Sponsor approval]   
1   18 December 2016  
IRAS Checklist XML [Checklist_22022017]      22 February 2017   
Letter from sponsor [Letter from sponsor]   1   18 December 2016  
Other [Email Clarification Regarding Sponsor Signature]      02 February 2017   
REC Application Form [REC_Form_02022017]      02 February 2017   
Research protocol or project proposal [Project proposal]   8   22 February 2017   
  219 
Summary CV for Chief Investigator (CI) [CV for Ms Sarah Bar-Yaacov]   2   01 February 2017   
Summary CV for supervisor (student research) [CV for Dr Beeching]  1   01 February 2017   
Summary, synopsis or diagram (flowchart) of protocol in non technical 
language [Study design]   
3   04 October 2016   
  
Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
  
After ethical review  
  
Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” 
gives detailed guidance on reporting requirements for studies with a favourable 
opinion, including:  
  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The HRA website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures.  
  
User Feedback  
  
The Health Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view of the service 
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you have received and the application procedure. If you wish to make your views 
known please use the feedback form available on the HRA website:  
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/     
  
HRA Training  
  
We are pleased to welcome researchers and R&D staff at our training days – see 
details at http://www.hra.nhs.uk/hra-training/    
  
17/EM/0074                          Please quote this number on all correspondence  
  
With the Committee’s best wishes for the success of this project.  
  
Yours sincerely,  
  
Mr John Aldridge Chair  
  
Email:NRESCommittee.EastMidlands-Nottingham1@nhs.net  
  
Enclosures:  “After ethical review – guidance for researchers”   
  
Copy to:   Julia West, Royal Liverpool And Broadgreen University Hospitals NHS 
Trust  
 Confidentiality Advise Team   
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Appendix B. Tables 
      
  
Appendix B 1. 381 proteins common to 10 sera analysed by MS 
Description Accession q Value 
Unique 
peptides 
Max fold 
change 
Confidence 
score 
14-3-3 protein zeta/delta P63104 0.18 3 1.23 192.31 
28S ribosomal protein S9, 
mitochondrial 
P82933 0.19 2 1.49 15.23 
5' exonuclease Apollo Q9H816 0.31 2 1.11 18.46 
72 kDa type IV collagenase P08253 0.26 2 1.55 32.8 
78 kDa glucose-regulated protein P11021 0.00 6 5.29 259.22 
A disintegrin and metalloproteinase 
with thrombospondin motifs 13 
Q76LX8 0.20 3 1.27 139.21 
Actin, cytoplasmic 1 P60709 0.41 5 1.41 1208.44 
Actin-related protein 2 P61160 0.05 2 1.89 35.37 
Adenosine deaminase 2 Q9NZK5 0.31 2 1.78 22.59 
Adenylate kinase 8 Q96MA6 0.36 3 1.34 14.71 
Adipocyte plasma membrane-
associated protein 
Q9HDC9 0.26 3 2.55 90.34 
Adiponectin Q15848 0.35 3 1.42 303.8 
Afamin P43652 0.00 28 11.06 1503.13 
Aggrecan core protein P16112 0.29 2 2.12 68.08 
Alpha-1-acid glycoprotein 1 P02763 0.27 5 1.34 600.54 
Alpha-1-acid glycoprotein 2 P19652 0.43 6 1.02 735.17 
Alpha-1-antichmotrypsin P01011 0.00 33 2.46 2633.26 
Alpha-1-antytrypsin P01009 0.04 44 2.45 3077.02 
Alpha-1-glycoprotein P04217 0.09 20 1.51 1933.95 
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Alpha-2-antiplasmin P08697 0.16 17 1.32 1219.36 
alpha-2-HS-glycoprotein P02765 0.14 14 1.53 1953.36 
Alpha-2-macroglobulin P01023 0.30 79 1.22 8223.76 
Alpha-actinin-1 P12814 0.19 5 2.30 299.63 
Aminopeptidase N P15144 0.02 5 2.79 231 
AMP deaminase 2 Q01433 0.44 2 1.55 22.88 
Angiotensinogen P01019 0.03 18 2.09 1917.19 
Antileukoproteinase P03973 0.22 3 52.83 55.24 
Antithrombin-III P01008 0.22 38 1.34 3335.62 
Apolipopriotein C-I P02654 0.12 5 2.09 152.26 
Apolipoprotein A-I P02647 0.03 30 2.45 1867.52 
Apolipoprotein A-II P02652 0.00 6 4.05 385.77 
Apolipoprotein A-IV P06727 0.34 29 1.33 2130.28 
Apolipoprotein B-100 P04114 0.33 344 1.13 28040.43 
Apolipoprotein C-II P02655 0.04 5 2.77 340.7 
Apolipoprotein C-III P02656 0.13 5 1.34 446.83 
Apolipoprotein C-IV P55056 0.02 7 5.29 189.46 
Apolipoprotein D P05090 0.15 8 1.43 403.02 
Apolipoprotein E P02649 0.02 23 2.50 1824.46 
Apolipoprotein F Q13790 0.19 3 1.29 84.72 
Apolipoprotein L1 O14791 0.35 15 1.13 943.81 
Apolipoprotein M O95445 0.00 11 8.08 462.07 
Apolipoprotein(a) P08519 0.20 54 1.19 3371.23 
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Attractin O75882 0.10 26 1.59 1585.89 
Autphagy-related protein 101 Q9BSB4 0.04 2 1.52 14.33 
Band 3 anion transport protein P02730 0.44 4 2.00 139.63 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
P98160 0.22 17 1.13 531.79 
Beta-2-glyvoprotein 1 P02749 0.01 15 2.37 1193.77 
Beta-Ala-his dipeptidase Q96KN2 0.04 16 1.85 732.49 
Biotinidase P43251 0.10 12 1.66 736.97 
BPI fold-containing family A 
member 1 
Q9NP55 0.19 5 47.43 485.21 
BPI fold-containing family B 
member 1 
Q8TDL5 0.43 8 3.17 305.11 
BPI fold-containing family B 
member 2 
Q8N4F0 0.34 2 127.38 31.58 
BTB/POZ domain-containing protein 
16 
Q32M84 0.02 3 1.68 23.68 
C4b-binding protein alpha chain P04003 0.31 33 1.10 2522.49 
C4b-binding protein beta chain P20851 0.48 9 1.01 621.25 
Cadherin-1 P12830 0.11 2 6.13 65.84 
Cadherin-5 P33151 0.00 7 1.84 229.41 
Caherin 13 P55290 0.34 2 1.23 79.03 
Capping protein, Arp2/3 and 
myosin-I linker protein 3 
Q8ND23 0.22 2 1.30 17.31 
Carbonic anhydrase 1 P00915 0.43 7 1.68 427.6 
Carboxypeptidase B2 Q96IY4 0.16 14 1.55 862.43 
Carboxypeptidase N catalytic chain P15169 0.07 15 1.71 837.64 
Carboxypeptidase N subunit 2 P22792 0.14 11 1.58 844.39 
Cartilage acidic protein 1 Q9NQ79 0.43 9 1.01 516.52 
Cartilage oligomeric matrix protein P49747 0.45 11 1.15 715.34 
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Caspase recruitment domain-
containing protein 11 
Q9BXL7 0.17 5 1.58 18.1 
Catalase P04040 0.32 4 2.73 174.64 
Cathepsin D P07339 0.30 4 1.22 77.27 
CD44 antigen P16070 0.40 2 3.53 52.24 
CD5 antigen-lie O43866 0.08 18 2.50 1189.55 
Cd9 antigen P21926 0.32 3 1.28 54.43 
Cell surface glycoprotein MUC18 P43121 0.01 6 1.93 106.98 
Centromere protein F P49454 0.08 7 2.53 18.52 
Centromere-associated protein E Q02224 0.29 4 1.17 25.08 
Ceruloplasmin P00450 0.26 75 1.13 7612.42 
Cholesteryl ester transfer protein P11597 0.13 12 1.68 602.72 
Cholinesterase P06276 0.07 14 1.46 659.4 
Chromodomain-helicase-DNA-
binding protein 1 
O14646 0.11 2 2.96 13.67 
Cllusterin P10909 0.13 22 1.21 1351.29 
Coagulation facor XIII B chain P05160 0.00 11 10.12 504.3 
Coagulation factor IX P00740 0.22 11 1.33 500.18 
Coagulation factor V P12259 0.08 39 1.83 1499.6 
Coagulation factor X P00742 0.30 12 1.15 549.63 
Coagulation factor XI P03951 0.09 25 1.81 1096.83 
Coagulation factor XIII A chain P00488 0.45 13 2.20 584.48 
Cofilin-1 P23528 0.30 3 1.41 18.64 
Cogulation factor XII P00748 0.02 16 2.43 1038.17 
Collagen alpha-1(VI) chain P12109 0.32 3 1.79 53.18 
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Collagen alpha-3(VI) chain P12111 0.00 9 2.01 198.78 
Collectin-11 Q9BWP8 0.12 3 1.99 69.67 
Complement C1q subcomponent 
subunit B 
P02746 0.00 10 1.82 676.8 
Complement C1q subcomponent 
subunit C 
P02747 0.00 6 1.78 587.22 
Complement C1r subcomponent P00736 0.12 31 1.29 1930.39 
Complement C1r subcomponent-
like protein 
Q9NZP8 0.01 6 1.93 417.88 
Complement C1s subcomponent P09871 0.15 31 1.19 2006.45 
Complement C2 P06681 0.00 25 2.04 1608.57 
Complement C3 P01024 0.09 163 1.28 15903.41 
Complement C4-A P0C0L4 0.36 3 1.47 10012.42 
Complement C4-B P0C0L5 0.36 6 1.47 10435.6 
Complement C5 P01031 0.00 96 1.65 6404.1 
Complement component C7 P10643 0.23 37 1.34 2585.14 
Complement component C8 alpha 
chain 
P07357 0.02 28 2.21 2076.58 
Complement component C8 beta 
chain 
P07358 0.13 29 1.57 2608.94 
Complement component C8 gamma 
chain 
P07360 0.01 12 2.56 1290.6 
Complement component C9 P02748 0.02 29 2.17 2136.23 
Complement factor B P00751 0.00 44 2.17 3472.63 
Complement factor C6 P13671 0.13 38 1.30 2594.94 
Complement factor D P00746 0.29 12 1.17 513.22 
Complement factor H P08603 0.30 62 1.14 5447.59 
Complement factor H-related 
protein 2 
P36980 0.47 3 1.08 447.41 
Complement factor H-related 
protein 5 
Q9BXR6 0.47 11 1.02 446.65 
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Complement factor I P05156 0.02 25 1.67 1897.11 
Complemet C1q subcomponent 
subunit A 
P02745 0.00 3 1.89 131.84 
Coronin-2A Q92828 0.07 2 2.24 16.69 
Corticosteroid-binding globulin P08185 0.06 15 2.04 1264.84 
C-reactive protein P02741 0.18 7 7.70 281.09 
Cyetein-rich secretory protein 3 P54108 0.27 3 1.31 80.5 
Cystatin-A P01040 0.27 3 3.90 57.39 
Cytoplasmic tRNA 2-thiolation 
protein 1 
Q7Z7A3 0.10 2 1.68 14.7 
Cytosol aminpeptidase P28838 0.28 11 1.58 255.34 
Deleted in malignant brain tumors 1 
protein 
Q9UGM3 0.13 9 201.24 660.15 
Dermicidin P81605 0.39 2 1.27 125.44 
Desmoplakin P15924 0.14 5 1.86 33.14 
Di-N-acetylchitobiase Q01459 0.45 4 1.10 51.54 
Dipeptidyl peptidase 4 P27487 0.16 5 1.31 100.79 
DNA excision repain protein ERCC-
6-like 2 
Q5T890 0.27 3 1.14 17.08 
DNA repair-scaffolding protein Q14159 0.47 2 1.10 17.44 
Docking protein 1 Q99704 0.32 2 1.67 14.82 
Dopamine beta-hydroxylase P09172 0.42 7 1.32 368.08 
Dynein heacy chain 11, axonemal Q96DT5 0.47 4 1.06 42.8 
Dynein heacy chain 8, aonemal Q96JB1 0.18 2 1.46 42.08 
Dynein heavy chain 10, axonemal Q8IVF4 0.23 7 1.17 66.11 
Dynein heavy chain 12, axonemal Q6ZR08 0.30 4 1.15 37.07 
Dynein heavy chain 5, axonemal Q8TE73 0.13 3 1.93 38.08 
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E3 ubiquitin-protein ligase UBR4 Q5T4S7 0.07 5 1.84 17.91 
Ectonuleotide 
pyrophosphatase/phophodiseterase 
family member 2 
Q13822 0.40 2 1.32 48.32 
EGF-containing fibulin-like 
extracellular matric protein 1 
Q12805 0.30 11 1.16 457.17 
Endoplasmin P14625 0.08 4 4.72 120.19 
Endothelial PAS domain-containing 
protein 1 
Q99814 0.26 3 1.24 14.2 
Erythrocyte band 7 integral 
membrane protein 
P27105 0.22 2 2.77 151.61 
Extracellular matric protein 1 Q16610 0.38 8 3.83 199.2 
Fermitin family homolog 3 Q86UX7 0.12 3 2.73 94.11 
Fetuin-b Q9UGM5 0.06 11 1.65 575.44 
Fibrinogen alpha chain P02671 0.35 10 1.72 360.86 
Fibrinogen beta chain P02675 0.43 7 1.60 282.19 
Fibrinogen gamma chain P02679 0.24 7 1.02 336.32 
Fibronectin P02751 0.09 81 1.64 7956.54 
Fibulin-1 P23142 0.04 14 2.14 590.49 
Ficolin-2 Q15485 0.14 9 1.62 464.55 
Ficolin-3 O75636 0.40 13 1.06 976.9 
Filaggrin-2 Q5D862 0.27 3 1.12 39.99 
Filamin-A P21333 0.00 32 1.75 1109.95 
Filamin-C Q14315 0.30 2 1.22 65.49 
Fructose-bisphosphate aldolase B P05062 0.31 2 1.66 89.77 
Fumarylacetoacetase P16930 0.23 2 2.26 27 
galectin-3-binding protein Q08380 0.30 19 1.30 1223.46 
Gelsolin P06396 0.23 38 1.55 2982.71 
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Glucose-6-phosphate isomerase P06744 0.21 2 2.10 54.06 
Glutathione peroxidase 3 P22352 0.36 7 1.09 295.37 
Glyceraldehyde-3-phosphate 
dehydorgenase 
P04406 0.38 4 2.33 154.51 
Golgin subfamily A member 6-like 
protein 22 
H0YM25 0.49 2 1.13 16.27 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
P62873 0.32 3 1.30 39.69 
Haptoglobin P00738 0.15 17 2.41 2903.42 
Haptoglobin-related protein P00739 0.13 11 1.96 2004.2 
Hemoglobin subunit alpha P69905 0.49 6 1.20 225.18 
Hemoglobin subunit beta P68871 0.25 10 1.28 660.51 
Hemopexin P02790 0.24 36 1.15 2661.47 
Heparin cofactor 2 P05546 0.01 30 2.48 1807.26 
Hepatocyte growth factor-like 
protein 
P26927 0.06 8 1.98 435.26 
Heptaocyte growth factor activator Q04756 0.33 11 1.16 431.78 
Hexokinase-1 P19367 0.26 2 1.94 15.64 
Histidine-rich glycoprotein P04196 0.01 24 1.96 2131.17 
Histone H4 P62805 0.44 2 1.24 23.49 
Hornerin Q86YZ3 0.45 4 1.03 207.13 
Hyaluronan-binding protein 2 Q14520 0.23 14 1.16 832.59 
Hydrocephalus-inducing protein 
homolog 
Q4G0P3 0.18 4 1.20 35.81 
ICOS ligand O75144 0.14 2 1.74 34.58 
Ig heavy chain V-I region HG3  P01743 0.00 2 5.31 191.83 
Ig heavy chain V-I region V35 P23083 0.07 6 4.61 285.9 
Ig heavy chain V-II region WAH P01824 0.01 2 9.72 50.83 
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Ig heavy chain V-III region BUT  P01767 0.00 2 8.50 307.08 
Ig heavy chain V-III region GA P01769 0.02 2 8.60 27.81 
Ig heavy chain V-III region GAL P01781 0.13 2 10.40 85.26 
Ig heavy chain V-III region VH26 P01764 0.00 2 5.70 196.98 
Ig heavy chain V-III region WEA  P01763 0.00 2 8.19 202.53 
Ig kappa chain V-I region CAR  P01596 0.01 2 18.79 126.59 
Ig kappa chain V-I region HK102 
(Fragment) 
P01602 0.03 2 3.61 258.36 
Ig kappa chain V-I region WEA  P01610 0.12 2 9.27 130.84 
Ig kappa chain V-III region B6  P01619 0.00 2 3.67 146.11 
Ig kappa chain V-III region 
IARC/BL41  
P06311 0.00 2 7.55 135.39 
Ig kappa chain V-III region VG 
(Fragment)  
P04433 0.00 3 4.05 186.08 
Ig kappa chain V-III region VH 
(Fragment)  
P04434 0.00 2 22.92 90.11 
Ig kappa chain V-IV region Len P01625 0.02 2 3.25 390.37 
Ig lambda chain V region 4A  P04211 0.00 2 10.37 83.58 
Ig lambda chain V-I region NEW P01701 0.09 2 19.71 72.49 
Ig lambda chain V-II region TRO  P01707 0.00 2 30.17 29.19 
Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1; 
TOPep_Count=5  
P80748 0.00 5 10.42 245.39 
Ig lambda chain V-III region SH P01714 0.00 3 6.48 291.99 
Ig mu heavy chain disease protein P04220 0.14 2 1.88 1716.85 
Immmunoglobulin heacy constant 
gamma 1 
P01857 0.00 6 9.28 1609.36 
immunoglobulin heacy constant 
alpha 1 
P01876 0.00 6 6.25 1574.71 
Immunoglobulin heacy constant 
alpha 2 
P01877 0.00 4 6.45 1109.68 
Immunoglobulin heavy constant 
delta 
P01880 0.07 11 29.33 659.5 
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Immunoglobulin heavy constant 
gamma 2 
P01859 0.00 5 16.15 1093.27 
Immunoglobulin heavy constant 
gamma 3 
P01860 0.00 6 13.10 1431.32 
Immunoglobulin heavy constant 
gamma 4 
P01861 0.00 6 11.09 1098.72 
Immunoglobulin heavy constant mu P01871 0.12 6 2.10 1968.38 
Immunoglobulin J chain P01591 0.07 5 2.11 426.69 
Immunoglobulin kappa constant P01834 0.00 5 5.93 1074.97 
Immunoglobulin lambda constant 7 A0M8Q6 0.00 2 8.84 407.76 
Immunoglobulin lambda-like 
polypeptide 1 
P15814 0.16 2 2.50 38.72 
Immunoglobulin lambda-like 
polypeptide 5 
B9A064 0.00 3 10.09 810.1 
Insulin-like growth factor-binding 
protein 3 
P17936 0.27 3 1.75 119.31 
Insulin-like growth factor-binding 
protein complex acid labile subunit 
P35858 0.49 24 1.17 1539.11 
Integrin alpha-Iib P08514 0.20 12 1.27 663.79 
Integrin beta-3 P05106 0.08 9 1.74 340.63 
Inter-alpha-trypsin inhibitor heacy 
chain H1 
P19827 0.14 38 1.60 4154.63 
Inter-alpha-trypsin inhibitor heacy 
chain H4 
Q14624 0.01 51 2.07 4552.24 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
Q06033 0.00 31 2.64 1932.16 
inter-alpha-trypsin inhibitor heavy 
chian H2 
P19823 0.07 45 1.60 4262.77 
Interleukin-1 receptor accessory 
protein 
Q9NPH3 0.35 2 4.88 52.92 
IQ motif and SEC7 domain-
containing protein 1 
Q6DN90 0.42 2 1.10 19.15 
Kallistatin P29622 0.14 21 1.83 1790.32 
Keratin, type I cytoseletal 17 Q04695 0.19 4 2.30 502.41 
Keratin, type I cytoskeletal 10 P13645 0.29 27 1.16 3011 
Keratin, type I cytoskeletal 14 P02533 0.37 4 1.17 1147.45 
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Keratin, type I cytoskeletal 16 P08779 0.48 9 1.04 987.68 
Keratin, type I cytoskeletal 28 Q7Z3Y7 0.45 2 1.00 198 
Keratin, type I cytoskeletal 9 K1C9_HUMAN 0.27 37 1.32 2498.39 
Keratin, type II cuticular Hb5 P78386 0.07 2 3.17 20.36 
Keratin, type II cytoskeletal 1 P04264 0.18 36 1.41 2827.24 
Keratin, type II cytoskeletal 2 
epidermal 
P35908 0.22 21 1.36 1974.27 
Keratin, type II cytoskeletal 5 P13647 0.30 13 1.18 930 
Keratinocyte proline-rich protein Q5T749 0.30 3 1.22 59.32 
Kinesin-like protein KIF28P B7ZC32 0.05 3 1.45 15.1 
Kininogen-1 P01042 0.14 33 1.21 2458.4 
Lactotransferrin P02788 0.29 38 13.90 2067.07 
Latent-transforming growth factor 
beta-binding protein 1 
Q14766 0.44 4 1.13 109.19 
Leucine-rich alpha-2-glycoprotein P02750 0.03 12 2.14 798.78 
Leukocyte immuniglobulin-like 
receptor subfamily A member 3 
Q8N6C8 0.34 2 2.66 49.55 
LINE-1 retrotransposable element 
ORF2 protein 
O00370 0.43 2 4.13 16.73 
Lipocalin-1 P31025 0.20 2 11.40 75.5 
Lipopolysaccharide-binding protein P18428 0.21 13 2.20 655.61 
L-lactate dehydorgenase B chain P07195 0.14 6 1.89 269.52 
L-lactate dehydrogenase A chain P00338 0.40 2 1.02 138.91 
Low affinity immunoglobulin 
gamma Fc region receptro III-A 
P08637 0.22 2 2.51 23.83 
LRP2-binding protein Q9P2M1 0.01 2 23.21 31.9 
L-selectin P14151 0.36 3 13.69 120.64 
Lumican P51884 0.00 12 5.92 828.14 
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Lymphatic vessel endothelial 
hyaluronic acid receptor 1 
Q9Y5Y7 0.18 4 1.26 57.93 
Lysosomal-trafficing regulator Q99698 0.21 5 1.99 25.5 
Lysosome-associated membrane 
glycoprotein 2 
P13473 0.35 2 1.43 123.63 
Lysozyme C P61626 0.22 9 1.99 262.25 
Macrophage mannose receptor 1 P22897 0.33 2 2.10 37.32 
Manganese-transpoting ATPase 
13A1 
Q9HD20 0.23 2 1.24 27.49 
Mannan-binding lectin serine 
protease 2 
O00187 0.15 8 1.25 330.97 
Mannan-binding lectin serine 
protesase 1 
P48740 0.37 15 1.08 697.2 
Mannose-binding protein C P11226 0.39 6 1.56 417.29 
Mannosyl-oligosaccharide 1,2- 
alpha-mannosidase IA 
P33908 0.07 4 3.59 133 
Matrix metalloproteinase-9 P14780 0.40 7 1.03 265.35 
Metalloproteinase inhibitor 1 P01033 0.43 6 1.09 253.91 
Mixed lineaeg kinase domain-like 
protein 
Q8NB16 0.05 3 1.92 13.97 
Mocnocyte differnetiation antigen 
CD14 
P08571 0.21 5 1.40 259 
Mucin-16 Q8WXI7 0.37 2 1.10 28.78 
Mucin-5B Q9HC84 0.26 8 1.65 193.14 
Multimerin-1 Q13201 0.27 5 2.71 190.66 
Myomegalin Q5VU43 0.01 6 2.71 34.4 
N-acetylmuramoyl-L-alanine 
amidase 
Q96PD5 0.26 22 1.20 2319.05 
NACT, LRR and PYD domains-
containing protein 12 
P59046 0.39 2 1.24 16.4 
Neural cell adhesion molecule 1 P13591 0.05 2 2.62 76.65 
Neural cell adhesion molecule L1-
like protein 
O00533 0.37 4 1.29 68.22 
Nidogen-1 P14543 0.26 8 1.23 234.91 
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Noelin Q99784 0.49 3 1.27 50.37 
Nucleolar protein 6 Q9H6R4 0.42 2 1.05 24.74 
Nucleolas pre-ribosoma-associated 
protein 1 
O60287 0.02 2 1.47 16.75 
Obscurin Q5VST9 0.16 3 1.95 43.62 
Panthetheinase O95497 0.33 2 2.74 67.45 
Peptidyl-prolyl cis-trans isomerase A P62937 0.29 3 1.18 52.9 
Periostin Q15063 0.25 8 2.87 292.19 
Perociredocin-2 P32119 0.34 3 1.23 103.73 
Phosphatidylcholine-sterol 
acyltrasferase 
P04180 0.13 6 1.64 408.46 
Phosphatidylinositol 3,4,5-
triphosphate-dependent Rac 
exchanger 1 protein 
Q8TCU6 0.07 2 2.95 23.52 
Phosphatidylinositol-glycan-specific 
phspholipase D 
P80108 0.29 22 1.49 1208.22 
Phospholipid transfer protein P55058 0.24 6 1.47 367.31 
Pigment epithelium-derived factor P36955 0.35 21 1.12 1400.25 
Plasma kallikrein P03952 0.17 33 1.48 1976.74 
Plasma protease C1 inhibitor P05155 0.43 27 1.02 1917.06 
Plasma serine proteas inhibitor P05154 0.14 13 1.46 679.42 
Plasminogen P00747 0.36 61 1.10 4672.49 
Plastin-2 P13796 0.14 22 2.11 927.63 
Platelet basic protein P02775 0.25 4 1.30 205.55 
Platelet factor 4 P02776 0.07 3 3.46 80.53 
Platelet glycoprotein Ib alpga chain P07359 0.00 5 11.60 137.38 
Platelet glycoprotein V P40197 0.29 5 1.19 297.1 
Polymeric immunoglobulin receptor P01833 0.32 9 3.22 348.05 
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Polyubiquitin-B P0CG47 0.36 3 1.50 110.39 
POTE ankyrin domain family 
member E 
Q6S8J3 0.31 2 1.39 643.77 
Pregnancy zone protein P20742 0.11 33 4.29 2790.76 
Prenylcystein oxidase 1 Q9UHG3 0.34 8 1.07 400.97 
Procollagen C-denopeptidase 
enhancer 1 
Q15113 0.31 5 1.19 162.91 
Profilin-1 P07737 0.35 2 1.19 53.65 
Prolactin inducible protein P12273 0.27 3 11.20 90.3 
Properdin P27918 0.01 4 10.53 197.63 
Proteasome subunit alpha type-3 P25788 0.22 2 20.40 33.32 
Proteasome subunit beta type-1 P20618 0.42 2 4.71 46.4 
Proteasome subunit beta type-8 P28062 0.18 2 21.39 129.46 
Protein AMBP P02760 0.02 23 1.97 1541.99 
Protein FAM184A Q8NB25 0.48 2 1.58 23.4 
Protein FAM186A A6NE01 0.02 2 2.10 19.78 
Protein kinase C zeta type Q05513 0.07 4 2.88 54.9 
Protein S100-A7 P31151 0.43 6 1.17 320.13 
Protein S100-A8 P05109 0.38 3 1.32 45.01 
Protein S100-A9 P06702 0.35 3 1.19 81.07 
Protein Shroom3 Q8TF72 0.24 2 1.31 22.26 
protein Z-dependent protease 
inhibitor 
Q9UK55 0.17 15 1.36 678.57 
Proteoglycan 4 Q92954 0.30 14 1.47 687.24 
Protesome subunut alpha type-6 P60900 0.12 6 4.51 139.14 
Prothrombin P00734 0.38 44 1.14 3752.56 
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Putative macrophage stimulating 1-
like protein 
Q2TV78 0.30 2 1.51 169.94 
Ras-related protein Rap-1b P61224 0.17 2 1.28 82.75 
Receptor-type tyrosine-protein 
phosphatase eta 
Q12913 0.30 2 1.15 22.2 
Retinol-binding protein 4 P02753 0.31 13 1.17 1275.49 
RNA-binding protein 25 P49756 0.47 2 2.92 14.9 
Scavenger receptor cystein-rich 
type 1 protein M130 
Q86VB7 0.43 4 3.07 147.88 
Secreted phosphoprotein 24 Q13103 0.09 3 3.61 177.91 
Seglycin P10124 0.12 4 1.97 144.12 
Selenoprotein P P49908 0.18 6 1.35 296.59 
Serine/threonine-protein kinase 
LMTK1 
Q6ZMQ8 0.21 2 1.24 18.3 
Serine/threonine-protein 
kinase/endoribonuclease IRE1 
O75460 0.03 2 3.45 24.29 
Serotransferrin P02787 0.37 56 1.07 5259.27 
Serpin B3 P29508 0.40 3 19.84 92.49 
Serum albumin P02768 0.02 56 4.08 5033.19 
serum amyloid a-1 protein P0DJI8 0.08 4 15.11 171.87 
Serum amyloid A-4 protein P35542 0.00 7 7.16 339.12 
Serum amyloid P-component P02743 0.25 9 1.20 533.41 
Serum paraoxonase/arylesterase 1 P27169 0.19 19 1.31 1488.82 
Serum paraoxonase/lactonase 3 Q15166 0.18 5 1.61 234.46 
Sex hormone-binding globulin P04278 0.34 15 1.35 740.99 
SH3 and multiple ankyrin repeat 
domains protein 1 
Q9Y566 0.00 4 4.50 25.95 
Solute carrier family 13 member 4 Q9UKG4 0.37 2 1.16 13.5 
SPARC P09486 0.36 6 1.20 190.24 
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Spectrin beta chain, erythrocytic P11277 0.02 3 3.57 18.66 
StAR-related lipeid transfeer protein 
9 
Q9P2P6 0.09 2 1.55 44.03 
Stress-70 protein, mitochondrial P38646 0.37 2 1.07 29.42 
Striated muscle preferentially 
expressed proein kinase 
Q15772 0.01 2 4.89 15.07 
Sulfhydryl oxidase 1 O00391 0.16 11 1.34 519.3 
Syntaxin-8 Q9UNK0 0.09 2 1.70 14.56 
Talin-1 Q9Y490 0.18 16 1.22 533.48 
Talin-2 Q9Y4G6 0.15 2 1.22 24.14 
Tenascin P24821 0.27 11 1.86 314.03 
Tenascin-X P22105 0.40 18 1.05 665.44 
Tetranectin P05452 0.04 8 2.22 496.42 
Thrombospondin-1 P07996 0.15 50 1.57 3811.8 
Thrombospondin-4 P35443 0.01 13 6.56 740.94 
Thyrocine-binding globulin P05543 0.01 20 1.94 1001.51 
Titin Q8WZ42 0.08 30 1.16 74.21 
Tonsoku-like protein Q96HA7 0.07 2 1.71 16.93 
TPR and ankyrin repeat-containing 
protein 1 
O15050 0.20 3 1.18 18.55 
Transforming growth factor-beta-
induced protein ig-h3 
Q15582 0.15 22 1.68 874.65 
Transketolase P29401 0.14 5 13.66 182.46 
Transthyretin P02766 0.27 13 1.27 1482.36 
Tryptophan--tRNA ligase, 
cytoplasmic 
P23381 0.32 2 27.53 77.63 
Tubulin beta-1 chain Q9H4B7 0.38 2 1.12 54.29 
Tyrosine-protein phosphatase non-
receptro type 4 
P29074 0.07 2 1.87 13.84 
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UTP--glucose 1-phosphate 
uridylyltransferase 
Q16851 0.46 4 1.47 61.34 
Vacular cell adhesion protein 1 P19320 0.09 10 3.67 329.99 
Vacuolar protein sortin-associated 
protein 11 homolog 
Q9H270 0.47 2 1.01 13.96 
Vasorin Q6EMK4 0.30 2 1.30 60.04 
Versican core protein P13611 0.25 6 1.43 114.52 
Vinculin P18206 0.02 3 5.05 64.08 
Vitamin K-dependent protein C P04070 0.00 6 3.53 163.29 
Vitamin K-dependent protein S P07225 0.29 28 1.14 1809.28 
Vitamin K-dependent protein z P22891 0.47 9 1.03 403.73 
Vitamine D-binding protein P02774 0.00 30 2.88 2213.23 
Vitelline mmbrane outer layer 
protein 1 homolg 
Q7Z5L0 0.18 2 62.39 201.5 
Vitronectin P04004 0.03 21 1.55 1569.07 
von Willbrand factor P04275 0.48 98 1.49 6619.24 
Xaa-Pro dipeptidase P12955 0.05 10 2.75 384.41 
Zinc finger protein 343 Q6P1L6 0.37 2 1.04 24.17 
Zinc-alpha-2-glycoprotein P25311 0.23 21 1.19 1341.12 
Zymogen granule protein 16 
homolog B 
Q96DA0 0.28 6 10.29 196.18 
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Appendix B 2. 357 protein identified in all sequential samples from  pergnant 
woman with HFRS 
Description Accession 
q 
Value 
Unique 
peptides 
Max fold 
change 
Confidence 
score 
14-3-3 protein epsilon P62258 0.00 2 Infinity 172.63 
14-3-3 protein gamma  P61981 0.07 2 Infinity 164.45 
14-3-3 protein zeta/delta  P63104 0.02 4 19.22 399.58 
78 kDa glucose-regulated protein  P05534 0.01 8 7.49 605.29 
Actin, cytoplasmic 1 P02763 0.00 10 2.87 1980.53 
Adenylyl cyclase-associated protein 1  P19652 0.02 11 1.65 1936.79 
Adiponectin  P01009 0.00 52 1.41 5929.02 
Afamin P04217 0.06 21 1.41 2860.38 
Alpha-1-acid glycoprotein 1  P08697 0.04 22 1.71 3029.33 
Alpha-1-acid glycoprotein 2  P02750 0.03 16 2.16 2017.87 
Alpha-1-antichymotrypsin  P01023 0.00 93 6.70 16163.67 
Alpha-1-antitrypsin P01011 0.01 53 2.33 6793.62 
Alpha-1B-glycoprotein  P17174 0.01 5 18.83 232.07 
Alpha-2-antiplasmin  P60709 0.00 8 4.20 2226.46 
Alpha-2-HS-glycoprotein  O43184 0.00 10 15.43 741.12 
Alpha-2-macroglobulin  Q15848 0.00 2 10.45 276.02 
Alpha-enolase  P43652 0.00 36 4.28 4785.93 
Amiloride-sensitive amine oxidase 
[copper-containing]  
P02768 0.00 68 134.91 11509.36 
Aminopeptidase N P04075 0.01 4 7.09 244.7 
Angiogenin  P05062 0.00 9 193.98 655.46 
Angiotensinogen  P35858 0.02 22 3.05 2787.64 
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Annexin A1  P02760 0.00 28 1.61 3444.31 
Antithrombin-III (Chain 33-464)  P28838 0.05 6 56687.60 318.88 
Apolipoprotein A-I  P15144 0.08 8 1.86 556.65 
Apolipoprotein A-II  P03950 0.00 3 23.51 132.83 
Apolipoprotein A-IV   P01019 0.07 27 1.73 4270.08 
Apolipoprotein B-100  P01008 0.04 45 1.68 5637.01 
Apolipoprotein C-I  P04083 0.19 2 349.11 153.36 
Apolipoprotein C-II  P19801 0.04 3 54.61 177.43 
Apolipoprotein C-III  P08519 0.00 6 3.01 599.14 
Apolipoprotein C-IV  P02647 0.00 49 3.71 5589.85 
Apolipoprotein D  P02652 0.00 8 4.13 1038.41 
Apolipoprotein E P06727 0.00 37 2.01 4037.02 
Apolipoprotein F  P04114 0.01 371 2.43 48749.19 
Apolipoprotein L1  P02654 0.00 5 4.35 402.04 
Apolipoprotein M  P02655 0.00 5 3.43 750.44 
Apolipoprotein(a)  P02656 0.00 5 5.28 881.53 
Asialoglycoprotein receptor 2  P55056 0.00 8 4.00 737.84 
Aspartate aminotransferase, 
cytoplasmic  
P05090 0.00 11 2.20 1245.6 
Attractin P02649 0.00 30 2.33 3597.58 
Azurocidin  Q13790 0.01 4 11.75 376.96 
Band 3 anion transport protein P02749 0.00 25 2.92 3201.91 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
O14791 0.00 11 2.45 1218.99 
Beta-1,4-galactosyltransferase 1  O95445 0.00 14 2.76 1123.75 
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Beta-2-glycoprotein 1 P07307 0.06 2 14.90 166.55 
Beta-2-microglobulin O75882 0.00 36 2.41 3278.48 
Beta-Ala-His dipeptidase  P61769 0.00 4 6.10 359.38 
Biotinidase  P02730 0.01 12 173.57 1123.63 
Bone marrow proteoglycan  P15291 0.09 3 3.04 211.76 
C-reactive protein (Chain 19-224) Q15582 0.07 15 1.91 1188.68 
C4b-binding protein alpha chain P30043 0.02 3 10440.34 178.88 
C4b-binding protein beta chain  P43251 0.03 11 1.65 1194.49 
Cadherin-1  Q86VB7 0.00 12 10.59 1014.12 
Cadherin-5  P02745 0.01 4 1.70 177 
Calmodulin  P02746 0.01 8 2.02 960.23 
Calreticulin  P02747 0.00 6 1.95 559.85 
Carbonic anhydrase 1 P00736 0.01 33 1.48 3872.99 
Carbonic anhydrase 2 Q9NZP8 0.01 9 1.50 1101.6 
Carboxypeptidase B2  P09871 0.02 30 1.46 3496.17 
Carboxypeptidase N catalytic chain P20160 0.00 2 9.67 69.03 
Carboxypeptidase N subunit 2  P04003 0.00 36 2.01 3730.25 
Cartilage oligomeric matrix protein  P20851 0.00 5 1.74 565.6 
Catalase P12830 0.23 2 30.37 146.16 
Cathelicidin antimicrobial peptide  P33151 0.03 7 11.35 481.48 
Cathepsin D P00915 0.00 10 28.73 1185.9 
Cathepsin G P00918 0.00 4 542.52 249.16 
CD44 antigen  P62158 0.04 3 55.30 159.4 
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CD5 antigen-like  P27797 0.03 2 12.46 76.21 
Cell surface glycoprotein MUC18  P49913 0.03 4 2.73 194.82 
Ceruloplasmin  Q01518 0.10 2 486.30 79.28 
Cholesteryl ester transfer protein  P04040 0.01 9 21.58 781.07 
Cholinesterase  P07339 0.02 2 34.32 54.13 
Choriogonadotropin subunit beta 
variant 1 
P08311 0.03 6 9.31 364.68 
Chorionic somatomammotropin 
hormone 1  
P08185 0.02 20 2.36 2777.98 
Clusterin  Q96IY4 0.00 14 2.29 1434.74 
Coactosin-like protein  P15169 0.01 18 1.94 1615.31 
Coagulation factor IX  P08571 0.01 11 2.66 992.4 
Coagulation factor V  P16070 0.23 2 1.41 114.19 
Coagulation factor VII  O43866 0.00 14 7.52 1820.85 
Coagulation factor X  P00450 0.02 87 1.34 15345.55 
Coagulation factor XI  P11597 0.01 7 19.64 476.31 
Coagulation factor XII  P00751 0.00 52 1.37 6071.33 
Coagulation factor XIII A chain  P00746 0.01 11 2.85 954.68 
Coagulation factor XIII B chain  P08603 0.00 70 1.69 9924.05 
Collagen alpha-1(III) chain P05156 0.00 26 1.51 3048.83 
Collagen alpha-1(VI) chain  A6NKQ9 0.01 2 630.76 205.94 
Collagen alpha-1(XVIII) chain P06276 0.00 12 3.18 953.58 
Collagen alpha-3(VI) chain  P10909 0.03 26 1.31 3089.26 
Collectin-11  Q96KN2 0.01 16 2.11 984.07 
Complement C1q subcomponent 
subunit A  
P06681 0.00 30 1.44 3390.61 
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Complement C1q subcomponent 
subunit B  
P01024 0.00 194 1.74 28824.39 
Complement C1q subcomponent 
subunit C  
P02461 0.00 2 Infinity 124.91 
Complement C1r subcomponent  P0C0L4 0.04 4 1.56 14917.33 
Complement C1r subcomponent-like 
protein  
P01031 0.01 104 1.60 11953.51 
Complement C1s subcomponent  P13671 0.02 44 1.98 5094.78 
Complement C2  P12109 0.01 4 24.62 233.08 
Complement C3  P12111 0.21 3 68.76 166.69 
Complement C4-A  P10643 0.00 37 1.43 3906.11 
Complement C5  P07357 0.00 20 2.26 2829.81 
Complement component C6  P07358 0.00 24 2.25 2756.11 
Complement component C7  P07360 0.00 11 1.62 1626.49 
Complement component C8 alpha 
chain  
P02748 0.01 33 1.36 4239.14 
Complement component C8 beta 
chain  
P39060 0.02 3 4.87 224.81 
Complement component C8 gamma 
chain  
Q9BWP8 0.03 3 3.77 151.67 
Complement component C9  P49747 0.01 5 5.32 661.58 
Complement factor B  Q14019 0.26 3 75.67 124.01 
Complement factor D  P22792 0.21 14 1.39 1719.03 
Complement factor H P54108 0.03 2 1.94 112.07 
Complement factor H-related 
protein 1 
P02741 0.00 9 52.19 685.54 
Complement factor H-related 
protein 2  
P07333 0.01 7 6.62 504.69 
Complement factor H-related 
protein 3  
P0DML2 0.00 6 4.97 829.34 
Complement factor H-related 
protein 5 
P13611 0.02 12 50.63 726.98 
Complement factor I  P02775 0.00 6 6.13 904.79 
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Corticosteroid-binding globulin P01034 0.01 7 8.15 667.03 
Cystatin-C  Q14118 0.03 3 20.03 80.58 
Cysteine-rich secretory protein 3  P81605 0.00 3 3.96 200.83 
Cytosol aminopeptidase  P59665 0.00 3 2.86 209.89 
Dermcidin  Q01459 0.02 3 2.13 163.88 
Di-N-acetylchitobiase  P09172 0.00 8 3.97 711.48 
Disintegrin and metalloproteinase 
domain-containing protein 12  
Q16610 0.00 12 3.91 940.23 
Dopamine beta-hydroxylase  P08246 0.11 3 4.79 113.75 
Dystroglycan  P06733 0.08 3 32.28 140.1 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 2  
P14625 0.14 3 81.60 205.94 
EGF-containing fibulin-like 
extracellular matrix protein 1 
Q13822 0.00 14 4.36 1066.78 
Endoplasmin  Q9UNN8 0.00 2 13.21 148.39 
Endothelial protein C receptor  P00488 0.16 2 219.88 94.77 
Extracellular matrix protein 1  P05160 0.01 8 3.28 442.63 
Ferritin light chain P00742 0.00 18 1.47 1453.77 
Fetuin-B  P03951 0.01 14 4.38 883.5 
Fibrinogen alpha chain P00748 0.00 21 1.77 2062.41 
Fibrinogen beta chain P12259 0.00 37 2.18 2391.36 
Fibrinogen gamma chain P08709 0.01 3 5.55 288.08 
Fibrinogen-like protein 1  P00740 0.00 16 3.53 1280.12 
Fibronectin  P23142 0.00 19 11.17 2140.42 
Fibulin-1  Q12805 0.00 12 5.93 941.16 
Ficolin-2  Q9Y6R7 0.01 10 10.25 462.8 
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Ficolin-3  Q15485 0.00 5 6.69 432.59 
Filamin-A  O75636 0.01 12 1.51 1517.03 
Flavin reductase (NADPH)  P02765 0.00 14 2.70 3262.98 
Follistatin-related protein 1 Q9UGM5 0.01 9 1.47 979.26 
Fructose-bisphosphate aldolase A  Q08830 0.17 2 49.14 62.98 
Fructose-bisphosphate aldolase B  Q03591 0.00 2 2.84 1679.54 
G-protein coupled receptor 126  P36980 0.03 2 1.57 585.29 
Galectin-3-binding protein  Q02985 0.08 4 1.80 525.25 
Gamma-glutamyl hydrolase  Q9BXR6 0.01 6 6.87 510.09 
Gelsolin P02671 0.00 11 6.11 716.56 
Glucose-6-phosphate isomerase  P02675 0.00 12 23.19 994.83 
Glutathione peroxidase 3  P02679 0.00 7 17.43 648.86 
Glutathione S-tanferase P P02751 0.00 73 24.63 7767.52 
Glutathione S-transferase omega-1  P21333 0.11 4 780.77 208.12 
Glyceraldehyde-3-phosphate 
dehydrogenase  
P02792 0.00 7 38.65 566.93 
Glycoprotein hormones alpha chain  Q12841 0.15 2 41.20 55.77 
Haptoglobin  P04406 0.03 5 4.50 630.75 
Haptoglobin-related protein  P06744 0.17 2 105.39 118.92 
Heat shock protein HSP 90-alpha  P52566 0.04 2 64.19 103.44 
Hemoglobin subunit alpha P06396 0.00 42 2.97 4407.8 
Hemoglobin subunit beta Q92820 0.04 4 2.12 218.79 
Hemoglobin subunit delta  P01215 0.00 3 6.35 113.87 
Hemopexin  Q86SQ4 0.01 5 16.77 312.58 
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Heparin cofactor 2  P07359 0.02 6 2.58 631.66 
Hepatocyte growth factor activator  P40197 0.01 6 39.17 640.62 
Hepatocyte growth factor-like 
protein 
P22352 0.00 7 2.19 423.63 
Histidine-rich glycoprotein P11021 0.02 4 3.69 319.12 
Histone H2A type 2-C  P78417 0.02 2 9802.37 108.37 
Histone H3.2  P09211 0.02 2 28.77 126.87 
Histone H4  Q16777 0.00 3 23.94 121.4 
HLA class I histocompatibility 
antigen, A-24 alpha chain  
Q71DI3 0.01 2 7.21 58.01 
Hornerin P62805 0.00 6 11.35 468.23 
Hyaluronan-binding protein 2  Q14520 0.01 19 1.82 1632.26 
Ig alpha-1 chain C region  P69905 0.01 11 13.90 1331.68 
Ig alpha-2 chain C region P68871 0.00 9 16.91 1929.11 
Ig delta chain C region  P02042 0.00 2 31.58 1404.05 
Ig gamma-1 chain C region  P02790 0.00 35 1.91 4488.09 
Ig gamma-2 chain C region  P05546 0.00 29 2.23 2455.42 
Ig gamma-3 chain C region  Q04756 0.00 8 23.27 461.44 
Ig gamma-4 chain C region  P26927 0.00 14 2.52 1386.49 
Ig heavy chain V-I region HG3  Q86YZ3 0.23 2 50.26 206.68 
Ig heavy chain V-I region V35  P00738 0.00 20 4.31 5369.83 
Ig heavy chain V-II region ARH-77  P00739 0.00 7 4.13 2920.48 
Ig heavy chain V-III region BUT  P04196 0.00 24 5.51 3217.09 
Ig heavy chain V-III region GA  P07900 0.08 2 26.46 178.33 
Ig heavy chain V-III region GAL  P01743 0.00 2 7.34 201.11 
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Ig heavy chain V-III region WEA  P23083 0.00 3 5.61 445.61 
Ig kappa chain C region  P06331 0.00 2 3.34 330.64 
Ig kappa chain V-I region CAR  P01763 0.05 2 15.35 262.83 
Ig kappa chain V-I region HK102 
(Fragment)  
P01767 0.00 3 6.69 398.8 
Ig kappa chain V-I region WEA  P01769 0.01 2 35.53 61.12 
Ig kappa chain V-III region VG 
(Fragment)  
P01781 0.00 4 4.80 257.93 
Ig kappa chain V-IV region Len  P18065 0.19 3 104.41 242.51 
Ig lambda chain V region 4A  P17936 0.01 7 2.58 571.67 
Ig lambda chain V-I region NIG-64  P22692 0.01 3 10.69 174.78 
Ig lambda chain V-III region LOI  P24592 0.16 2 6.23 111 
Ig lambda chain V-III region SH  P05155 0.05 37 1.65 4646.01 
Ig lambda chain V-IV region MOL  P05362 0.01 7 21.27 622.81 
Ig lambda-7 chain C region  P01344 0.00 4 2.67 422.25 
Ig mu chain C region  P01876 0.00 6 9.70 2229.61 
IgGFc-binding protein  P01877 0.00 3 14.44 1573 
Immunoglobulin J chain  P01880 0.03 7 19.18 605.2 
Immunoglobulin lambda-like 
polypeptide 5  
P01857 0.00 6 13.08 2048.44 
Insulin-like growth factor II (Chain 
25-91)  
P01859 0.00 5 31.53 1491.8 
Insulin-like growth factor-binding 
protein 2  
P01860 0.00 6 18.62 1758.66 
Insulin-like growth factor-binding 
protein 3  
P01861 0.00 3 47.85 1042.33 
Insulin-like growth factor-binding 
protein 4  
P01871 0.00 9 2.85 3984.06 
Insulin-like growth factor-binding 
protein 6  
P01591 0.00 7 3.07 722.78 
Insulin-like growth factor-binding 
protein complex acid labile subunit  
P01834 0.00 8 8.27 1914.79 
  247 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
B9A064 0.00 3 9.40 1210.73 
Inter-alpha-trypsin inhibitor heavy 
chain H2  
P05154 0.00 15 4.77 1042.4 
Inter-alpha-trypsin inhibitor heavy 
chain H3  
Q6H9L7 0.02 5 20.76 232.44 
Inter-alpha-trypsin inhibitor heavy 
chain H4  
P19827 0.01 51 2.30 7548.04 
Intercellular adhesion molecule 1 P19823 0.00 55 2.52 7261.15 
Isthmin-2  Q06033 0.00 45 3.04 4989.64 
Kallistatin  Q14624 0.01 63 1.71 8607.9 
Keratin-associated protein 11-1  P13645 0.04 27 2.02 4556 
Keratin, type I cytoskeletal 10  P02533 0.02 5 5.00 1256.91 
Keratin, type I cytoskeletal 14  P04264 0.00 30 1.79 3760.58 
Keratin, type II cytoskeletal 1  P13647 0.00 7 2.54 973.54 
Keratin, type II cytoskeletal 5  P48668 0.11 2 17.57 851.76 
Keratin, type II cytoskeletal 6C  P29622 0.00 16 5.21 1672.78 
Kininogen-1  P03952 0.00 37 2.10 3772.72 
L-lactate dehydrogenase A chain  P01042 0.00 39 1.76 4221.49 
L-lactate dehydrogenase B chain  P14618 0.25 2 98.90 122.29 
L-selectin  Q8IUC1 0.03 2 Infinity 129.85 
Lactotransferrin P01596 0.07 2 56.91 91.87 
Leucine-rich alpha-2-glycoprotein  P01602 0.00 2 3.66 284.72 
Leucyl-cystinyl aminopeptidase  P01610 0.23 2 39.19 213.65 
Leukocyte immunoglobulin-like 
receptor subfamily A member 3 
P04433 0.00 3 6.48 244.19 
Lipopolysaccharide-binding protein  P01625 0.00 3 8.81 621.68 
Lumican  A0M8Q6 0.00 2 9.43 650.93 
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Lymphatic vessel endothelial 
hyaluronic acid receptor 1  
P18428 0.01 17 5.43 1769.49 
Lysozyme C Q9UIQ6 0.00 5 48.52 344.07 
Macrophage colony-stimulating 
factor 1 receptor  
P04180 0.01 7 1.89 874.1 
Macrophage mannose receptor 1  P00338 0.10 2 Infinity 193.12 
Mannan-binding lectin serine 
protease 1  
P07195 0.01 4 7.64 344.29 
Mannan-binding lectin serine 
protease 2  
Q08380 0.00 24 3.64 3292.45 
Mannose-binding protein C  Q8N6C8 0.03 3 6.96 213.11 
Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IA  
Q07954 0.01 4 38.96 265.37 
Matrix metalloproteinase-9  P51884 0.01 13 1.81 1502.96 
Metalloproteinase inhibitor 1  P04211 0.04 2 4.16 91.49 
Moesin  P01702 0.01 2 2.24 63.55 
Monocyte differentiation antigen 
CD14  
P01714 0.01 3 3.64 409.8 
Myeloperoxidase  P80748 0.00 2 7.46 265.87 
N-acetylmuramoyl-L-alanine amidase  P06889 0.01 2 3.21 172.43 
Neuropilin-1 P14151 0.06 4 1.73 153.4 
Neutrophil collagenase  P61626 0.00 6 1.87 279.78 
Neutrophil defensin 1  Q9Y5Y7 0.04 4 2.68 173.45 
Neutrophil elastase  P33908 0.08 4 2.62 282.52 
Neutrophil gelatinase-associated 
lipocalin  
P48740 0.01 13 1.47 1433.51 
Nidogen-1  O00187 0.00 10 2.00 696.32 
Nucleobindin-1  P11226 0.01 7 1.84 1023.75 
Olfactomedin-4  P22894 0.01 2 11.75 161.6 
Out at first protein homolog  P14780 0.01 14 1.86 990.76 
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Pantetheinase P26038 0.21 3 7.31 131.46 
Pappalysin-1  P22897 0.01 5 15.62 200.83 
Pentraxin-related protein PTX3 P43121 0.07 2 3.33 124.72 
Peptidase inhibitor 16 P80188 0.00 3 3.18 228.36 
Peptidyl-prolyl cis-trans isomerase A P14543 0.00 15 2.93 867.79 
Periostin  Q6P988 0.01 4 10.90 302.7 
Peroxiredoxin-2 O14786 0.28 2 15.90 136.12 
Peroxiredoxin-6  Q02818 0.02 5 32.72 330.22 
Phosphatidylcholine-sterol 
acyltransferase 
Q86UD1 0.03 3 5.94 149.78 
Phosphatidylinositol-glycan-specific 
phospholipase D  
Q6UX06 0.05 3 13.02 225.86 
Phospholipid transfer protein  Q13219 0.00 37 38.02 3617.2 
Pigment epithelium-derived factor  Q9UHG3 0.01 13 4.32 908.17 
Plasma kallikrein  P36955 0.03 20 1.51 2063.15 
Plasma protease C1 inhibitor  P12955 0.15 4 1.49 263.08 
Plasma serine protease inhibitor  P05164 0.00 14 4.45 1044.77 
Plasminogen P98160 0.09 5 11.67 194.38 
Plastin-2  Q96PD5 0.00 21 3.74 3611.86 
Platelet basic protein  P80108 0.03 19 2.33 1911.43 
Platelet factor 4  Q6UXB8 0.05 2 1.73 180.36 
Platelet glycoprotein Ib alpha chain  P01833 0.00 17 6.21 1496.35 
Platelet glycoprotein V  P02776 0.00 3 5.39 306.07 
Poliovirus receptor  P00747 0.00 68 2.29 9045.17 
Polymeric immunoglobulin receptor  P13796 0.00 18 5.00 1542.8 
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Polyubiquitin-C  P55058 0.04 13 2.46 1290.42 
Pregnancy zone protein  P27169 0.00 22 5.56 2816.57 
Pregnancy-specific beta-1-
glycoprotein 1  
Q15063 0.03 4 10.18 263.47 
Pregnancy-specific beta-1-
glycoprotein 11  
P62937 0.00 6 15.05 443.38 
Pregnancy-specific beta-1-
glycoprotein 2 
P32119 0.01 8 47.58 425 
Pregnancy-specific beta-1-
glycoprotein 4 
P30041 0.01 3 7.20 229.56 
Pregnancy-specific beta-1-
glycoprotein 6  
P13727 0.00 11 12.49 1118.35 
Pregnancy-specific beta-1-
glycoprotein 9  
Q92954 0.03 8 2.11 654.72 
Prenylcysteine oxidase 1 P04070 0.00 7 2.99 561.74 
Profilin-1  P07737 0.00 3 17.00 223.51 
Prolow-density lipoprotein receptor-
related protein 1  
P27918 0.00 7 4.87 523.11 
Properdin  P07225 0.01 24 2.09 3261.23 
Prostaglandin-H2 D-isomerase  P22891 0.00 12 2.20 982.69 
Proteasome subunit alpha type-2  P25787 0.01 2 94.80 149.41 
Proteasome subunit alpha type-3  P25788 0.11 2 303.43 149.18 
Proteasome subunit alpha type-5  P28066 0.13 4 363.02 301.64 
Proteasome subunit alpha type-6  P60900 0.04 3 716.32 261.71 
Proteasome subunit alpha type-7  O14818 0.00 5 27.68 336.78 
Proteasome subunit beta type-1 P20618 0.00 2 17.13 251.37 
Proteasome subunit beta type-3  P49720 0.19 2 149.38 61.91 
Proteasome subunit beta type-4  P28070 0.00 2 Infinity 134.23 
Proteasome subunit beta type-9  P28065 0.06 2 1844.03 182.97 
Protein AMBP P11464 0.00 3 9.30 1249.66 
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Protein notum homolog  Q9UQ72 0.01 3 42.75 755.62 
Protein S100-A7  P11465 0.01 2 107.36 859.05 
Protein S100-A8  Q00888 0.00 4 15.45 853.98 
Protein S100-A9  Q00889 0.01 2 13.81 635.33 
Protein Z-dependent protease 
inhibitor 
Q13046 0.02 4 5.11 978.28 
Proteoglycan 4  Q00887 0.01 8 6.89 1105.15 
Prothrombin  P41222 0.10 2 3.69 215.91 
Putative pregnancy-specific beta-1-
glycoprotein 7  
P26022 0.00 7 79.12 521.78 
Pyruvate kinase PKM  P15151 0.00 3 6.02 165.54 
Retinoic acid receptor responder 
protein 2  
P20742 0.01 51 2.78 8179.84 
Retinol-binding protein 4 O00391 0.01 12 1.91 1100.1 
Rho GDP-dissociation inhibitor 2 Q99969 0.02 2 3.94 80.73 
Ribonuclease 4 P02753 0.00 15 5.00 2008.66 
Ribonuclease pancreatic P07998 0.00 2 64.15 164.79 
Scavenger receptor cysteine-rich 
type 1 protein M130  
P34096 0.02 5 14.15 245.52 
Secreted phosphoprotein 24  P31151 0.21 2 5.58 135.65 
Selenoprotein P  P05109 0.00 4 4.48 281.82 
Serotransferrin P06702 0.00 8 6.00 860.88 
Serpin A11  P0DJI8 0.00 3 226.16 1293.71 
Serum albumin P0DJI9 0.00 2 18.76 894.78 
Serum amyloid A-1 protein  P35542 0.00 5 2.23 691.5 
Serum amyloid A-2 protein P02743 0.04 6 1.35 827.48 
Serum amyloid A-4 protein  P49908 0.00 5 4.22 455.32 
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Serum amyloid P-component  Q9H299 0.02 2 23.50 66.11 
Serum paraoxonase/arylesterase 1  P04278 0.03 22 2.83 3159.95 
Sex hormone-binding globulin  Q86U17 0.04 2 2.61 74.07 
SH3 domain-binding glutamic acid-
rich-like protein 3  
Q13103 0.02 4 1.86 618.89 
SPARC  P09486 0.10 2 6.42 104.4 
SPARC-like protein 1  Q14515 0.33 2 7.39 42.75 
Spectrin alpha chain, erythrocytic 1  P02549 0.15 3 622.34 108.18 
Spectrin beta chain, erythrocytic  P11277 0.16 2 Infinity 154.55 
Sulfhydryl oxidase 1  P23381 0.02 5 59.40 297.25 
Talin-1  P37802 0.00 5 39.33 376.11 
Tenascin  P24821 0.06 6 7.65 318.9 
Tenascin-X  P22105 0.09 5 4.22 244.47 
Tetranectin  P05452 0.00 8 3.29 945.88 
Thrombospondin-1  P05543 0.05 22 1.55 2729.16 
Thrombospondin-4  P00734 0.00 42 2.32 7064.65 
Thyroxine-binding globulin  P01033 0.01 4 6.84 338.89 
Transforming growth factor-beta-
induced protein ig-h3  
P29401 0.02 5 13.51 258.23 
Transgelin-2  Q9Y490 0.03 6 261.89 441.48 
Transketolase  P60174 0.17 2 340.98 182 
Transthyretin  P67936 0.21 2 116.57 200.27 
Triosephosphate isomerase  P02787 0.00 80 4.39 12211.26 
Tropomyosin alpha-4 chain  P02788 0.00 27 4.76 2256.95 
Tryptophan--tRNA ligase, 
cytoplasmic  
P07996 0.00 30 6.33 3132.49 
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U5 small nuclear ribonucleoprotein 
200 kDa helicase 
P35443 0.02 7 33.20 847.99 
UTP--glucose-1-phosphate 
uridylyltransferase  
P02766 0.00 13 5.21 3142.71 
Vascular cell adhesion protein 1  O75643 0.32 2 2.15 30.81 
Vasorin  P0CG48 0.00 4 5.96 235.84 
Versican core protein  Q16851 0.00 7 46.28 362.77 
Vinculin  Q6EMK4 0.06 3 3.30 253.74 
Vitamin D-binding protein  P19320 0.01 15 3.62 865.28 
Vitamin K-dependent protein C  P18206 0.02 6 12.57 347.65 
Vitamin K-dependent protein S  O95497 0.03 5 2.08 363.57 
Vitamin K-dependent protein Z  P02774 0.03 48 1.50 7746.83 
Vitronectin  P04004 0.00 26 1.86 3054.04 
von Willebrand factor  P04275 0.00 107 8.58 11433.97 
Xaa-Pro dipeptidase  P25311 0.01 23 2.47 2582.1 
Zinc-alpha-2-glycoprotein  Q9UK55 0.01 11 1.65 1188.48 
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Appendix B 3. Proteins clustered by GProX 
Biological function  
(GO annotation) 
Description Accession 
Cluster 
membership 
Cluster 1 
Cell adhesion 
Disintegrin and metalloproteinase 
domain-containing protein 12  
O43184 0.7 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 1 
P11464 0.7 
Oxidoreductase Flavin reductase (NADPH)  P30043 0.6 
Pregnancy Fibrinogen alpha chain  P02671 0.6 
Protease 
Mannan-binding lectin serine 
protease 2  
O00187 0.8 
Pregnancy Adiponectin  Q15848 0.7 
Pregnancy/ Coagulation Coagulation factor VII  P08709 0.7 
Immunity/ 
Inflammation 
Macrophage colony-stimulating 
factor 1 receptor  
P07333 0.8 
Receptor G-protein coupled receptor 126  Q86SQ4 0.8 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 4  
Q00888 0.9 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 9  
Q00887 0.9 
Vitamin B5 metabolism Pantetheinase  O95497 0.9 
Pregnancy Leucyl-cystinyl aminopeptidase  Q9UIQ6 0.9 
Pregnancy 
Chorionic somatomammotropin 
hormone 1  
P0DML2 0.9 
Pregnancy Pappalysin-1  Q13219 0.9 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 2  
P11465 0.9 
Pregnancy Bone marrow proteoglycan  P13727 0.9 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 11  
Q9UQ72 0.9 
Pregnancy 
Pregnancy-specific beta-1-
glycoprotein 6  
Q00889 0.9 
Lipid metabolism Apolipoprotein C-IV P55056 0.6 
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Structural protein Collagen alpha -1(VI) chain P12109 0.6 
Oxidoreductase 
Amiloride-sensitive amine oxidase 
(copper-containing) 
P19801 0.6 
Cluster 2 
Acute phase response Fibrinogen gamma chain  P02679 0.6 
Cell adhesion Galectin-3-binding protein  Q08380 0.9 
Acute phase response C-reactive protein (Chain 19-224) P02741 0.9 
Cell movement 
EGF-containing fibulin-like 
extracellular matrix protein 1  
Q12805 0.6 
Proteolysis Proteasome subunit beta type-4  P28070 0.6 
Proteolysis Proteasome subunit beta type-1  P20618 0.7 
Coagulation Endothelial protein C receptor  Q9UNN8 0.6 
Angiogenesis Angiogenin  P03950 0.7 
Acute phase response Alpha-1-acid glycoprotein 1  P02763 0.8 
Growth factor binding 
Insulin-like growth factor-binding 
protein 4  
P22692 0.6 
Acute phase response 
Lipopolysaccharide-binding 
protein  
P18428 0.6 
Innate immunity Macrophage mannose receptor 1  P22897 0.6 
Protease inhibitor Cystatin-C  P01034 0.6 
Acid protease Cathepsin D P07339 0.6 
Cell adhesion/ 
angiogenesis 
Thrombospondin-4  P35443 0.6 
Innate immunity 
Scavenger receptor cysteine-rich 
type 1 protein M130  
Q86VB7 0.6 
Actin-binding Plastin-2  P13796 0.6 
Cell adhesion Olfactomedin-4  Q6UX06 0.6 
Platelet activation 
Inter-alpha-trypsin inhibitor heavy 
chain H3  
Q06033 0.6 
Endonuclease Ribonuclease pancreatic  P07998 0.9 
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Angiogenesis Leucine-rich alpha-2-glycoprotein  P02750 0.6 
Cell adhesion Collagen alpha-1(XVIII) chain  P39060 0.6 
Oxidoreductase/ 
transferase 
Glutathione S-transferase omega-1  P78417 0.7 
Wnt signalling pathway Protein notum homolog  Q6P988 0.8 
Lactate metabolism L-lactate dehydrogenase B chain  P07195 0.8 
Acute phase response Ferritin light chain  P02792 0.7 
Acute phase response Pentraxin-related protein PTX3  P26022 0.8 
Acute phase response Serum amyloid A-1 protein  P0DJI8 0.7 
Structural Collagen alpha-1(III) chain  P02461 0.8 
Humoral immunity 
HLA class I histocompatibility 
antigen, A-24 alpha chain 
P05534 0.7 
Proteolysis Proteasome subunit alpha type-2  P25787 0.8 
Acute phase response / 
platelet activation 
Alpha-1-antichymotrypsin  P01011 0.8 
Platelet activation Metalloproteinase inhibitor 1  P01033 0.8 
Endocytic receptor 
Prolow-density lipoprotein 
receptor-related protein 1  
Q07954 0.9 
Cell adhesion Vascular cell adhesion protein 1  P19320 0.9 
Secreted glycoprotein Isthmin-2  Q6H9L7 0.8 
- Out at first protein homolog  Q86UD1 0.9 
Proteolysis Proteasome subunit alpha type-6  P60900 0.8 
Proteolysis Proteasome subunit alpha type-7 O14818 0.6 
Humoral immunity Beta-2-microglobulin P61769 0.7 
Endonuclease Ribonuclease 4 P34096 0.6 
Cluster 3 
Oxidative stress Carbonic anhydrase 2 P00918 0.7 
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Oxidative stress Haemoglobin subunit beta P68871 0.8 
Ubiquitin Polyubiquitin-C  P0CG48 0.8 
Oxidative stress Protein S100-A9  P06702 0.6 
Oxidative stress Protein S100-A8  P05109 0.8 
Oxidative stress 
Peptidyl-prolyl cis-trans isomerase 
A 
P62937 0.8 
Oxidative stress Haemoglobin subunit delta  P02042 0.8 
Oxidative stress / 
neutrophil activity 
Myeloperoxidase  P05164 0.8 
Cell motility Actin, cytoplasmic 1  P60709 0.7 
Neutrophil activity Neutrophil defensin 1  P59665 0.7 
Neutrophil activity Neutrophil collagenase P22894 0.6 
Oxidative stress Haemoglobin subunit alpha P69905 0.6 
Oxidative stress Glutathione S-transferase P  P09211 0.7 
Cellular Ca2+ -response Calmodulin  P62158 0.9 
Oxidative stress Haemoglobin subunit alpha P69905 0.7 
Nucleasome 
component 
Histone H4 P62805 0.6 
Cell motility Profilin-1 P07737 0.6 
Oxidative stress Band 3 anion transport protein P02730 0.6 
Oxidative stress Peroxiredoxin-2 P32119 0.6 
Cluster 4 
Humoral immunity Ig heavy chain V-II region ARH-77  P06331 0.7 
Humoral immunity Immunoglobulin J chain  P01591 0.7 
Humoral immunity Ig mu chain C region  P01871 0.7 
Humoral immunity 
Ig kappa chain V-I region HK102 
(Fragment)  
P01602 0.6 
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Acute phase response Albumin P02768 0.8 
Humoral immunity Ig alpha-1 chain C region  P01876 0.9 
Humoral immunity Ig gamma-4 chain C region  P01861 0.9 
Humoral immunity Ig alpha-2 chain C region  P01877 0.9 
Humoral immunity 
Immunoglobulin lambda-like 
polypeptide 5  
B9A064 0.9 
Humoral immunity Ig kappa chain C region  P01834 1 
Humoral immunity Ig gamma-1 chain C region  P01857 0.9 
Humoral immunity Ig lambda-7 chain C region  A0M8Q6 0.9 
Haemoglobin binding Haptoglobin-related protein  P00739 0.9 
Humoral immunity Ig gamma-2 chain C region  P01859 0.8 
Immunity/Inflammation CD5 antigen-like  O43866 0.8 
Acute phase response Serotransferrin P02787 0.8 
Humoral immunity Ig lambda chain V-III region LOI  P80748 0.9 
Humoral immunity Ig gamma-3 chain C region  P01860 0.9 
Protease inhibitor Alpha-2-macroglobulin  P01023 0.8 
Acute phase response Apolipoprotein A-II  P02652 0.9 
Acute phase response Apolipoprotein A-I P02647 0.6 
Humoral immunity Ig heavy chain V-I region HG3  P01743 0.7 
Humoral immunity Ig heavy chain V-III region GA  P01769 0.9 
Humoral immunity Ig delta chain C region  P01880 0.9 
Humoral immunity Ig heavy chain V-I region V35  P23083 0.9 
Humoral immunity 
Ig kappa chain V-III region VG 
(Fragment)  
P04433 0.9 
Humoral immunity 
Ig kappa chain V-I region HK102 
(Fragment) 
U6CXY5 0.7 
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Humoral immunity Ig heavy chain V-III region GAL  P01781 0.9 
Humoral immunity Ig lambda chain V-III region SH  P01714 0.9 
Humoral immunity Ig lambda chain V region 4A  P04211 0.9 
Humoral immunity Ig heavy chain V-III region BUT  P01767 0.9 
Complement C4b-binding protein alpha chain P04003 0.7 
Hydrolase Serum paraoxonase/arylesterase 1 P27169 0.7 
Humoral immunity Ig kappa chain V-IV region LEN P01625 1 
Pregnancy 
Choriogonadotropin subunit beta 
variant 1 
A6NKQ9 0.6 
Oxidative stress Peroxiredoxin 6 P30041 0.6 
Complement 
Complement C1q subcomponent 
subunit B 
P02746 0.6 
Cluster 5 
Coagulation Platelet glycoprotein V  P40197 0.8 
Vitamin-E-binding 
protein / Acute phase 
response 
Afamin  P43652 0.7 
Acute phase response 
Inter-alpha-trypsin inhibitor heavy 
chain H2  
P19823 0.8 
Acute phase response 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
  0.8 
Complement Properdin  P27918 0.8 
Coagulation Heparin cofactor 2  P05546 0.8 
Platelet activation Selenoprotein P  P49908 0.9 
Innate immunity 
N-acetylmuramoyl-L-alanine 
amidase  
Q96PD5 0.9 
Platelet activation Beta-2-glycoprotein 1  P02749 0.9 
Coagulation Plasminogen  P00747 0.9 
Coagulation Prothrombin  P00734 0.9 
Coagulation / Acute 
phase response 
Transthyretin  P02766 0.9 
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Acute phase response Retinol-binding protein 4 P02753 0.6 
Complement/ Innate 
immunity 
Ficolin-2  Q15485 0.9 
Coagulation Kallistatin  P29622 0.9 
Coagulation Plasma serine protease inhibitor  P05154 0.9 
Coagulation Plasma kallikrein  P03952 1 
Coagulation Histidine-rich glycoprotein  P04196 1 
Coagulation Vitamin K-dependent protein S  P07225 0.9 
Coagulation Vitamin K-dependent protein C P04070 0.6 
Platelet activation Thrombospondin-1 P07996 0.7 
Platelet activation Platelet basic protein P02775 0.7 
Platelet activation Tetranectin P05452 0.6 
Lipid metabolism Apolipoprotein C-I P02654 0.6 
Coagulation Coagulation factor XI P03951 0.7 
Protein binding and 
transport 
Zinc--alpha-2-glycoprotein P25311 0.9 
Inflammatory response Attractin O75882 0.6 
Coagulation Carboxypeptidase B2 Q96IY4 0.6 
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Appendix B 4. 211 proteins identified in HEK213T cells by MS 
Description Accession 
-LOG  
P-value 
Unique 
peptides 
Max 
fold 
change 
Confidence 
score 
10 kDa heat shock protein, 
mitochondrial 
P61604 1.073 3 1.56 12.74 
3-hydroxyacyl-CoA 
dehydrogenase type-2 
Q99714 0.617 2 -1.09 9.47 
39S ribosomal protein L39, 
mitochondrial 
Q9NYK5 0.433 3 -0.23 19.26 
40S ribosomal protein S11 P62280 0.724 4 1.42 21.04 
40S ribosomal protein S12 P25398 0.308 3 0.47 25.94 
40S ribosomal protein S14 P62263 0.49 5 1.44 47.41 
40S ribosomal protein S19 P39019 0.291 7 -0.55 62.08 
40S ribosomal protein S2 P15880 0.347 3 -0.24 8.22 
40S ribosomal protein S20 P60866 1.049 5 -0.98 12.03 
40S ribosomal protein S21 P63220 0.101 6 0.12 62.96 
40S ribosomal protein S28 P62857 0.668 5 1.79 37.13 
40S ribosomal protein S29 P62273 0.238 4 0.69 7.62 
40S ribosomal protein S30 P62861 0.14 2 0.32 7.26 
40S ribosomal protein S3a P61247 0.814 6 1.07 21.05 
40S ribosomal protein S4, X 
isoform 
P62701 0.853 2 0.52 7.35 
40S ribosomal protein S6 P62753 0.795 2 -2.23 14.81 
40S ribosomal protein S7 P62081 0.003 2 0.02 21.47 
40S ribosomal protein S8 P62241 0.248 2 0.24 36.96 
40S ribosomal protein SA P08865 2.04 2 -1.25 5.68 
4F2 cell-surface antigen heavy 
chain 
P08195 0.45 2 0.91 11.69 
60 kDa heat shock protein, 
mitochondrial 
P10809 0.16 28 0.21 323.31 
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60S ribosomal protein L12 P30050 0.787 2 0.63 11.22 
60S ribosomal protein L13 P26373 0.772 6 0.91 90.37 
60S ribosomal protein L14 P50914 0.335 2 0.32 5.98 
60S ribosomal protein L15 P61313 2.83 2 -3.11 5.40 
60S ribosomal protein L19 P84098 0.359 3 0.29 9.16 
60S ribosomal protein L21 P46778 0.012 2 -0.08 8.06 
60S ribosomal protein L23a P62750 2.307 3 1.83 5.93 
60S ribosomal protein L24 P83731 0.543 3 2.13 9.68 
60S ribosomal protein L26 P61254 0.024 8 -0.06 39.07 
60S ribosomal protein L28 P46779 0.104 7 0.15 40.85 
60S ribosomal protein L29 P47914 0.457 5 1.45 25.56 
60S ribosomal protein L31 P62899 1.194 3 2.78 5.13 
60S ribosomal protein L34 P49207 0.022 2 -0.08 8.81 
60S ribosomal protein L4 P36578 0.024 2 0.13 12.23 
60S ribosomal protein L6 Q02878 0.024 4 0.02 10.93 
60S ribosomal protein L7a P62424 0.165 4 0.38 11.69 
60S ribosomal protein L8 P62917 0.294 6 0.76 17.78 
7-dehydrocholesterol reductase Q9UBM7 0.363 3 1.39 11.93 
78 kDa glucose-regulated 
protein 
P11021 0.088 5 0.58 39.31 
Actin, cytoplasmic 1 P60709 2.237 2 -1.47 323.31 
Actin, cytoplasmic 2 P63261 0.055 2 -0.56 87.37 
Alanine aminotransferase 2 Q8TD30 0.586 2 -0.74 6.19 
Alpha-enolase P06733 1.229 7 -1.18 19.02 
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Annexin A2 P07355 0.486 2 -0.46 9.04 
ATP synthase subunit alpha, 
mitochondrial 
P25705 1.177 10 1.72 86.47 
ATP synthase subunit beta, 
mitochondrial 
P06576 0.62 10 1.55 108.66 
ATP synthase subunit d, 
mitochondrial 
O75947 1.156 2 1.92 3.71 
ATP synthase subunit e, 
mitochondrial 
P56385 1.275 2 2.59 15.42 
ATP synthase subunit O, 
mitochondrial 
P48047 0.683 4 1.36 11.42 
B-cell receptor-associated 
protein 31 
P51572 0.277 2 0.38 5.21 
Basigin P35613 1.2 3 2.19 32.82 
Beta-2-microglobulin P61769 0.331 2 0.88 2.91 
BolA-like protein 2 Q9H3K6 0.448 4 -0.73 39.42 
CAAX prenyl protease 1 
homolog 
O75844 0.79 2 2.76 2.92 
Calmodulin-like protein 5 Q9NZT1 1.018 2 2.27 12.38 
Calnexin P27824 0.041 6 0.22 25.48 
CD151 antigen P48509 0.318 2 1.15 5.95 
Cellular nucleic acid-binding 
protein 
P62633 0.387 5 -0.71 59.47 
Cofilin-1 P23528 0.204 5 0.29 69.41 
Coiled-coil domain-containing 
protein 47 
Q96A33 0.4 2 0.77 5.08 
Cold-inducible RNA-binding 
protein 
Q14011 0.612 2 1.01 7.21 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
Q07021 0.792 2 -2.94 47.81 
Crk-like protein P46109 0.471 3 -1.64 32.34 
CTP synthase 1 P17812 1.541 5 -1.63 51.29 
Cystathionine beta-synthase P0DN79 1.63 4 -1.86 29.23 
Cysteine and glycine-rich 
protein 2 
Q16527 1.353 4 -1.60 34.62 
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Cytochrome b-c1 complex 
subunit 1, mitochondrial 
P31930 0.38 4 -1.15 16.82 
Cytochrome b-c1 complex 
subunit 2, mitochondrial 
P22695 0.909 2 1.67 41.98 
Cytochrome b-c1 complex 
subunit 6, mitochondrial 
P07919 1.66 4 1.68 62.00 
Cytochrome c oxidase subunit 
5A, mitochondrial 
P20674 0.724 4 2.43 27.46 
Cytochrome c oxidase subunit 
5B, mitochondrial 
P10606 2.046 5 3.86 15.56 
Cytochrome c oxidase subunit 
6B1 
P14854 1.136 4 3.29 25.94 
Cytochrome c oxidase subunit 
6C 
P09669 0.645 3 2.73 7.09 
Cytoplasmic dynein 1 
intermediate chain 2 
Q13409 0.797 2 1.25 42.34 
D-3-phosphoglycerate 
dehydrogenase 
O43175 1.645 6 0.24 60.06 
Deoxyuridine 5-triphosphate 
nucleotidohydrolase, 
mitochondrial 
P33316 1.545 6 -2.19 77.66 
DnaJ homolog subfamily A 
member 1 
P31689 0.17 2 0.57 15.70 
DnaJ homolog subfamily A 
member 2 
O60884 0.976 2 1.28 19.90 
Dolichol-phosphate 
mannosyltransferase subunit 1 
O60762 1.368 2 1.92 6.19 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit 
P39656 2.775 2 4.03 10.48 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1 
P04843 1.203 10 2.06 78.34 
Dynamin-like 120 kDa protein, 
mitochondrial 
O60313 1.02 6 -1.11 47.85 
Elongation factor 1-alpha 1 P68104 0.806 11 -0.92 51.78 
Elongation factor 1-gamma P26641 0.041 5 -0.05 40.30 
Elongation factor 2 P13639 0.361 9 -0.24 45.89 
Elongation factor Tu, 
mitochondrial 
P49411 0.342 11 -0.64 64.84 
Emerin P50402 1.47 3 1.93 35.01 
Endoplasmin P14625 1.221 2 1.76 6.72 
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ES1 protein homolog, 
mitochondrial 
P30042 2.293 4 -0.93 11.16 
Eukaryotic translation initiation 
factor 3 subunit I 
Q13347 1.89 3 2.07 10.27 
F-actin-capping protein subunit 
alpha-1 
P52907 0.094 3 -0.46 37.60 
F-actin-capping protein subunit 
beta 
P47756 0.738 3 -2.09 32.66 
Far upstream element-binding 
protein 2 
Q92945 0.552 6 1.61 25.63 
Fatty acid synthase P49327 0.516 3 -1.51 10.65 
Fructose-bisphosphate aldolase 
A 
P04075 0.002 4 0.01 43.68 
Glucosidase 2 subunit beta P14314 0.444 4 1.07 21.73 
Glutamine synthetase P15104 0.314 3 -0.81 35.70 
GTP-binding nuclear protein 
Ran 
P62826 0.213 3 0.28 8.46 
Guanine nucleotide-binding 
protein subunit beta-2-like 1 
P63244 0.201 2 -0.51 7.74 
Guanine nucleotide-binding 
protein subunit beta-like 
protein 1 
Q9BYB4 0.951 3 -1.92 14.94 
Heat shock 70 kDa protein 
1B;Heat shock 70 kDa protein 
1A 
P0DMV9 0.357 6 0.37 113.74 
Heat shock cognate 71 kDa 
protein 
P11142 0.139 10 0.20 105.76 
Heat shock protein HSP 90-beta P08238 1.141 3 1.36 58.95 
Heme oxygenase 1 P09601 1.178 2 2.00 11.10 
Heme oxygenase 2 P30519 0.691 3 1.81 25.80 
Heterogeneous nuclear 
ribonucleoprotein A1 
P09651 0.118 4 0.49 50.41 
Heterogeneous nuclear 
ribonucleoprotein K 
P61978 1.188 3 -1.89 11.31 
Heterogeneous nuclear 
ribonucleoprotein M 
P52272 0.353 7 -0.86 11.65 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
P22626 0.01 4 0.05 16.79 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
P07910 0.122 2 -0.56 14.12 
Histone H1.4 P10412 0.275 2 0.64 7.35 
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Histone H2A.V Q71UI9 0.931 2 -2.60 3.98 
Hydroxysteroid dehydrogenase-
like protein 2 
Q6YN16 0.409 3 -0.86 23.64 
Importin subunit beta-1 Q14974 0.744 2 1.37 12.50 
Inosine-5-monophosphate 
dehydrogenase 2 
P12268 0.319 3 -0.56 4.84 
Ketosamine-3-kinase Q9HA64 0.769 4 -2.15 31.41 
L-lactate dehydrogenase A 
chain 
P00338 0.502 4 1.41 29.22 
Lamina-associated polypeptide 
2, isoforms beta/gamma 
P42167 0.396 2 0.73 0.88 
Large neutral amino acids 
transporter small subunit 1 
Q01650 0.192 3 0.44 30.16 
LIM domain and actin-binding 
protein 1 
Q9UHB6 0.743 3 0.81 13.16 
Macrophage migration 
inhibitory factor 
P14174 0.186 8 -0.46 89.56 
Malate dehydrogenase, 
mitochondrial 
P40926 0.054 2 0.08 7.98 
MARCKS-related protein P49006 2.388 6 5.09 62.64 
Membrane-associated 
progesterone receptor 
component 1 
O00264 1.022 6 1.69 16.09 
Methionine-R-sulfoxide 
reductase B2, mitochondrial 
Q9Y3D2 0.321 2 0.55 2.52 
MICOS complex subunit MIC19 Q9NX63 0.523 7 2.11 35.26 
MICOS complex subunit MIC25 Q9BRQ6 0.451 2 1.45 11.06 
MICOS complex subunit MIC60 Q16891 0.051 4 -0.17 10.32 
Myosin light polypeptide 6 P60660 0.672 7 -2.65 72.27 
Myosin-10 P35580 0.524 2 -0.40 10.13 
NAD(P) transhydrogenase, 
mitochondrial 
Q13423 0.803 2 1.72 4.57 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 7 
O95182 1.663 3 2.69 19.25 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 10 
O96000 0.524 3 1.51 17.83 
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NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
6, mitochondrial 
O75380 1.393 3 2.91 25.68 
NADPH--cytochrome P450 
reductase 
P16435 0.315 2 0.69 2.33 
Neutral amino acid transporter 
B(0) 
Q15758 1.178 4 2.63 30.28 
Non-POU domain-containing 
octamer-binding protein 
Q15233 1.523 3 -2.19 15.87 
Nuclease-sensitive element-
binding protein 1 
P67809 0.559 6 0.53 88.87 
Nucleolin P19338 0.905 5 2.22 55.45 
Nucleophosmin P06748 0.045 3 -0.18 13.77 
OCIA domain-containing 
protein 1 
Q9NX40 0.439 2 1.54 4.35 
Peptidyl-prolyl cis-trans 
isomerase A 
P62937 0.411 9 -0.83 37.77 
Peroxiredoxin-1 Q06830 1.889 7 -2.73 62.15 
Phenylalanine--tRNA ligase 
alpha subunit 
Q9Y285 0.128 2 -0.22 15.53 
Phenylalanine--tRNA ligase beta 
subunit 
Q9NSD9 1.352 4 -1.38 7.89 
Plasma membrane calcium-
transporting ATPase 4 
P23634 0.423 2 1.48 12.42 
Plasminogen activator inhibitor 
1 RNA-binding protein 
Q8NC51 0.647 6 1.56 51.47 
Plastin-3 P13797 0.566 3 -1.54 13.54 
Poly [ADP-ribose] polymerase 1 P09874 0.421 2 1.22 6.72 
Poly(rC)-binding protein 1 Q15365 0.681 2 -1.39 56.41 
Polypeptide N-
acetylgalactosaminyltransferase 
2 
Q10471 0.75 5 1.56 36.11 
PRA1 family protein 2 O60831 1.029 2 2.39 15.88 
Prohibitin P35232 0.402 7 1.15 45.32 
Prohibitin-2 Q99623 0.743 7 2.91 27.28 
Proteasomal ubiquitin receptor 
ADRM1 
Q16186 1.682 2 1.62 26.27 
Protein deglycase DJ-1 Q99497 0.445 4 0.45 19.73 
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Protein disulfide-isomerase P07237 0.558 4 0.87 7.63 
Protein disulfide-isomerase A3 P30101 1.021 3 0.79 35.62 
Protein disulfide-isomerase A6 Q15084 0.068 5 0.22 41.32 
Protein FAM3C Q92520 0.256 4 1.15 14.81 
Protein S100-A8 P05109 0.574 3 -1.47 9.82 
Protein S100-A9 P06702 0.536 2 -1.33 11.00 
Protein transport protein Sec61 
subunit beta 
P60468 0.23 3 -0.78 37.67 
Prothymosin alpha P06454 0.551 3 2.49 62.35 
Putative transferase CAF17, 
mitochondrial 
Q5T440 2.379 2 -1.82 16.34 
Pyruvate dehydrogenase E1 
component subunit alpha, 
somatic form, mitochondrial 
P08559 2.162 3 1.87 17.03 
Ras-related protein Rab-1A P62820 0.037 2 -0.12 8.11 
Ras-related protein Rab-21 Q9UL25 0.246 2 0.59 12.15 
Ras-related protein Rab-6A P20340 0.439 3 1.18 6.12 
Ras-related protein Rab-7a P51149 0.051 4 0.18 48.91 
Retinol dehydrogenase 14 Q9HBH5 0.36 2 1.01 6.01 
RuvB-like 1 Q9Y265 0.433 2 0.42 6.47 
RuvB-like 2 Q9Y230 0.544 2 1.30 3.93 
Secretory carrier-associated 
membrane protein 1 
O15126 0.073 2 0.47 42.01 
SEOV glycoprotein NP_942557.1 1.788 17 6.28 106.14 
Sideroflexin-1 Q9H9B4 2.382 2 3.71 28.26 
Single-stranded DNA-binding 
protein, mitochondrial 
Q04837 2.478 3 3.13 20.38 
Small nuclear ribonucleoprotein 
Sm D2 
P62316 2.927 2 4.49 13.50 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
P05023 0.821 12 1.41 238.29 
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Solute carrier family 35 
member F6 
Q8N357 0.242 2 0.57 5.36 
Stress-70 protein, 
mitochondrial 
P38646 0.055 12 -0.10 128.45 
Stress-induced-phosphoprotein 
1 
P31948 1.482 4 3.68 70.66 
Stromal cell-derived factor 2-
like protein 1 
Q9HCN8 2.74 4 4.54 53.78 
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
P31040 1.317 7 1.69 22.20 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur 
subunit, mitochondrial 
P21912 0.685 2 1.23 4.06 
Superoxide dismutase [Cu-Zn] P00441 2.365 2 3.93 1.77 
Thioredoxin domain-containing 
protein 5 
Q8NBS9 0.162 5 0.61 62.89 
Thioredoxin-related 
transmembrane protein 2 
Q9Y320 0.26 2 0.54 10.15 
THO complex subunit 4 Q86V81 0.83 4 2.17 25.09 
Threonine--tRNA ligase, 
mitochondrial 
Q9BW92 0.509 3 -0.27 7.79 
Transferrin receptor protein 1 P02786 0.12 4 -0.72 25.66 
Transgelin-2 P37802 0.031 2 -0.09 21.71 
Transitional endoplasmic 
reticulum ATPase 
P55072 1.55 4 1.42 22.36 
Transmembrane emp24 
domain-containing protein 10 
P49755 2.268 2 2.55 9.01 
Transmembrane protein 109 Q9BVC6 1.307 2 -1.03 8.53 
Trifunctional purine 
biosynthetic protein adenosine-
3 
P22102 1.231 5 -1.86 21.38 
Tropomyosin alpha-3 chain P06753 0.505 7 -0.73 46.05 
Tubulin alpha-1A chain Q71U36 1.833 8 -0.74 185.92 
Tubulin beta chain;Tubulin 
beta-2A chain 
P07437 0.019 3 0.02 36.52 
Tubulin beta-4B chain P68371 0.362 4 -0.23 108.30 
Ubiquitin-60S ribosomal protein 
L40 
P62987 1.355 3 2.51 23.99 
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UDP-glucose:glycoprotein 
glucosyltransferase 1 
Q9NYU2 0.821 5 2.07 14.67 
Uncharacterized protein C4orf3 Q8WVX3 0.844 2 2.51 11.20 
UPF0449 protein C19orf25 Q9UFG5 0.597 3 1.84 40.50 
Vesicle-associated membrane 
protein-associated protein B/C 
O95292 1.363 3 2.66 9.15 
Vesicle-fusing ATPase P46459 0.947 2 1.59 18.47 
Vesicle-trafficking protein 
SEC22b 
O75396 0.901 4 1.73 80.33 
Vimentin P08670 0.657 25 -0.63 323.31 
Voltage-dependent anion-
selective channel protein 2 
P45880 0.5 2 1.22 4.10 
Y-box-binding protein 3 P16989 0.649 2 1.80 13.63 
Zinc finger CCCH-type antiviral 
protein 1-like 
Q96H79 0.584 4 -2.45 10.39 
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Appendix C. Published data 
 
Oral presentations 
 
• April 2017: Microbiology Society Annual Conference 2017, Edinburgh; Serum 
proteins associated with acute hantavirus infection in a pregnant woman 
• January 2017: HPRU Phd Meeting, London; Using label free proteomics for 
discovery of host biomarkers of hantavirus infection 
• December 2016: HPRU EZI 3rd Annual Conference, Liverpool; Serum proteins 
associated with acute hantavirus infection in a pregnant woman 
• February 2016: Hantavirus Workshop, Liverpool; Proteomic analysis of 
hantavirus-infected human serum 
• January 2016: HPRU EZI 2nd Annual Conference, London; Proteomic analysis of 
hantavirus-infected human serum 
• March 2015: HPRU EZI Meeting, Porton Down; Diagnostic and immune 
predictors of acute kidney injury in patients infected with hantaviruses in the UK 
Poster presentations 
• April 2017: 27th ECCMID, Vienna; Serum proteins associated with acute 
hantavirus infection in a pregnant woman 
• November 2016: Infection and Global Health Day, University of Liverpool: 
Serum proteins associated with acute hantavirus infection in a pregnant woman 
• November 2015: Infection and Global Health Day, University of Liverpool; 
Proteomic analysis of hantavirus-infected human serum 
• September 2015: Public Health England Annual Conference, Coventry; 
Proteomic analysis of hantavirus-infected human serum 
  272 
 
Publications 
• Longitudinal characterisation of the serum plasma proteome in a pregnant 
woman during acute orthohantavirus infection. Sarah B. Bar-Yaacov, Stuart D. 
Armstrong, Ollie Wildman, Ewa Zatyka, Jackie M. Duggan, Tim J.G. Brooks, 
Nicholas J. Beeching, Julian A. Hiscox – in submission.  
 
  
  
 
